{"title":"Pharmaceuticals","description":"\u003cp\u003eThe pharmaceutical industry is a cornerstone of global healthcare, impacting patients, providers, and stakeholders alike. As the landscape evolves, staying abreast of developments is paramount for success. Hardmanwell.com offers a diverse array of pharmaceutical reports, furnishing indispensable insights into market trends, industry hurdles, and emerging prospects\u003c\/p\u003e\n\u003cp\u003eInsights from Our Pharmaceutical Reports We delve into various segments within the pharmaceutical realm, encompassing biopharmaceuticals, clinical trials, dietary supplements, drug discovery, manufacturing, packaging, over-the-counter and prescription drugs, research and development, vaccines, and more. Our research furnishes invaluable data on market dynamics, catalysts for change, company and product profiles, and regulatory assessments. We explore disruptive trends like gene editing, precision medicine, and artificial intelligence, empowering clients to anticipate and adapt to market shifts effectively. Hardmanwell.com: Your Trusted Data Partner Hardmanwell.com boasts over two decades of experience as a premier market research provider, consolidating reports from leading firms to offer unparalleled convenience. Our dedicated research specialists offer personalized assistance and expert guidance, ensuring clients navigate the vast information landscape with ease. With our extensive repository of reports, you can make informed decisions that propel your business forward with confidence.\u003c\/p\u003e","products":[{"product_id":"global-hysteroscopy-market-2023-2030","title":"Global Hysteroscopy Market - 2023-2030","description":"\u003cp\u003eGlobal Hysteroscopy Market - 2023-2030\u003cbr\u003e\nGlobal Hysteroscopy Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eHysteroscopy is primarily used to identify and treat conditions that cause abnormal uterine bleeding, heavy menstrual bleeding, irregular spotting between periods, and bleeding after menopause. The procedure allows the surgeon to look inside of uterus with a tool called a hysteroscope. It is typically performed in a hospital or outpatient surgical center and is usually done under general or spinal anesthesia.\u003c\/p\u003e\n\n\u003cp\u003eHysteroscopy can be a part of the diagnostic process, as well as the treatment process. Diagnostic hysteroscopy identifies structural irregularities in the uterus and also can be used to confirm the results of other tests such as an ultrasound. Operative hysteroscopy treats an abnormality detected during a diagnostic hysteroscopy and endometrial ablation is a common procedure that treats abnormal uterine bleeding.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, significant growth drivers such as increasing technological advancements, product launches, and rising investments give rise to future market growth. Significant key players like Medtronic Plc., Olympus Corporation, B. Braun Melsungen AG, Stryker Corporation, Hologic Inc., and others are actively operating in the market.\u003c\/p\u003e\n\n\u003cp\u003eDynamics\u003c\/p\u003e\n\n\u003cp\u003eIncreasing Product Launches for Hysteroscopy Devices\u003c\/p\u003e\n\n\u003cp\u003eHysteroscopy is done using a hysteroscope which is a thin, lighted tube that is inserted into the vagina to examine the cervix and inside of the uterus. The product launches by major companies help to drive market growth and these effective research and developments help in product launches for new diagnoses, and treatments to improve care for millions of people with gynecological diseases.\u003c\/p\u003e\n\n\u003cp\u003eFor instance, in July 2023, GenWorks Health launched a mechanical hysteroscopic tissue removal system that uses a simple mechanical approach for removing intrauterine tissues. It is a minimally invasive system that has been demonstrated to be quicker and can also completely remove endometrial fibroids and polyps.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, in June 2022, UroViu Corporation launched the new Hystero-V, a single-use hysteroscope compatible with UroViu's Always Ready endoscopy platform. The 12-Fr, semi-rigid, Hystero-V features a hydrophilic coating enabling gentle insertion and superior visualization for highly effective intrauterine examinations. Hence, due to the above factors, the market is expected to boost over the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eRising Investments in Hysteroscopy\u003c\/p\u003e\n\n\u003cp\u003eHysteroscopy is a minimally invasive intervention that can be used to diagnose and treat many intrauterine and endocervical problems. The major investments from key companies help to drive market growth and these effective funds from national organizations and companies help to transform research discoveries into new diagnoses and treatments for gynecology diseases.\u003c\/p\u003e\n\n\u003cp\u003eFor instance, in October 2020, Meditrina raised $13 million to commercialize the Aveta system for treating intrauterine pathologies. The Aveta system is designed to use a proprietary expandable working channel hysteroscope, along with a fluid management and resection system, for hysteroscopic tissue chip resection under continuous flow conditions\u003c\/p\u003e\n\n\u003cp\u003eDrawbacks Associated with Hysteroscopy will Hamper the Market Growth\u003c\/p\u003e\n\n \u003cp\u003eDrawbacks associated with hysteroscopy include the high cost of hysteroscopy devices and procedures, lack of trained professionals in developing countries, risk of complications and infections associated with the procedure, lack of awareness and reluctance towards minimally invasive procedures in some regions, stringent regulations for approval of hysteroscopy devices and limited access to advanced healthcare facilities in rural areas. For instance, in the United States, the total cost of hysteroscopy varies between $2800 and $4800. Hence, these factors are limiting the market growth.\u003c\/p\u003e\n\n\u003cp\u003eSegment Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe global hysteroscopy market is segmented based on product, application, end users, and region.\u003c\/p\u003e\n\n\u003cp\u003eTissue Removal Hysteroscopy Systems from the Product Type Segment Accounted for Approximately XX% of the Global Hysteroscopy Market\u003c\/p\u003e\n\n \u003cp\u003eThe use of mechanical tissue removal hysteroscopy systems is more frequently implemented as the first-line approach for the treatment of intrauterine pathology. Hysteroscopic tissue removal and retrieval is a procedure performed under local or general anesthesia that allows the doctor to check inside the uterus and remove any polyps or fibroids under direct vision. Tissue removal hysteroscopy systems are expected to hold the largest market share over the period forecast owing to increasing product launches and technical advancements.\u003c\/p\u003e\n\n\u003cp\u003eFor instance, in November 2022, Medtronic plc, launched the TruClear system, a mechanical hysteroscopic tissue removal system used for the safe and effective treatment of intrauterine abnormalities (IUA). TruClear is a next-generation device that provides practitioners with a clear operative field and patients with gentle mechanical resection during the procedure to help efficiently execute a hysteroscopy.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, in February 2021, VirtaMed launched a hysteroscopy and gynecological laparoscopy mixed tissue removal platform. VirtaMed’s hysteroscopy system has been updated to include 16 cases for MyoSure tissue removal, added to over 50 cases in diagnostics, polypectomy, myomectomy, and tissue ablation. Hence, the above factors help to accelerate the market growth.\u003c\/p\u003e\n\n\u003cp\u003eGeographical Penetration\u003c\/p\u003e\n\n\u003cp\u003eNorth America Accounted for Approximately 38.4% of the Market Share in 2022\u003c\/p\u003e\n\n\u003cp\u003eThe global hysteroscopy market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the hysteroscopy market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising prevalence and incidence of hysterectomy, and product launches in hysteroscopy devices.\u003c\/p\u003e\n\n\u003cp\u003eFor instance, according to the Centers for Disease Control and Prevention,2022, it states that hysterectomy is the second most common surgical procedure for women and approximately 600,000 hysterectomies are performed in the United States each year. Additionally, From 2012 to 2020, the age-standardized hysterectomy prevalence among adult U.S. women was 17.9%. It steadily increased with each consecutive age group and was highest among women aged more than 80 years (48.8%).\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, in December 2020, Hologic, Inc. launched its Omni hysteroscope which is an innovative three-in-one modular scope with advanced visualization capabilities designed for both diagnostic and therapeutic hysteroscopic procedures. The Omni scope, which received 510(k) clearance from the U.S. Food and Drug Administration (FDA) is designed to help physicians streamline the process of diagnosing and treating patients\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eThe major global players in the market include Medtronic Plc., Olympus Corporation, B. Braun Melsungen AG, Stryker Corporation, Hologic Inc., CooperSurgical Inc., XION GmbH, Richard Wolf GmbH, Karl Storz SE \u0026amp; Co., Delmont Imaging among others.\u003c\/p\u003e\n\n\u003cp\u003eCOVID-19 Impact Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe COVID-19 pandemic has had a significant impact on the global hysteroscopy market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, device launches, and consultations worldwide. Many hospitals are focused on COVID-19 cases, and this reduces the diagnosis of many patients suffering from various gynecology and obstetrics disorders.\u003c\/p\u003e\n\n \u003cp\u003eMoreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the hysteroscopy market is expected to be moderately affected over the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eBy Product\u003cbr\u003e\n• Fluid Management Hysteroscopy Systems\u003cbr\u003e\n • Tissue Removal Hysteroscopy Systems\u003cbr\u003e\n • Hand-held Hysteroscopy Systems\u003cbr\u003e\n • Hysteroscopes\u003cbr\u003e\nFlexible hysteroscopes\u003cbr\u003e\nRigid hysteroscopes\u003cbr\u003e\nContact hysteroscopes\u003cbr\u003e\n• Hysterosheaths\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Application\u003cbr\u003e\n• Tubal Sterilization\u003cbr\u003e\n• Hysterectomy\u003cbr\u003e\n• Polypectomy\u003cbr\u003e\n • Myomectomy\u003cbr\u003e\n• Endometrial Ablation\u003cbr\u003e\n • Others\u003c\/p\u003e\n\n\u003cp\u003eBy End Users\u003cbr\u003e\n• Hospitals\u003cbr\u003e\n• Ambulatory Surgical Centers\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Region\u003cbr\u003e\n• North America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\n• Europe\u003cbr\u003e\nGermany\u003cbr\u003e\nU.K.\u003cbr\u003e\nFrance\u003cbr\u003e\nItaly\u003cbr\u003e\nSpain\u003cbr\u003e\nRest of Europe\u003cbr\u003e\n• South America\u003cbr\u003e\nBrazil\u003cbr\u003e\nArgentina\u003cbr\u003e\nRest of South America\u003cbr\u003e\n• Asia-Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nRest of Asia-Pacific\u003cbr\u003e\n• Middle East and Africa\u003c\/p\u003e\n\n\u003cp\u003eKey Developments\u003cbr\u003e\n• In October 2022, UroViu Corporation secured a medical equipment ECAT contract for VA DoD Purchasing. The single-use platform ranges from a 12-Fr diagnostic semi-rigid cystoscope and equivalent hysteroscope, a 14-Fr injection cystoscope with an integrated needle for drug delivery, to a flexible, deflectable, and rotatable 16.5-Fr cystoscope.\u003cbr\u003e\n• In October 2021, Hologic, Inc. launched an expanded Omni suite, a comprehensive gynecological surgical offering. The expanded Omni suite aims to optimize diagnostic and operative hysteroscopy in Europe, Africa, and the Middle East (EMEA). The expanded offering includes the Omni 30° hysteroscope, Omni Lok cervical seal, and Omni 5 French seal.\u003c\/p\u003e\n\n\u003cp\u003eWhy Purchase the Report?\u003cbr\u003e\n• To visualize the global hysteroscopy market segmentation based on product, application, end users, and region, as well as understand key commercial assets and players.\u003cbr\u003e\n• Identify commercial opportunities by analyzing trends and co-development.\u003cbr\u003e\n • Excel data sheet with numerous data points of global hysteroscopy market-level with all segments.\u003cbr\u003e\n• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.\u003cbr\u003e\n• Product mapping available as excel consisting of key products of all the major players.\u003c\/p\u003e\n\n\u003cp\u003eThe global hysteroscopy market report would provide approximately 69 tables, 70 figures, and 195 Pages.\u003c\/p\u003e\n\n\u003cp\u003eTarget Audience 2023\u003cbr\u003e\n• Manufacturers\/ Buyers\u003cbr\u003e\n• Industry Investors\/Investment Bankers\u003cbr\u003e\n• Research Professionals\u003cbr\u003e\n• Emerging Companies\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 195 Pages \/ MCW16248263","offer_id":47648651018546,"sku":null,"price":5220.0,"currency_code":"USD","in_stock":true}]},{"product_id":"generic-pharmaceutical-manufacturing-in-canada-industry-market-research-report","title":"Generic Pharmaceutical Manufacturing in Canada - Industry Market Research Report","description":"\u003cp\u003eGeneric Pharmaceutical Manufacturing in Canada - Industry Market Research Report\u003cbr\u003e\nGeneric Pharmaceutical Manufacturing in Canada\u003c\/p\u003e\n\n\u003cp\u003eOver the five years to 2023, Canadian generic pharmaceutical manufacturers have accounted for a climbing share of total drug prescriptions dispensed by volume. According to 2021 data from the Patented Medicine Prices Review Board (latest data available), average generic drug prices in Canada have declined more than 50.0% over the past decade. To cut healthcare costs, many provinces and territories have set more stringent price caps for generic drugs, effectively preventing generics from exceeding a set share of the brand-name drug equivalent's price.\u003c\/p\u003e\n\n\u003cp\u003eThe Generic Pharmaceutical Manufacturing industry in Canada develops prescription and over-the-counter drug products that are used to prevent or treat illnesses in humans or animals. Generic drugs are produced and distributed without patent protection, and industry operators are not significantly engaged in the research and development of new drugs. The industry does not include manufacturers of nutritional supplements or cosmetic beauty products.\u003c\/p\u003e\n\n\u003cp\u003eThis report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 41 Pages \/ MCW16248264","offer_id":47648651116850,"sku":null,"price":1050.0,"currency_code":"USD","in_stock":true}]},{"product_id":"american-cannabis-company-inc-ammj-pinx-analytics-extensive-financial-metrics-and-benchmarks-against-averages-and-top-companies-within-its-industry","title":"American Cannabis Company Inc (AMMJ:PINX): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry","description":"\u003cp\u003eAmerican Cannabis Company Inc (AMMJ:PINX): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry\u003cbr\u003e\nAmerican Cannabis Company Inc (AMMJ:PINX): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry.\u003c\/p\u003e\n\n\u003cp\u003eKey Findings:This unique new report provides deep financial benchmarks for American Cannabis Company Inc (AMMJ:PINX) compared to its top competitors and compared to the average for all companies within its primary industry.This benchmarking study for American Cannabis Company Inc (AMMJ:PINX) includes growth forecast for its primary industry for the current year and the next 7 years. The purpose of this report is to provide vital corporate-specific benchmarks, comparing the Subject Company to its top competitors (on a company-by-company basis) and to the averages within its primary industry for all key metrics. This is a unique report containing high-value data. The report begins with a superb overview of the primary industry of the Subject Company, including historical industry revenues, revenue forecasts and CAGR. Then the report moves into industry averages and metrics, then into data specific to the Subject Company, with comparative data for the Subject Company's top competitors.\u003c\/p\u003e\n\n\u003cp\u003eThis report will save countless hours of research and analytical work for the end user.\u003c\/p\u003e\n\n\u003cp\u003eCore Benefits:\u003c\/p\u003e\n\n\u003cp\u003e1) Comprehensive benchmarks for the Subject Company:\u003c\/p\u003e\n\n\u003cp\u003ea. Benchmarked against the leading firms in its primary industry\u003cbr\u003e\nb. Benchmarked against the average for publicly-held companies (U.S.) in its industry.\u003cbr\u003e\nc. This includes financial results, ratios, operating\/financial statements and metrics in one package, including both the latest year and 6 most-recent historical years.\u003c\/p\u003e\n\n\u003cp\u003e2) A snapshot overview of the company's primary industry, including current and historic revenues and employment, along with a long term forecast for industry growth, with CAGR (compound annual growth rate), employee population and much more.\u003c\/p\u003e\n\n\u003cp\u003e3) Detailed rankings of the Subject Company against top companies within the industry (U.S.-based firms) for key items including:\u003c\/p\u003e\n\n\u003cp\u003ea. Approximate market capitalization\u003cbr\u003e\nb. Employees\u003cbr\u003e\nc. Revenues\u003cbr\u003e\nd. Net income\u003cbr\u003e\ne. 3-Year revenue growth (%)\u003cbr\u003e\nf. 3-Year income growth (%)\u003cbr\u003e\ng. Return on assets (%)\u003cbr\u003e\nh. Return on equity (%)\u003cbr\u003e\ni. Return on invested capital (%)\u003c\/p\u003e\n\n\u003cp\u003e4) Leading competitors’ profiles.\u003c\/p\u003e \n\n\u003cp\u003eApproximately 70 pages in length. \u003cbr\u003e\nApproximately 28 Charts.\u003c\/p\u003e \n\n\u003cp\u003eThe region is the USA. This report is part of the Plunkett's Corporate Benchmarks series, published by Plunkett Research, Ltd. Plunkett has unique capabilities for creating corporate and industry information, due to research that we have been conducting for more than 20 years. Our access to hundreds of industry tables from our own databases, along with our databases of public and private company information, industry trends analysis and other resources, have been utilized in preparing this report.\u003c\/p\u003e \n\n\u003cp\u003eSimilar reports are available for all significant, U.S. publicly-held firms.\u003c\/p\u003e \n\n\u003cp\u003eDesigned to benefit:\u003c\/p\u003e\n\n\u003cp\u003eInvestment Firms, Private Equity, Hedge Funds, Lenders, Appraisers and Consultants.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 78 Pages \/ MCW16248265","offer_id":47648651182386,"sku":null,"price":2994.0,"currency_code":"USD","in_stock":true}]},{"product_id":"cannabis-production-in-canada-industry-market-research-report","title":"Cannabis Production in Canada - Industry Market Research Report","description":"\u003cp\u003eCannabis Production in Canada - Industry Market Research Report\u003cbr\u003e\nCannabis Production in Canada\u003c\/p\u003e\n\n\u003cp\u003eCannabis producers in Canada have blossomed in recent years as recreational products were legalized in 2018, opening up massive growth. Since Health Canada opened up medicinal cannabis production to more players in 2013, producers have grown continuously as they invest in production capabilities to produce quality products. As consumers shifted from illegal cannabis purchases to the licensed recreational market, cannabis growers have grown significantly, but revenue is expected to expand 17.5% in 2023 alone as the novelty of legal cannabis has worn off and most the black market has shifted to licensed purchases, which has decreased growth. Revenue has ballooned at a CAGR of 43.4% to reach $13.1 billion over the past five years.\u003c\/p\u003e\n\n\u003cp\u003eThe Cannabis Production industry in Canada includes all companies licensed by Health Canada to cultivate, produce and sell products containing marijuana for medical and recreational consumption. The value of medical marijuana grown privately and illegal purchases of cannabis products for recreational use are both excluded from this industry.\u003c\/p\u003e\n\n\u003cp\u003eThis report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 34 Pages \/ MCW16248267","offer_id":47648651280690,"sku":null,"price":1050.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-vulvodynia-pain-management-market-2023-2030","title":"Global Vulvodynia Pain Management Market - 2023-2030","description":"\u003cp\u003eGlobal Vulvodynia Pain Management Market - 2023-2030\u003cbr\u003e\nGlobal Vulvodynia Pain Management Market reached US$ XX billion in 2022 and is expected to reach US$ XX  billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eVulvodynia is a chronic pain condition of the vulva (outer female genitals). It usually lasts over three months, and there's no known cause. Vulvodynia affects women of all age groups; the onset of symptoms is most common among women between 18 and 25. It is estimated that approximately 15 percent of women will suffer chronic vulvar pain at some point.\u003c\/p\u003e\n\n\u003cp\u003eA Harvard study funded by the National Institutes of Health found that 60 percent of women who suffer from the condition consult at least three healthcare professionals in seeking a diagnosis, and 40 percent of those remained undiagnosed. According to an NIH-funded study done at Rutgers Robert Wood Johnson Medical School and reported by the National Vulvodynia Association, around 75% of women with vulvodynia feel \"\"out of control\"\" of their bodies. 60% say the condition interferes with their enjoyment of life.\u003c\/p\u003e\n\n \u003cp\u003eFurthermore, increasing awareness about female hygiene, recent drug discoveries, pipeline drugs are few factors that drive the market in the forthcoming period.\u003c\/p\u003e\n\n\u003cp\u003eDynamics\u003c\/p\u003e\n\n\u003cp\u003eIncreasing Product Launches\u003c\/p\u003e\n\n\u003cp\u003eNew Products are more focused on overcoming the challenges present in obsolete drugs.  Combination drugs are also experimented with to cure the disease in a better way. Topical creams are often preferred due to their healing ability. A few symptoms of vulvodynia disease are treated using topical creams including vaginal dryness and itching.  These topical creams are useful in numbing the pain and reducing further complications.\u003c\/p\u003e\n\n \u003cp\u003eFor instance, In July 2023, Aesthetic pharmaceutical company Croma Pharma launched a new self-occluding topical local anesthetic cream Pliaglis. Pliaglis is a combination topical anesthetic containing both Tetracaine and Lidocaine which is used for treating vulvodynia in females.\u003c\/p\u003e\n\n  \u003cp\u003eRising Clinical Trials\u003c\/p\u003e\n\n \u003cp\u003eThere is an increased number of clinical trials ongoing for proper treatment of vulvodynia. As there is no targeted therapy for vulvodynia apart from antidepressants, anticonvulsants, etc. Pain management is the only treatment that is prioritized in vulvodynia patients.\u003c\/p\u003e\n\n \u003cp\u003eFor instance, in May 2023, the Medical University of Lublin is conducting phase 2 clinical trials to test the effect of LDN (Low doses of Naltrexone) on pain perception and quality of life in women with different types of vulvodynia. The estimated completion date is December 31, 2026.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, in February 2023, Université de Sherbrooke is conducting clinical trials to investigate the feasibility and acceptability of a dry needling treatment for women suffering from provoked vestibulodynia. The estimated completion date is May 1, 2024.\u003c\/p\u003e\n\n \u003cp\u003eOnset of Side Effects\u003c\/p\u003e\n\n \u003cp\u003eSide effects of certain drugs, such as steroids, lead to few complications, especially in females, as they disrupt the hormonal balance in the body. According to the National Institute of Health 2022 issue, females who use steroids may have problems with their menstrual cycles because steroids can disrupt the maturation and release of eggs from the ovaries.\u003c\/p\u003e\n\n \u003cp\u003eSegment Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe global is segmented based on disease type, drug class, route of administration, end-user, and region.\u003c\/p\u003e\n\n\u003cp\u003eThe  Local Anesthetics Segment Accounted for Approximately XX% of the Market Share\u003c\/p\u003e\n\n \u003cp\u003eLocal anesthetics, such as lidocaine, are used as a topical treatment for vulvodynia. This ointment numbs the pain for some time near the vulvar region. Pain and itching are two critical symptoms in patients suffering from vulvodynia. The treatment mainly focuses on decreasing the pain near the vulva.\u003c\/p\u003e\n\n \u003cp\u003eFor instance, according to Sexual Medicine in April 2022, a symptom-oriented therapy with local anesthetics provides an efficient and easy-to-apply approach to treating vulvodynia, especially if integrating the novel perineal pudendal injection technique. Thus, the advantage of local anesthesia to treat vulvodynia is expected to drive the segment's growth.\u003c\/p\u003e\n\n\u003cp\u003eGeographical Analysis\u003c\/p\u003e\n\n\u003cp\u003eNorth America accounted for Approximately XX% of the Market Share in 2022\u003c\/p\u003e\n\n\u003cp\u003eNorth America is dominating the global vulvodynia treatment market and is estimated to hold a significant market size over the forecast period owing to the rising prevalence of vulvodynia, and the presence of ongoing research and development activities in the region. The rising prevalence of vulvodynia is expected to drive the growth of the market over the forecast period.\u003c\/p\u003e\n\n \u003cp\u003eFor instance, according to the NIH-funded Harvard study, an estimated 6 million women in America will suffer from Vulvodynia. Despite the high number of those affected, the pain is left misdiagnosed or untreated. A survey conducted by the University of Michigan found that, out of the 2,269 women in the metro Detroit area, 25 % said that they had experienced vulvar pain. Among the 25 %, only 2 % admitted to seeking medical treatment for the pain.\u003c\/p\u003e\n\n \u003cp\u003eAlthough it is shocking to know that few women speak up about their pain, even more, alarming is that those that discussed the discomfort with their doctor were misdiagnosed. Also, according to the US’s National Vulvodynia Association, as many as 16% of women experience the condition at some point. Due to the above factors, the North American region is expected to hold the largest share in the market\u003c\/p\u003e\n\n \u003cp\u003eCOVID-19 Impact Analysis\u003c\/p\u003e\n\n\u003cp\u003eCoronavirus disease (COVID-19) broke out towards the end of December 2019 in China; soon, it spread rapidly to various countries, leading to an outburst of pandemics. Due to the restrictions imposed to control the spread of the infection globally, the manufacturing, import, and export of medicine and healthcare services to patients with chronic illness have been affected. Hence, the management of pain among suspected vulvodynia patients suffered from more severe complications.\u003c\/p\u003e\n\n \u003cp\u003eBy Disease Type\u003cbr\u003e\n• Generalized Vulvodynia\u003cbr\u003e\n• Localized Vulvodynia\u003c\/p\u003e\n\n\u003cp\u003eBy Drug Class\u003cbr\u003e\n • Local Anesthetics\u003cbr\u003e\n• Antidepressants\u003cbr\u003e\nAmitriptyline\u003cbr\u003e\n Nortriptyline\u003cbr\u003e\n Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)\u003cbr\u003e\n• Anticonvulsants\u003cbr\u003e\n• Opioids\u003cbr\u003e\nOxycodone\u003cbr\u003e\n Hydrocodone\u003cbr\u003e\nOthers\u003cbr\u003e\n• Anti Epilepsy Drugs\u003cbr\u003e\nGabapentin\u003cbr\u003e\nPregabalin\u003cbr\u003e\nOthers\u003cbr\u003e\n• Topical Hormone Creams\u003cbr\u003e\n• Hormone Inhibitors\u003cbr\u003e\n• Anti-inflammatory Drugs\u003cbr\u003e\nSteroids\u003cbr\u003e\nMast Cell Inhibitors\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Route of Administration\u003cbr\u003e\n• Oral\u003cbr\u003e\n• Parenteral\u003cbr\u003e\n• Topical\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n \u003cp\u003eBy End User\u003cbr\u003e\n• Hospitals and Clinics\u003cbr\u003e\n• Homecare\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Region\u003cbr\u003e\n• North America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\n• Europe\u003cbr\u003e\nGermany\u003cbr\u003e\nU.K.\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nRest of Europe\u003cbr\u003e\n• South America\u003cbr\u003e\nBrazil\u003cbr\u003e\nArgentina\u003cbr\u003e\nRest of South America\u003cbr\u003e\n• Asia-Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nRest of Asia-Pacific\u003cbr\u003e\n• Middle East and Africa\u003c\/p\u003e\n\n\u003cp\u003eKey Developments\u003cbr\u003e\n• In December 2022, SCYNEXIS Inc. declared that the US Food and Drug Administration (FDA) approved a second indication for BREXAFEMME (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).\u003cbr\u003e\n• Norwegian University of Science and Technology collaborated with St. Olavs Hospital to conduct clinical trials comparing multidisciplinary treatment with standard care for women with vulvodynia. The estimated completion date is June 2024.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eThe major global players in the vulvodynia pain management market include Taro Pharmaceuticals U.S.A., Inc., Teva Pharmaceuticals, Acura Pharmaceuticals, Inc., Purdue Pharma LP, Alvogen Inc., Amneal Pharmaceuticals, Mallinckrodt Pharmaceuticals, Lupin Pharmaceuticals, Alembic Pharmaceuticals, and Merck \u0026amp; Co, Inc. among others.\u003c\/p\u003e\n\n\u003cp\u003eWhy Purchase the Report?\u003cbr\u003e\n• To visualize the global vulvodynia pain management segmentation based on disease type, drug class, route of administration, end-user, and region, as well as understand key commercial assets and players.\u003cbr\u003e\n• Identify commercial opportunities by analyzing trends and co-development.\u003cbr\u003e\n • Excel data sheet with numerous data points of vulvodynia management market-level with all segments.\u003cbr\u003e\n• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.\u003cbr\u003e\n• Product mapping available as Excel consisting of key products of all the major players.\u003c\/p\u003e\n\n\u003cp\u003eThe global vulvodynia pain management market report would provide approximately 53 tables, 54 figures, and 195 Pages.\u003c\/p\u003e\n\n\u003cp\u003eTarget Audience 2023\u003cbr\u003e\n• Manufacturers\/ Buyers\u003cbr\u003e\n• Industry Investors\/Investment Bankers\u003cbr\u003e\n• Research Professionals\u003cbr\u003e\n• Emerging Companies\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 195 Pages \/ MCW16248268","offer_id":47648651378994,"sku":null,"price":5220.0,"currency_code":"USD","in_stock":true}]},{"product_id":"israel-ischemic-heart-disease-ihd-drugs-market-disease-class-angina-pectoris-myocardial-infarction-by-drug-class-anti-dyslipidemic-drugs-calcium-channel-blockers-beta-blockers-ace-inhibitors-arbs-vasodilators-antithrombotic-agents-by-regio","title":"Israel ischemic heart disease (IHD) Drugs Market, Disease Class (Angina Pectoris, Myocardial Infarction), By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), By Regio","description":"\u003cp\u003eIsrael ischemic heart disease (IHD) Drugs Market, Disease Class (Angina Pectoris, Myocardial Infarction), By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), By Region, Competition, Forecast \u0026amp; Opportunities, 2028F\u003cbr\u003e\nIsrael ischemic heart disease (IHD) Drugs Market is expected to grow at an impressive rate during the forecast period, 2024-2028. The major factors include the rising prevalence of chronic diseases such as cardiovascular diseases, cancer, and diabetes and the growing adoption of technological advancement. The increasing awareness of the masses toward interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of ischemic heart diseases is one of the key factors driving the growth of the Israel ischemic heart diseases market.   Additionally, the unhealthy lifestyle and lack of physical activity are projected to promote the growth of the Israel ischemic heart disease (IHD) drugs market   during the forecast period. According to World Health Organization 2020, diabetes mellitus deaths in Israel reached to around 1,913 or 5.44% of total deaths. The age adjusted death rate is 13.96 per 100,000 of population.\u003c\/p\u003e\n\n\u003cp\u003eIschemic heart disease is a condition that occurs when the blood supply to the heart is reduced or blocked, leading to damage of heart muscle tissue. This is mostly caused by atherosclerosis, a buildup of plaque in the arteries that supply blood to the heart, which can narrow or block these arteries. The most common symptom of ischemic heart disease is angina in which the heart does not get proper oxygen. Risk factors for ischemic heart disease include age, smoking, high blood pressure, high cholesterol, diabetes, family history, and a sedentary lifestyle.\u003c\/p\u003e\n\n\u003cp\u003eThe rise in awareness related to complications associated with heart disease is a major factor that fuels the growth of the Israel ischemic heart disease (IHD) drugs market. Moreover, the increase in geriatric population and sedentary lifestyle boost the growth of the market. However, high cost of drugs, alternative therapies, and change in lifestyle are anticipated to hinder the growth of the Israel ischemic heart diseases market. Conversely, the rise in healthcare infrastructure is expected to offer lucrative opportunities   to the market players during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eRising Prevalence of Ischemic Heart Disease\u003c\/p\u003e \n\n\u003cp\u003eThe increasing prevalence of ischemic heart disease drugs in Israel is driven by a combination of factors. These include the high prevalence of heart issues   in the country, the aging population, and the growing demand for effective treatments. In addition, the Israeli government has launched several initiatives to improve the prevention and management of cardiovascular diseases, including ischemic heart disease. For instance, according to the World Health Organization (WHO), ischemic heart disease accounted for approximately 8.9 million deaths in 2019. The increasing prevalence of risk factors such as obesity, diabetes, and high blood pressure has contributed to the rising incidence of ischemic heart disease, which, in turn, drives the demand for drugs to treat and manage the condition, thereby propelling the growth of the Israel ischemic heart disease (IHD) drugs market  . For instance, according to the research articles, around half (49%) of the patients with heart failure had ischemic heart disease, 44% had irregular heart rhythm (atrial fibrillation), and   34.5% had diabetes.\u003c\/p\u003e \n\n\u003cp\u003eMany Israelis have adopted healthier lifestyles, including increased physical activity and healthier diets, which can help prevent and manage cardiovascular disease. However, lifestyle changes may not be enough to prevent or manage the condition in all cases, and drugs may be necessary to control symptoms and prevent complications. Moreover, the increasing prevalence of ischemic heart disease drugs in Israel is driven by a combination of factors, including the high prevalence of the condition, the aging population, advances in drug development and technology, government initiatives, and lifestyle changes. Thus, with the increasing demand for effective drugs to treat and manage ischemic heart diseases, the growth of the Israel ischemic heart disease (IHD) drugs market is projected to grow during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eDevelopment of Healthcare Infrastructure\u003c\/p\u003e\n\n\u003cp\u003eIsrael is known for its innovative and advanced healthcare infrastructure, and the country has a thriving pharmaceutical industry. Advances in drug development and technology have led to the introduction of new and improved drugs to treat ischemic heart disease, which is subjected to propel the growth of the Israel ischemic heart disease (IHD) drugs market  . Several other factors that will boost the growth of the Israel ischemic heart disease (IHD) drugs market include growing initiatives by private and government organizations and rising   awareness for drugs with its maximum efficacy to treat ischemic heart diseases. A few organizations dealing with the products of heart diseases drugs have taken initiatives to conduct a camp and checked the blood pressure and made them aware of various aspects of high blood pressure.   Such factors have driven the growth of the Israel ischemic heart disease (IHD) drugs market  . A major Israel’s healthcare authority is the National Health Insurance Law, which allows every resident to choose 1 of 4 health plans regardless of age, pre-existing conditions, or health status. The different quality measures of essential cardiovascular therapeutics are monitored by health maintenance organizations and by the Medical Quality Division of the Ministry of Health in Israel. The government had developed a society called Israel Heart Society which is a member of the European Society of Cardiology to promote the prevention and treatment of heart diseases, encourage professional and scientific knowledge and education, increase the awareness of cardiovascular health, and advocate for cardiovascular therapeutic. The Israel Heart Society conducts national surveys to describe cardiac health status and trends in therapeutic management. The most established survey is the Acute Coronary Syndrome Israeli Survey. All these efforts across the country are responsible for propelling the growth of Israel ischemic heart diseases drugs market.\u003c\/p\u003e\n\n\u003cp\u003ePublic health campaigns have also played a role in increasing awareness of the health risks associated with ischemic heart disease in Israel. These campaigns aim to educate the public about the importance of healthy lifestyle choices, such as diet and exercise. They also encourage people to get their blood pressure checked regularly and to seek medical treatment if their blood pressure is high. To increase awareness of ischemic issues in Israel, a few outreach programs, educational efforts, and public health campaigns have been taken forward. The main objectives of these programs are to inform the public about the causes of ischemic heart diseases, the value of healthy heart, and the advantages of treatments and formulation of drugs. The Israel’s Ministry of Health has also taken steps to address the growing prevalence of cardiovascular diseases by implementing national guidelines for the prevention, diagnosis, and treatment of the condition. These initiatives aim to increase awareness, improve access to healthcare, and support research and development in the field of ischemic heart stroke, which, in turn, will drive the growth of the Israel ischemic heart disease (IHD) drugs market during the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation\u003c\/p\u003e\n\n\u003cp\u003eThe Israel ischemic heart disease (IHD) drugs market can be segmented by disease class, drug class, and region. By disease class, the market can be segmented into angina pectoris, myocardial infarction. Based on drug class, the market can be segmented into anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, ACE inhibitors, ARBs, vasodilators, and antithrombotic agents.\u003c\/p\u003e\n\n \u003cp\u003eMarket Players\u003c\/p\u003e\n\n\u003cp\u003ePfizer Pharmaceuticals Israel Ltd, MERCK SERONO LTD., GlaxoSmithKline Israel Ltd, Bayer-Israel, Novartis Pharma Israel Ltd, Sanofi-Aventis Israel Ltd, Eli Lilly Israel, Actelion Pharmaceuticals Israel Ltd, Bristol-Myers Squibb Israel Ltd, and Roche Pharmaceuticals (Israel) Ltd.. are some of the leading companies operating in the Israel ischemic heart disease (IHD) Drugs Market.\u003c\/p\u003e\n\n\u003cp\u003eReport Scope:\u003c\/p\u003e\n\n\u003cp\u003eIn this report, the Israel ischemic heart disease (IHD) Drugs Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:Israel ischemic heart disease (IHD) Drugs Market, By Disease ClassAngina PectorisMyocardial Infarction Israel ischemic heart disease (IHD) Drugs Market, By Drug ClassAnti-Dyslipidemic DrugsCalcium Channel BlockersBeta-BlockersACE InhibitorsARBsVasodilatorsAntithrombotic Agents Israel ischemic heart disease (IHD) Drugs Market, By Region:The Mediterranean coastal plainThe Central HillsThe Jordan Rift ValleyThe Negev DesertCompetitive Landscape\u003cbr\u003e\nCompany Profiles: Detailed analysis of the major companies present in the Israel ischemic heart disease (IHD) drugs market.\u003c\/p\u003e \n\n\u003cp\u003eCompany InformationDetailed analysis and profiling of additional market players (up to five).Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.  Single User license will be delivered in PDF format without printing rights\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 83 Pages \/ MCW16248269","offer_id":47648651510066,"sku":null,"price":4200.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-pneumonia-therapeutics-market-2023-2030","title":"Global Pneumonia Therapeutics Market - 2023-2030","description":"\u003cp\u003eGlobal Pneumonia Therapeutics Market - 2023-2030\u003cbr\u003e\nGlobal Pneumonia Therapeutics Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003ePneumonia is characterized by inflammation and fluid accumulation in the lungs which is caused by a bacterial, viral, or fungal infection. Bacterial pneumonia tends to be more common and more severe than viral pneumonia. Pneumonia is a common illness, with millions of people diagnosed each year in the United States.\u003c\/p\u003e\n\n\u003cp\u003eThe global pneumonia therapeutics market has witnessed significant growth in recent years due to the usage of the Ceftolozane\/tazobactam drug that is licensed for the treatment of pneumonia at a dosage of 3 g every 8 hours. Pneumonia symptoms can range from mild to serious which include a cough with or without mucus, fever, chills, and trouble breathing.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, significant growth drivers such as increasing product approvals, and research and developments give rise to future market growth. Significant key players like Pfizer Inc., LGM Pharma LLC, Teva Pharmaceuticals Ltd., Sanofi S.A, Baxter International Inc., and others are actively operating in the market.\u003c\/p\u003e\n\n\u003cp\u003eMarket Dynamics\u003c\/p\u003e\n\n\u003cp\u003eRising product approvals for pneumonia treatment\u003c\/p\u003e\n\n \u003cp\u003ePneumonia infection makes it difficult to breathe and can cause a fever and cough with yellow, green, or bloody mucus. The product approvals by major companies help to drive market growth and these product approvals help in getting new treatments and improve care for millions of people with pneumonia infections.\u003c\/p\u003e\n\n\u003cp\u003eFor instance, in May 2023, Innoviva Specialty Therapeutics, Inc. declared that the U.S. Food and Drug Administration (FDA) approved XACDURO co-packaged for intravenous use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.\u003c\/p\u003e\n\n \u003cp\u003eAdditionally, in January 2023, Alkem Laboratories launched an antibiotic drug Zidavi, a novel combination of ceftazidime and avibactam which is indicated for various ailments like complicated urinary tract infections and as an effective alternative to meropenem and colistin in hospital-acquired pneumonia (HAP). Thus, owing to the above factors the market is expected to boost over the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eIncreasing technological advancements for pneumonia treatment\u003c\/p\u003e\n\n\u003cp\u003eThe global pneumonia therapeutics market has witnessed significant growth due to various recent technological advancements. Pneumonia is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced technological advancements in treating severe pneumonia cases help to accelerate market growth.\u003c\/p\u003e\n\n\u003cp\u003eFor instance, in December 2022, a research team at Swansea University developed an AI-ENABLED SYSTEM called ‘digital twin’ to help prioritize treatment for pneumonia patients who require urgent intensive care and ventilator support. This new innovative system is potentially seen more quickly and receives the most effective treatment based on data from previous pneumonia sufferers. It can also provide real-time feedback on how a patient’s health is likely to vary based on their current known condition using periodic input data from the patient’s vitals such as heart rate, and respiration rate.\u003c\/p\u003e\n\n\u003cp\u003eSide effects associated with antibiotic drugs are expected to hamper global market growth\u003c\/p\u003e\n\n \u003cp\u003eThere are multiple types of antibiotics that commonly used to treat pneumonia infections and and can have some uncomfortable side effects. These can include gastrointestinal discomfort such as nausea, vomiting, diarrhea, upset stomach, loss of appetite, clay-colored stools, and stomach pain. It can also cause skin issues like hives, yeast infections including oral thrush, and allergic reactions. Thus, the above factors are expected to hamper the market growth.\u003c\/p\u003e\n\n\u003cp\u003eSegment Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe global pneumonia therapeutics market is segmented based on type, treatment, route of administration, distribution channel, and region.\u003c\/p\u003e\n\n\u003cp\u003eAntibacterial drugs from the treatment segment accounted for approximately xx% of the global pneumonia therapeutics market share\u003c\/p\u003e\n\n \u003cp\u003eAntibacterial Drugs are expected to hold the largest market share over the period forecast owing to increasing clinical trials of bacterial pneumonia treatment drugs. A total of 324 clinical trials were performed for the treatment of community-acquired pneumonia. For instance, according to clinicalTrials.gov, on July 3, 2023, Paratek Pharmaceuticals Inc. conducted a clinical trial on Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia. The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia. The intervention include antibacterial drug Omadacycline and Moxifloxacin IV for injection, and oral tablets.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, on March 8, 2023, Evopoint Biosciences Inc., conducted a clinical trial on Imipenem\/Cilastatin-XNW4107 Versus Imipenem\/Cilastatin\/Relebactam for Treatment of Participants with Bacterial Pneumonia. The study aims to compare treatment with Imipenem\/Cilastatin-XNW4107 (IMI-XNW4107) with imipenem\/cilastatin\/relebactam (IMI\/REL) in participants with hospital-acquired or ventilator-associated bacterial pneumonia.\u003c\/p\u003e\n\n \u003cp\u003eGeographical Penetration\u003c\/p\u003e\n\n\u003cp\u003eNorth America accounted for approximately 38.4% of the market share in 2022\u003c\/p\u003e\n\n\u003cp\u003eThe global pneumonia therapeutics market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the pneumonia therapeutics market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising incidence of pneumonia diseases, product approvals, and research and developments in pneumonia therapeutics.\u003c\/p\u003e\n\n\u003cp\u003eFor instance, according to the Centers for Disease Control and Prevention 2022, pneumococcal pneumonia causes an estimated 150,000 hospitalizations each year in the United States. The number of visits to emergency departments with pneumonia as the primary diagnosis is 1.5 million and 50,000 deaths from pneumonia disease every year.\u003c\/p\u003e\n\n\u003cp\u003eIn June 2023, Eagle Pharmaceuticals, Inc. declared that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act and Fast Track Designation for CAL02, a first-in-class non-biological bacterial virulence neutralizer, anti-infective agent being developed to treat severe community-acquired bacterial pneumonia (SCABP) as an add-on therapy to standard of care.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, in June 2021, The FDA has approved omadacycline, an oral-only dosing regimen, for the treatment of community-acquired bacterial pneumonia. Omadacycline is a novel antibiotic with once-daily oral and IV formulations for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.\u003c\/p\u003e\n\n\u003cp\u003eCOVID-19 Impact Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe COVID-19 pandemic has had a significant impact on the global pneumonia therapeutics treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in pneumonia therapeutics research and product launches. Clinical trials are vital for developing new treatments and improving outcomes in the pneumonia therapeutics market.\u003c\/p\u003e\n\n \u003cp\u003eHowever, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the pneumonia therapeutics market is expected to be moderately affected over the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eBy Type\u003cbr\u003e\n• Community-acquired Pneumonia\u003cbr\u003e\nBacterial Pneumonia\u003cbr\u003e\nViral Pneumonia\u003cbr\u003e\nFungal Pneumonia\u003cbr\u003e\n• Hospital-acquired Pneumonia\u003cbr\u003e\n• Healthcare-associated Pneumonia\u003cbr\u003e\n • Ventilator-associated Pneumonia\u003cbr\u003e\n • Aspiration Pneumonia\u003c\/p\u003e\n\n\u003cp\u003eBy Treatment\u003cbr\u003e\n• Prevention Vaccines\u003cbr\u003e\n • Antibacterial Drugs\u003cbr\u003e\nDelafloxacin (Baxdela)\u003cbr\u003e\nAzithromycin (Zithromax)\u003cbr\u003e\nAztreonam (Azactam)\u003cbr\u003e\nErtapenem (Invanz)\u003cbr\u003e\n Others\u003cbr\u003e\n • Antifungal Drugs\u003cbr\u003e\nItraconazole\u003cbr\u003e\nFluconazole\u003cbr\u003e\nTriazoles\u003cbr\u003e\nOthers\u003cbr\u003e\n• Antiviral Drugs\u003cbr\u003e\nRibavirin\u003cbr\u003e\nAmantadine\u003cbr\u003e\nAcyclovir\u003cbr\u003e\n Others\u003c\/p\u003e\n\n\u003cp\u003eBy Route of Administration\u003cbr\u003e\n• Oral\u003cbr\u003e\n• Parenteral\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Distribution Channel\u003cbr\u003e\n• Hospital Pharmacy\u003cbr\u003e\n• Retail Pharmacy\u003cbr\u003e\n• Online Pharmacy\u003c\/p\u003e\n\n\u003cp\u003eBy Region\u003cbr\u003e\n• North America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\n• Europe\u003cbr\u003e\nGermany\u003cbr\u003e\nU.K.\u003cbr\u003e\nFrance\u003cbr\u003e\nItaly\u003cbr\u003e\nSpain\u003cbr\u003e\nRest of Europe\u003cbr\u003e\n• South America\u003cbr\u003e\nBrazil\u003cbr\u003e\nArgentina\u003cbr\u003e\nRest of South America\u003cbr\u003e\n• Asia-Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nRest of Asia-Pacific\u003cbr\u003e\n• Middle East and Africa\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eThe major global players in the market include Pfizer Inc., Dr. Reddy's Laboratories, LGM Pharma LLC, Teva Pharmaceuticals Ltd., AdvaCare Pharma, Baxter International Inc., Innoviva Specialty Therapeutics Inc., F. Hoffmann-La Roche Ltd, Sanofi S.A, Lupin Limited among others.\u003c\/p\u003e\n\n\u003cp\u003eKey Developments\u003cbr\u003e\n• In January 2023, Aeolian Biotech Corp. launched an improved pneumococcal conjugate vaccine, ‘iPCV22’, to address the threat of circulating and emerging pneumococcal serotypes. Aeolian’s iPCV22 vaccine potentially covers 95 percent of invasive pneumococcal disease in adults.\u003cbr\u003e\n• In May 2023, Gates Foundation funded $200M to develop affordable childhood vaccines and to support delivery of vaccines to prevent pneumonia, meningitis, and neonatal sepsis.\u003cbr\u003e\n • In June 2023, Aridis Pharmaceuticals, Inc. reported that its AR-301 clinical program is being considered for availing the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs. AR-301, ARDS’ proprietary monoclonal antibody candidate was developed as an adjunctive therapy to be implemented along with standard-of-care antibiotics for the treatment of pneumonia caused by Gram-positive bacteria, Staphylococcus aureus.\u003c\/p\u003e\n\n\u003cp\u003eWhy Purchase the Report?\u003cbr\u003e\n• To visualize the global pneumonia therapeutics market segmentation based on type, treatment, route of administration, distribution channel, and region, as well as understand key commercial assets and players.\u003cbr\u003e\n• Identify commercial opportunities by analyzing trends and co-development.\u003cbr\u003e\n • Excel data sheet with numerous data points of global pneumonia therapeutics market-level with all segments.\u003cbr\u003e\n• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.\u003cbr\u003e\n• Product mapping available as excel consisting of key products of all the major players.\u003c\/p\u003e\n\n\u003cp\u003eThe global pneumonia therapeutics market report would provide approximately 69 tables, 71 figures, and 195 Pages.\u003c\/p\u003e\n\n\u003cp\u003eTarget Audience 2023\u003cbr\u003e\n• Manufacturers\/ Buyers\u003cbr\u003e\n• Industry Investors\/Investment Bankers\u003cbr\u003e\n• Research Professionals\u003cbr\u003e\n• Emerging Companies\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 195 Pages \/ MCW16248270","offer_id":47648651608370,"sku":null,"price":5220.0,"currency_code":"USD","in_stock":true}]},{"product_id":"cbd-product-manufacturing-in-the-us-industry-market-research-report","title":"CBD Product Manufacturing in the US - Industry Market Research Report","description":"\u003cp\u003eCBD Product Manufacturing in the US - Industry Market Research Report\u003cbr\u003e\nCBD Product Manufacturing in the US\u003c\/p\u003e\n\n\u003cp\u003eIn 2018, CBD products became legal at the federal level. Prior to this, CBD products were illegal at the federal level but legal in many states and with increased frequency. As a result, many areas had a framework in place, so robust growth followed. Still, with states increasingly legalizing CBD products prior to the federal legalization, explosive growth had been ongoing. As the pandemic hit, consumers reduced spending, and CBD producers contended with possibilities of a saturated market. More likely, the industry is normalizing, indicated by relatively slower growth in recent years. Over the past five years, revenue has been growing at a CAGR of 19.9% and is estimated to reach $1.3 billion in 2023 when revenue growth will slow to 0.7%.\u003c\/p\u003e\n\n\u003cp\u003eCompanies in this industry use hemp to produce cannabidiol (CBD) oil, which is used to create supplements, foods and concentrates.\u003c\/p\u003e\n\n\u003cp\u003eThis report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 35 Pages \/ MCW16248272","offer_id":47648651673906,"sku":null,"price":1314.0,"currency_code":"USD","in_stock":true}]},{"product_id":"medical-recreational-marijuana-growing-in-the-us-industry-market-research-report","title":"Medical \u0026 Recreational Marijuana Growing in the US - Industry Market Research Report","description":"\u003cp\u003eMedical \u0026amp; Recreational Marijuana Growing in the US - Industry Market Research Report\u003cbr\u003e\nMedical \u0026amp; Recreational Marijuana Growing in the US\u003c\/p\u003e\n\n\u003cp\u003eThe industry, which includes establishments that grow marijuana for medical and recreational use, flourished over the five years to 2023. Legislative victories over recent years, proved that the cannabis industry is one of the fastest growing industries in the US. Consumer attitudes are also accelerating legalization efforts at the state level. Gallup reports that an estimated 80.0% of US citizens approve of legal access to medical marijuana, while 60.0% approve of full adult use legalization. The growing acceptance of medical marijuana is providing growers and investors with unprecedented opportunities. As a result, industry revenue increased at a CAGR of 30.5% to $22.6 billion over the five years to 2023, including an increase of 11.8% in 2023 alone.\u003c\/p\u003e\n\n\u003cp\u003eThis industry’s establishments grow marijuana for medical and recreational use. Most operators are nonprofit collectives that provide medical marijuana to other collective members. Transactions are typically conducted on a donation basis because the sale and distribution of marijuana is illegal in most states that permit medical marijuana. The industry also includes operators in Colorado and Washington, which grow medical and recreational marijuana on a for-profit basis.\u003c\/p\u003e\n\n\u003cp\u003eThis report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 33 Pages \/ MCW16248273","offer_id":47648651739442,"sku":null,"price":1314.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-behavioral-rehabilitation-market-2023-2027","title":"Global Behavioral Rehabilitation Market 2023-2027","description":"\u003cp\u003eGlobal Behavioral Rehabilitation Market 2023-2027\u003cbr\u003e\nThe behavioral rehabilitation market is forecasted to grow by USD 16.89 bn during 2022-2027, accelerating at a CAGR of 3.95% during the forecast period. The report on the behavioral rehabilitation market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\u003c\/p\u003e\n\n\u003cp\u003eThe report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of behavioral disorders, increase in availability of therapeutic options, and rising government initiatives.\u003c\/p\u003e\n\n\u003cp\u003eTechnavio's behavioral rehabilitation market is segmented as below:\u003c\/p\u003e\n\n\u003cp\u003eBy TypeOutpatientInpatientResidentialBy TherapyCounselingMedicationSupport servicesBy Geographical LandscapeNorth AmericaEuropeAsiaRest of World (ROW)This study identifies the increasing number of digital detoxification programs as one of the prime reasons driving the behavioral rehabilitation market growth during the next few years. Also, advent of online counseling and increasing preference for partial hospitalization program (PHP) will lead to sizable demand in the market.\u003c\/p\u003e\n\n\u003cp\u003eThe report on the behavioral rehabilitation market covers the following areas:Behavioral rehabilitation market sizingBehavioral rehabilitation market forecastBehavioral rehabilitation market industry analysisThe robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading behavioral rehabilitation market vendors that include Acadia Healthcare Co. Inc., Addcounsel Ltd., Advocate Health Care, American Addiction Centers, Athena Behavioral Health, Aurora Behavioral Health System, Baxter Regional Medical Center, BHG Holdings LLC, Centene Corp., Haven Behavioral Healthcare Inc., Headspace Inc., Kliniken Schmieder Foundation and Co. KG, Niznik Behavioral Health, People Care Inc., Promises Behavioral Health LLC, RHA Health Services, Springstone Inc., THE BALANCE, Universal Health Services Inc., and Veda Rehabilitation and wellness Pvt. Ltd.. Also, the behavioral rehabilitation market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.\u003c\/p\u003e\n\n\u003cp\u003eThe study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.\u003c\/p\u003e \n\n\u003cp\u003eThe publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 155 Pages \/ MCW16248275","offer_id":47648659702066,"sku":null,"price":3000.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-mental-health-software-market-2023-2030","title":"Global Mental Health Software Market - 2023-2030","description":"\u003cp\u003eGlobal Mental Health Software Market - 2023-2030\u003cbr\u003e\nGlobal Mental Health Software Market reached US$ 2.6 billion in 2022 and is expected to reach US$ 7.5 billion by 2030, growing with a CAGR of 15.2% during the forecast period 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eAs societies openly discuss mental health issues so the demand for accessible and effective solution rises and there is also growing concerns regarding mental health and the need for better mental health care. The stigma around mental health is decreasing day by day and also encouraging individuals to talk about their mental health and seek treatments. Mental health software offers a private platform and discreet way to access support.\u003c\/p\u003e\n\n \u003cp\u003eThe proliferation of telehealth and remote care solutions, accelerated by the COVID-19 pandemic, has extended to mental health care. Teletherapy and remote counseling sessions have become more common and mental health software plays a key role in facilitating these services. Increasing attention related to workplace mental health led to the implementation of mental health software. According to data.gov, mental health treatment increases from 84,700 to 88,950.\u003c\/p\u003e\n\n\u003cp\u003eAsia-Pacific is among the growing regions in the global mental health software market holding about 1\/4th of the market. The region has witnessed a rise in awareness which is driven by public campaigns. As there is a high percentage of smartphone user’s mental health software has easily reached a large number of populations. According to the report by WHO in India, there are 2443 disability-adjusted and 100000 population, the economic loss from mental health conditions is estimated at US$ 1.03 trillion.\u003c\/p\u003e\n\n \u003cp\u003eDynamics\u003c\/p\u003e\n\n\u003cp\u003eGovernment Awareness Boosts the Market\u003c\/p\u003e\n\n\u003cp\u003eGovernment increases awareness campaigns that bring mental health issues into the spotlight and leads to an increase in public campaigns that recognize the importance of mental well-being and encourage conversations around mental health. Government campaigns and awareness reduces the stigma associated with mental health problems, making individuals more comfortable. For instance, on 12 May 2023, colleges in Odisha announces Mo College Abhiyan under higher education and signed MoU with the Indian psychiatric society.\u003c\/p\u003e\n\n\u003cp\u003eFor instance, on 5 October 2021, Union Minister for Health and Family Welfare, Shri Mansukh Mandaviya emphasized the importance of mental health because the health of a person is an integral part of overall well-being. On 10 October worlds mental health day, the union ministry of Health and family welfare observes the mental health awareness campaign and this global day were dedicated to raising awareness about mental health concerns.\u003c\/p\u003e\n\n \u003cp\u003eCollaboration Between Companies\u003c\/p\u003e\n\n \u003cp\u003eCollaborations allow companies to integrate their specialized offerings to create comprehensive solutions. For example, partnerships between software providers and healthcare organizations can result in platforms that combine assessment tools, electronic health records, practice management and patient communication tools and this comprehensive approach enhances the value proposition for healthcare providers and improves patient care.\u003c\/p\u003e\n\n\u003cp\u003eFor instance, On 15 August 2023, Mental Health Technologies announced a partnership with Meditab Software, a prominent healthcare solutions provider, to integrate its all-inclusive Electronic Health Record system, Intelligent Medical Software, with mental health technologies' automated behavioral health assessment software and this partnership with Meditab's, which serves thousands of healthcare professionals and clinics, aims to streamline patient assessments and enhance medical practice workflows.\u003c\/p\u003e\n\n \u003cp\u003eAdvancement in Technologies\u003c\/p\u003e\n\n \u003cp\u003eThe rise in the telehealth platforms and teletherapy services revolutionized mental health care. The integration of video conferencing, real-time chat and secure messaging within mental health software allows individuals to receive therapy and counseling services remotely and the adoption of these technologies increased the accessibility of mental health services, especially for those in remote areas or with mobility constraints.\u003c\/p\u003e\n\n\u003cp\u003eFor instance, on 17 August 2023, Unite Us, a leading software company focused on improving health and well-being through cross-sector collaboration, introduced a new secure chat feature called Unite Us Chat and this feature is integrated into the Unite Us Platform and is designed to enhance real-time collaboration for comprehensive care delivery. By enabling direct communication between organizations within the platform, Unite Us Chat aims to overcome barriers to accessing essential social services and drivers of health.\u003c\/p\u003e\n\n\u003cp\u003eStrong Therapeutic Conditions\u003c\/p\u003e\n\n \u003cp\u003eMany mental health software solutions rely on digital communication platforms and virtual interactions which lack depth and had nuances of face-to-face interactions between a patient and a mental health professional. Some individuals may find it challenging to establish a strong therapeutic alliance without the physical presence of a clinician. As there are some individuals and lack of in-person engagement leads to increase difficulties.\u003c\/p\u003e\n\n \u003cp\u003eSome mental health software provides tools, resources and self-healing strategies, it should not replace professional mental health care, especially for individuals with severe or complex mental health conditions. In some cases, misusing or over-relying on software could delay or hinder appropriate treatment and these factors downfalls the growth of the mental health software market.\u003c\/p\u003e\n\n\n\n\u003cp\u003eSegment Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe global mental health software market is segmented based on component, delivery model, functionality, end-user and region.\u003c\/p\u003e\n\n\u003cp\u003eAdoption of Mobile Apps Boosts the Software Segment’s Growth\u003c\/p\u003e\n\n\u003cp\u003eThe software segment is expected to be the major segment fueling the market growth with a share of about 1\/3rd in 2022. Mobile apps are designed for mental health users with tools that are used for self-care, stress management and meditation and these apps often offer exercises and mindful practices also educational content that supports individuals in managing their mental well-being on day-to-day basics. Online platforms connect individuals seeking mental health support and in online apps there are licensed therapists based on their preferences.\u003c\/p\u003e\n\n\u003cp\u003eBspr Inc. and BHQ Corp. jointly introduced the beta version of the \"\"Braincure\"\" smartphone app, featuring the internationally standardized Brain Healthcare Quotient brain health index and 18 Guidelines for Your Brain Health and this innovative app, launched in California, U.S. from September 2023, is designed to estimate and enhance brain health through daily activities aligned with BHQ Actions.\u003c\/p\u003e\n\n\u003cp\u003eGeographical Penetration\u003c\/p\u003e\n\n\u003cp\u003eAdvanced Technology and Clinical Solution in North America\u003c\/p\u003e\n\n\u003cp\u003eNorth America is the dominant region in the global mental health software market covering more than 1\/3rd of the market. The region witnessed an increase in mental health awareness which led to have increased demand for accessible and effective mental health solutions. It has advanced technology and a digital platform that facilitated the development and adoption of mental health software platforms.\u003c\/p\u003e\n\n \u003cp\u003eFor instance, on 26 July 2023, Rethink Behavioral Health partnered with Netsmart, a leading healthcare software and solutions provider, to integrate their autism care resources and Applied Behavior Analysis clinical solution with the Netsmart CareFabric platform and this collaboration aims to enhance the accessibility and quality of care for individuals with autism and intellectual and developmental disabilities.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eThe major global players in the market include Advanced Data Systems, Cerner, Core Solutions, AdvancedMD, Kareo, Netsmart, Nextgen Healthcare, The Echo Group, Mediware and Allscripts.\u003c\/p\u003e\n\n\u003cp\u003eCOVID-19 Impact Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe pandemic led to increased stress, anxiety and depression due to factors like social isolation, health concerns and economic uncertainty and this surge in mental health issues resulted in a higher demand for mental health services and software solutions to provide support and interventions. Lockdowns and social distancing measures in place for in-person mental health services became challenging. Mental health software solutions had to adapt to enable remote consultations and therapy sessions through video conferencing and virtual platforms.\u003c\/p\u003e\n\n\u003cp\u003eMental health software played a crucial role in providing tools for remote monitoring and self-care. Apps and platforms offered resources for managing stress, anxiety and mental well-being at home. The pandemic accelerated the development and adoption of digital therapeutic interventions and these interventions include mobile apps, online cognitive behavioral therapy programs and virtual reality-based therapies that individuals could access remotely.\u003c\/p\u003e\n\n\u003cp\u003eAI Impact\u003c\/p\u003e\n\n\u003cp\u003eAI algorithms analyze vast amounts of patient data to generate personalized treatment plans based on individual needs, symptoms and history, this can lead to more targeted and effective interventions, ensuring that each patient receives tailored care. AI-powered tools can analyze patterns in patient behavior, speech and language to detect early signs of mental health conditions. and these tools enable timely intervention and preventive measures, potentially reducing the severity of disorders.\u003c\/p\u003e\n\n\u003cp\u003eAI algorithms can process large datasets to identify trends, treatment outcomes and risk factors associated with mental health conditions, this data-driven approach helps mental health professionals refine their practices and make evidence-based decisions. AI-powered teletherapy platforms facilitate remote mental health consultations and these platforms analyze facial expressions, tone of voice and others to provide therapists with valuable insights during virtual sessions.\u003c\/p\u003e\n\n\u003cp\u003eFor instance, on 16 August 2023, Abridge, a startup specializing in generative AI-powered medical note-taking, secured significant partnerships to expand the utilization of its technology in the healthcare sector. One of these partnerships involves collaboration with Epic, a prominent electronic health record provider. Abridges generative AI for clinical documentation will be integrated into Epic's EHR workflow as part of Epic's \"\"Partners and Pals\"\" program, which aims to foster collaborations with various vendors.\u003c\/p\u003e\n\n\u003cp\u003eRussia- Ukraine War Impact\u003c\/p\u003e\n\n \u003cp\u003eThe ongoing war-associated stress across people leads to a higher demand for mental health services, including software tools that offer counseling, therapy and resources to help individuals cope with anxiety, trauma and other mental health issues resulting from the war. The conflict impact on individuals that leads to exposed to traumatic events can result in post-traumatic stress disorder and other trauma-related conditions. Mental health software could play a crucial role in providing resources for managing and treating these conditions remotely.\u003c\/p\u003e\n\n\u003cp\u003eMental health software that offers remote counseling and therapy sessions could bridge this gap and provide individuals with access to much-needed support. Mental health software might also be utilized to promote community resilience and support networks among affected populations. Virtual support groups, community forums and educational resources can help individuals connect and share their experiences while fostering a sense of solidarity.\u003c\/p\u003e\n\n\u003cp\u003eBy Component\u003cbr\u003e\n* Software\u003cbr\u003e\n* Services\u003c\/p\u003e\n\n\u003cp\u003eBy Delivery Model\u003cbr\u003e\n* Subscription Models\u003cbr\u003e\n* Ownership Models\u003c\/p\u003e\n\n\u003cp\u003eBy Functionality\u003cbr\u003e\n* Clinical Functionality\u003cbr\u003e\n* Administrative Functionality\u003cbr\u003e\n* Financial Functionality\u003c\/p\u003e\n\n\u003cp\u003eBy End-User\u003cbr\u003e\n* Community Clinics\u003cbr\u003e\n* Hospitals\u003cbr\u003e\n* Private Practices\u003cbr\u003e\n* Others\u003c\/p\u003e\n\n\u003cp\u003eBy Region\u003cbr\u003e\n* North America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\n* Europe\u003cbr\u003e\nGermany\u003cbr\u003e\nUK\u003cbr\u003e\nFrance\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nRest of Europe\u003cbr\u003e\n* South America\u003cbr\u003e\nBrazil\u003cbr\u003e\nArgentina\u003cbr\u003e\nRest of South America\u003cbr\u003e\n* Asia-Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nRest of Asia-Pacific\u003cbr\u003e\n* Middle East and Africa\u003c\/p\u003e\n\n\u003cp\u003eKey Developments\u003cbr\u003e\n* On 17 August 2023, Peloton announced the launch of its new initiative Peloton for Business that offers a range of B2B wellbeing solutions across various sectors, this full-service offering includes equipment and content-based solutions, aimed at empowering individuals with access to Peloton's fitness and wellness classes.\u003cbr\u003e\n* On 2 August 2023, The Delaware Division of Public Health and the Delaware Division of Professional Regulation introduced significant enhancements to the Mental Health and Substance Use Disorder section of the My Healthy Community Dashboard and these improvements are found in the Prescription Monitoring Program tab and provide insights into prescription drug dispensing trends in Delaware.\u003cbr\u003e\n* On 15 May 2023, TELUS Health introduced \"\"Total Mental Health,\"\" a groundbreaking solution designed to offer employees access to a dedicated team of care professionals. The service entails personalized care journeys that encompass unlimited mental health counseling, therapist-guided iCBT (internet-based cognitive behavioral therapy) programs, digital tools, assessments and continuous tracking and feedback.\u003c\/p\u003e\n\n\u003cp\u003eWhy Purchase the Report?\u003cbr\u003e\n* To visualize the global mental health software market segmentation based on component, delivery model, functionality, end-user and region, as well as understand key commercial assets and players.\u003cbr\u003e\n* Identify commercial opportunities by analyzing trends and co-development.\u003cbr\u003e\n * Excel data sheet with numerous data points of mental health software market-level with all segments.\u003cbr\u003e\n* PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.\u003cbr\u003e\n* Product mapping available as excel consisting of key products of all the major players.\u003c\/p\u003e\n\n\u003cp\u003eThe global mental health software market report would provide approximately 69 tables, 66 figures and 202 pages.\u003c\/p\u003e\n\n\u003cp\u003eTarget Audience 2023\u003cbr\u003e\n• Manufacturers\/ Buyers\u003cbr\u003e\n• Industry Investors\/Investment Bankers\u003cbr\u003e\n• Research Professionals\u003cbr\u003e\n• Emerging Companies\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 202 Pages \/ MCW16248276","offer_id":47648661602610,"sku":null,"price":5220.0,"currency_code":"USD","in_stock":true}]},{"product_id":"hemoglobin-a1c-testing-devices-and-kits-market","title":"Hemoglobin A1c Testing Devices and Kits Market","description":"\u003cp\u003eHemoglobin A1c Testing Devices and Kits Market\u003c\/p\u003e\n\n\u003cp\u003eReport Scope:\u003c\/p\u003e\n\n\u003cp\u003eThis report aims to provide a comprehensive study of the global market for Hemoglobin A1c Testing Devices \u0026amp; Kits. It describes the different types of Hemoglobin A1c Testing Devices \u0026amp; Kits products, technology, and their current and historical market revenues.\u003c\/p\u003e\n\n\u003cp\u003eThis report discusses the implications of the trends mentioned above in the context of the current size and growth of the diabetes market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M\u0026amp;A activity. Five-year global sales forecasts are provided for the leading drug and device categories as well as breakdowns of the diabetes market by country.\u003c\/p\u003e\n\n\u003cp\u003eMajor players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the Market for Hemoglobin A1c Testing Devices and Kits.\u003c\/p\u003e\n\n\u003cp\u003eThis report segments the global market by these geographic regions: North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data is provided for 2022 as the base year, 2023, and forecast through year-end 2028.\u003c\/p\u003e\n\n\u003cp\u003eReport Includes:\u003c\/p\u003e\n\n\u003cp\u003e131 data tables and 46 additional tables\u003c\/p\u003e\n\n\u003cp\u003eAn overview of the global market landscape related to the hemoglobin A1c testing devices and kits\u003c\/p\u003e\n\n\u003cp\u003eIn-depth analysis of global market trends, featuring historical revenue data for 20202022, estimated figures for 2023, as well as forecasts for 2023-2028. This analysis includes projections of Compound Annual Growth Rates (CAGRs) spanning through 2028\u003c\/p\u003e\n\n\u003cp\u003eEvaluation of the current market size and revenue growth prospects specific to hemoglobin A1c testing devices and kits, accompanied by a comprehensive market share analysis categorized by technology, end user, and geographical region\u003c\/p\u003e\n\n\u003cp\u003eUnderstanding of the upcoming market potential for hemoglobin A1c test devices and kits, and areas of focus to forecast this market into various segments and sub-segments\u003c\/p\u003e\n\n\u003cp\u003eIn-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, regulations, prospects, and contributions to the overall market\u003c\/p\u003e\n\n\u003cp\u003eDiscussion of the role and importance of ESG in HbA1c test devices and kits market, consumer attitudes, risks and opportunity assessment, and ESG practices in the industry\u003c\/p\u003e\n\n\u003cp\u003eIdentification of the major stakeholders and analysis of their company competitive landscape based on recent developments, key financials and segmental revenues, and operational integration\u003c\/p\u003e\n\n\u003cp\u003eDetailed profiles of leading market participants including Abbott, Siemens Healthineers, Bayer AG, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., and Bio-Rad Laboratories Inc., providing a descriptive overview of their respective businesses\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 282 Pages \/ MCW16248277","offer_id":47648669827378,"sku":null,"price":6600.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-gynecology-surgical-devices-market-2023-2030","title":"Global Gynecology Surgical Devices Market - 2023-2030","description":"\u003cp\u003eGlobal Gynecology Surgical Devices Market - 2023-2030\u003cbr\u003e\nGlobal Gynecology Surgical Devices Market reached US$ 8.7 billion in 2022 and is expected to reach US$ 16.1 billion by 2030, growing with a CAGR of 6.5% during the forecast period 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eThe range of gynecology surgery instruments includes curettes and scoops, hysterectomy instruments, uterine dilators, probes, vulva and urethral spreaders, vaginal speculums, and myoma screws and knives. The increase in the number of launches and increase in the strategies by the companies are expected to drive the market growth.\u003c\/p\u003e\n\n \u003cp\u003eThe North America region is expected to hold a significant position in the market share. The increase in the number of launches by the key companies and their collaborations are expected to hold the region in the dominant position. The hysteroscopy segment holds a significant market share. The increased number of treatment launches associated with the devices expected to hold the segment in the leading position.\u003c\/p\u003e\n\n \u003cp\u003eDynamics\u003c\/p\u003e\n\n\u003cp\u003eIncreased Number of Launches of the Devices are Expected to Accelerate the Market Growth\u003c\/p\u003e\n\n\u003cp\u003eAn increased number of product launches and an increase in technological advancements will drive market growth. The launches of highly advanced products also contribute to the growth of the market. For instance, on 01 November 2022, India Medtronic, a wholly owned subsidiary of Medtronic plc, stated the launch of the TruClear system, a mechanical hysteroscopic tissue removal system used for the safe and effective treatment of intrauterine abnormalities (IUA).\u003c\/p\u003e\n\n \u003cp\u003eAdditionally, on June 06, 2023, Ceek Women's Health, a medical device company, launched the Nella Single-Use Vaginal Speculum with Integrated Sidewall Retractors and LED Light. The Nella Single-Use vaginal speculum is a unique product that combines several features into one easy-to-use device. Thus, the launches of the devices are expected to drive the market growth.\u003c\/p\u003e\n\n\u003cp\u003eIncrease in the Gynecological Surgeries  are Expected to Drive the Market Growth\u003c\/p\u003e\n\n\u003cp\u003eIncrease in the number of gynecological surgeries is expected to drive the market growth. The increase in the number of hysterectomy surgeries is expected to drive the market growth. For instance, according to the Regents of the University of Michigan, Hysterectomy is the second most common surgery performed on reproductive-age women in the U.S. after cesarean section. More than 400,000 hysterectomies are performed in the U.S. each year, with nearly 68 percent done for benign conditions that involve abnormal uterine bleeding, uterine fibroids, and endometriosis.\u003c\/p\u003e\n\n \u003cp\u003eAdditionally, according to NHS England, it is estimated that 235,223 referrals to colposcopy were reported in 2021-22, an increase of 33.2% from 2020-21 (176,561). 67.7% of referrals were reported as being triggered by a screening test, and 20.8% of referrals were clinically indicated as the women holding the symptoms of cervical abnormality. Thus, the increase in the number of coloscopy procedures is also involved in driving the market growth. Safety Issues Associated with Few Gynecology Surgical Devices are Expected to Hamper the Market Growth.\u003c\/p\u003e\n\n\u003cp\u003eSome of the complications of the surgical devices are infection, abdominal wall hematoma, and postoperative urinary retention. Short-term voiding dysfunction after placement of a synthetic mid-urethral sling is common. Additionally, the cost associated with the devices can affect the market growth. High costs of the devices create alternative choices and options for the patients. Furthermore, stringent regulatory approval procedures to ensure product safety are restraining the market's growth.\u003c\/p\u003e\n\n\u003cp\u003eSegment Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe global gynecology surgical devices market is segmented based on product type, application, end-user, and region.\u003c\/p\u003e\n\n\u003cp\u003eHysteroscopy Segment Holds a Significant Position in the Market Share\u003c\/p\u003e\n\n\u003cp\u003eThe increased number of launches of hysteroscopy devices is holding the segment in the dominant market share. For instance, on September 30, 2021, Hologic, Inc., a global leader in women's health, has launched its expanded Omni suite, a comprehensive gynecological surgical offering designed to optimize diagnostic and operative hysteroscopy in Europe, Africa, and the Middle East (EMEA). The offering includes a versatile Omni 30° hysteroscope, the Omni Lok cervical seal and the Omni 5 French seal, which complement the company’s existing portfolio of GYN surgical solutions and extend physicians’ choices.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, on July 27, 2023, GenWorks, a healthcare solutions provider launched  its mechanical hysteroscopic tissue removal system which uses a simple mechanical approach for removing intrauterine tissues. This is an effective solution that offers better access and improved outcomes. Thus, increase in the number of launches of the hysteroscopes are elevating the market growth.\u003c\/p\u003e\n\n \u003cp\u003eGeographical Penetration\u003c\/p\u003e\n\n\u003cp\u003eNorth America Holds the Largest Market Share in the Global Gynecology Surgical Devices Market\u003c\/p\u003e\n\n\u003cp\u003eNorth America is expected to hold a significant market share. The increased number of company collaborations and launches of the products in the region are holding the region in the leading market share. For instance, on November 30, 2022, Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures launched the moresolution Power Morcellator, which is manufactured by TROKAMED GmbH and is available in the U.S. through a distribution agreement with Olympus America, Inc. The moresolution Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens.\u003c\/p\u003e\n\n \u003cp\u003eOn August 12, 2021, Innovia Medical launched a single-use instrument product line called Cervical Rotating Biopsy Punch in the U.S. It supports urgently needed procedures like cancer diagnosis. Thus, the number of launches of the products in the region by the major players expands the growth of the region in the market share.\u003c\/p\u003e\n\n \u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eThe global gynecology surgical devices market is fragmented, with the presence of many local and international players. Ethicon Inc., Cooper Companies Inc., Medtronic, Hologic, Inc., KARL STORZ SE \u0026amp; Co. KG, Boston Scientific Corporation, Olympus Corporation, Stryker, SternMed GmbH., and Richard Wolf GmbH  are the leading Companies with a significant market share.\u003c\/p\u003e\n\n \u003cp\u003eCOVID-19 Impact Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global gynecological surgical devices market growth. The COVID-19 pandemic caused disruption in consultation for gynecological disease diagnoses such as abdominal diseases, uterine infections, and others. The delayed consultations have impacted the treatment processes and, thus, impacted the market growth.\u003c\/p\u003e\n\n\u003cp\u003eThe delay in manufacturing the surgical devices by the key companies and the stringent rules and regulations by the governments have impacted the market growth. Thus, COVID-19 has impacted the market growth negatively. Thus, this factor was anticipated to restrain the demand for gynecology surgical devices market and restrain the market growth.\u003c\/p\u003e\n\n\u003cp\u003eBy Product Type\u003cbr\u003e\n• Trocars\u003cbr\u003e\n • Vaginal Speculums\u003cbr\u003e\n• Uterine Curettes\u003cbr\u003e\n• Scissors\u003cbr\u003e\n• Needle Holders\u003cbr\u003e\n• Dilators\u003cbr\u003e\n• Uterine Depressors\u003c\/p\u003e\n\n\u003cp\u003eBy End-User\u003cbr\u003e\n• Hospitals\u003cbr\u003e\n• Clinics\u003cbr\u003e\n• Ambulatory Surgical Centers\u003c\/p\u003e\n\n\u003cp\u003eBy Region\u003cbr\u003e\n• North America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\n• Europe\u003cbr\u003e\nGermany\u003cbr\u003e\nUK\u003cbr\u003e\nFrance\u003cbr\u003e\nItaly\u003cbr\u003e\nSpain\u003cbr\u003e\nRest of Europe\u003cbr\u003e\n• South America\u003cbr\u003e\nBrazil\u003cbr\u003e\nArgentina\u003cbr\u003e\nRest of South America\u003cbr\u003e\n• Asia-Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nRest of Asia-Pacific\u003cbr\u003e\n• Middle East and Africa\u003c\/p\u003e\n\n\u003cp\u003eWhy Purchase the Report?\u003cbr\u003e\n• To visualize the global gynecology surgical devices market segmentation based on product type, end-user, and region, as well as understand key commercial assets and players.\u003cbr\u003e\n• Identify commercial opportunities by analyzing trends and co-development.\u003cbr\u003e\n • Excel data sheet with numerous data points of gynecology surgical devices market-level with all segments.\u003cbr\u003e\n• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.\u003cbr\u003e\n• Product mapping available as excel consisting of key products of all the major players.\u003c\/p\u003e\n\n\u003cp\u003eThe global gynecology surgical devices market report would provide approximately 61 tables, 58 figures, and 186 Pages.\u003c\/p\u003e\n\n\u003cp\u003eTarget Audience 2023\u003cbr\u003e\n• Manufacturers\/ Buyers\u003cbr\u003e\n• Industry Investors\/Investment Bankers\u003cbr\u003e\n• Research Professionals\u003cbr\u003e\n• Emerging Companies\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 186 Pages \/ MCW16248278","offer_id":47648671760690,"sku":null,"price":5220.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-ophthalmology-devices-market-2023-2027","title":"Global Ophthalmology Devices Market 2023-2027","description":"\u003cp\u003eGlobal Ophthalmology Devices Market 2023-2027\u003cbr\u003e\nThe ophthalmology devices market is forecasted to grow by USD 19.93 bn during 2022-2027, accelerating at a CAGR of 4.65% during the forecast period. The report on the ophthalmology devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\u003c\/p\u003e\n\n\u003cp\u003eThe report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of ophthalmic diseases, technological advances in ophthalmology devices, and a rising number of initiatives to increase awareness and customer training.\u003c\/p\u003e\n\n\u003cp\u003eTechnavio's ophthalmology devices market is segmented as below:\u003c\/p\u003e\n\n\u003cp\u003eBy ProductVision careOphthalmology surgical devicesOphthalmology diagnostic devicesBy End-userHospitals and eye clinicsAcademic and research laboratoriesOthersBy Geographical LandscapeNorth AmericaEuropeAsiaRest of World (ROW)This study identifies the increasing medical tourism for low-cost ophthalmology surgeries as one of the prime reasons driving the ophthalmology devices market growth during the next few years. Also, the rising focus of vendors to strengthen their presence in emerging markets and strategic collaborations and M\u0026amp;A will lead to sizable demand in the market.\u003c\/p\u003e\n\n\u003cp\u003eThe report on the ophthalmology devices market covers the following areas:Ophthalmology devices market sizingOphthalmology devices market forecastOphthalmology devices market industry analysisThe robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading ophthalmology devices market vendors that include Alcon Inc., Lumenis Be Ltd., Bausch Health Companies Inc., Carl Zeiss AG, Danaher Corp., EssilorLuxottica, HOYA CORP., Johnson and Johnson, NIDEK Co. Ltd., The Cooper Companies Inc., LUMIBIRD SA, EyeQue Corp., Glaukos Corp., Digital Diagnostics Inc., IRIDEX Corp., TOPCON CORP., Metall Zug AG, LENSAR Inc., STAAR Surgical Co., and Ziemer Ophthalmic Systems AG. Also, the ophthalmology devices market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.\u003c\/p\u003e\n\n\u003cp\u003eThe study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.\u003c\/p\u003e \n\n\u003cp\u003eThe publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 173 Pages \/ MCW16248279","offer_id":47648671858994,"sku":null,"price":3000.0,"currency_code":"USD","in_stock":true}]},{"product_id":"mental-health-substance-abuse-services","title":"Mental Health \u0026 Substance Abuse Services","description":"\u003cp\u003eMental Health \u0026amp; Substance Abuse Services\u003cbr\u003e\nBrief Excerpt from Industry Overview Chapter:\u003c\/p\u003e\n\n\u003cp\u003eCompanies in this industry provide outpatient and residential care and treatment for individuals with mental health and substance abuse illnesses. Major companies include Acadia Healthcare, Hazelden Betty Ford Foundation, and Spectrum Health (all based in the US), along with the Centre for Addiction and Mental Health (Canada) and the Crossroads Centre Antigua.\u003c\/p\u003e\n\n\u003cp\u003eCOMPETITIVE LANDSCAPE\u003c\/p\u003e\n\n\u003cp\u003eDemand for mental health and substance abuse services is driven by availability of new drugs and treatments and funding policies of health care insurance programs. The profitability of individual facilities depends on controlling costs and attracting physician referrals. Large companies have advantages in group purchasing and in marketing to physicians and managed health care companies. Small facilities compete effectively by providing superior patient service, integrating treatment with follow-up procedures, and specializing by treatment or demographic group.\u003c\/p\u003e\n\n\u003cp\u003ePRODUCTS, OPERATIONS \u0026amp; TECHNOLOGY\u003c\/p\u003e\n\n\u003cp\u003eOutpatient facilities account for about 60% of industry revenue; residential facilities account for about 40%. Revenue for mental health and substance abuse facilities comes primarily from patient care. Nonprofit organizations such as Hazelden Betty Ford also receive government grants and private contributions. About two-thirds of mental health and substance abuse service providers are nonprofit organizations.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ - \/ MCW16248280","offer_id":47648671924530,"sku":null,"price":155.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-breast-cancer-diagnostics-market-2023-2030","title":"Global Breast Cancer Diagnostics Market - 2023-2030","description":"\u003cp\u003eGlobal Breast Cancer Diagnostics Market - 2023-2030\u003cbr\u003e\nGlobal Breast Cancer Diagnostics Market reached US$ XX billion in 2022 and is expected to reach US$ XX  billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eAccording to the World Health Organization, breast cancer is the most commonly diagnosed type of cancer globally. The number of registered diagnostic breast cancer cases ase count has been estimated to climb from about 2.3 million new diagnoses in 2020 and is expected to more than 3 million in 2040. Invasive ductal carcinoma is the most common type of breast cancer, which starts in the mammary glands and spreads to nearby tissue. For every 10 breast cancer cases, 7 to 8 are invasive ductal carcinoma.\u003c\/p\u003e\n\n  \u003cp\u003eAging is one of the most prevalent causes of breast cancer in women. According to the American Cancer Society, in February 2022, 1 out of 8 women younger than 45 years, 2 out of 3 in 55 years or older.\u003c\/p\u003e\n\n\u003cp\u003eDynamics\u003c\/p\u003e\n\n\u003cp\u003eAdvancements in diagnostic technologies\u003c\/p\u003e\n\n \u003cp\u003eAdvancements in breast cancer screening provide better outcomes when compared to conventional mammography. Integrating Artificial intelligence and deep learning makes breast cancer screening more accurate and reliable. Integration of machine learning with diagnostic techniques lead to more accurate treatment outcomes in breast cancer patients.\u003c\/p\u003e\n\n \u003cp\u003eFor instance,  in January 2022, Duke University researchers created an Artificial Intelligence (AI) platform to analyze potentially cancerous lesions in mammography scans and determine whether patients should receive invasive biopsies. This AI helped to detect suspicious lesions that could be used to train students on how to read mammography images and can help physicians make health care decisions. Furthermore, this AI technology could be used for making wise decisions.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, in February 2023, FathomX Pte Ltd. launched mammography using AI and deep learning to conduct R\u0026amp;D for early breast cancer diagnosis. In mammography-based breast cancer screening, the company's proprietary AI technology makes it possible to detect signs of cancerous tissue on X-ray images more quickly and accurately.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, the prevalence of breast cancer, the need for early diagnosis, and product approvals are a few factors that drive the market in the forthcoming period.\u003c\/p\u003e\n\n\u003cp\u003eFalse positive results\u003c\/p\u003e\n\n\u003cp\u003eFalse-positive results are more common in women who are younger, have dense breasts, have had breast biopsies, have breast cancer in the family, or are taking estrogen. About half of the women getting annual mammograms over a 10-year period will have a false-positive finding at some point. Past history reduces their odds of a false-positive finding by about half.\u003c\/p\u003e\n\n\u003cp\u003eSegment Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe global breast cancer diagnostics is segmented based on cancer type, test type, spread,  stage, end user, and region.\u003c\/p\u003e\n\n\u003cp\u003eThe  Mammography Segment Accounted for Approximately XX% of the Market Share\u003c\/p\u003e\n\n \u003cp\u003eEarly detection is crucial in improving breast cancer treatment. Innovations in screening methods have played a pivotal role in detecting breast cancer at its earliest stages. Digital mammography and tomosynthesis have replaced traditional film mammography, providing more precise and detailed images. Unlike conventional mammography, digital mammography and contrast-enhanced mammography offer better diagnosis and, thus, better treatment.\u003c\/p\u003e\n\n \u003cp\u003eFor instance, in January 2023, Bayer's iodine-based contrast agent Ultravist-300, -370 received the green light for indication extension for contrast-enhanced mammography (CEM) in a European Workshare Procedure. CEM is an emerging modality combining digital mammography with the administration of a contrast agent. Strategically expands Bayer's portfolio in breast imaging, including contrast agents and injectors. These factors are likely to increase the mammography segment in the forecast period.\u003c\/p\u003e\n\n  \u003cp\u003eGeographical Analysis\u003c\/p\u003e\n\n\u003cp\u003eNorth America accounted for Approximately XX% of the Market Share in 2022\u003c\/p\u003e\n\n\u003cp\u003eNorth America dominated the breast cancer diagnostics market in 2022. It is estimated to hold the largest market size over the forecast period (2022-2029) owing to rising breast cancer cases and increasing technological advancements in cancer diagnosis. For instance, as per the statistics from Breastcancer.org, as of January 2022, over 3.8 million women with a history of breast cancer in the U.S., and about 1 in 8 U.S. women (about 13%) in their lifetime would develop invasive breast cancer.\u003c\/p\u003e\n\n \u003cp\u003eIn 2022, around 287,850 new cases of invasive breast cancer were diagnosed in U.S. women, also 51,400 new cases of non-invasive (in situ) breast cancer. In 2022 about 2,710 new cases of invasive breast cancer were detected in men. In 2022, over about 43,250 women in the U.S. died from breast cancer. In addition, increasing development by manufacturers in breast cancer diagnostics is driving the market growth in this region.\u003c\/p\u003e\n\n \u003cp\u003eCOVID-19 Impact Analysis\u003c\/p\u003e\n\n\u003cp\u003eCOVID-19 has negatively impacted the global market during the outbreak since, to prevent the COVID-19 infection, various restrictions and regulations were employed, making it difficult for people to perform mammography and other breast cancer diagnostic tests affecting the market. Furthermore, a retrospective study of cases diagnosed by a reference service in the public health system of Campinas, SP, Brazil, concluded that amid the COVID-19 pandemic, breast cancer diagnoses declined. Moreover, the cases detected indicated a worsened prognosis as early detection was not performed.\u003c\/p\u003e\n\n\u003cp\u003eMany healthcare facilities postponed non-urgent procedures and screenings, which affected the number of women getting regular tests. Additionally, fears of contracting the virus in healthcare settings and mobility restrictions further reduced screening rates. Due to these above factors, the market has seen a decline rate during the pandemic period.\u003c\/p\u003e\n\n\u003cp\u003eBy Cancer Type\u003cbr\u003e\n• Invasive lobular breast cancer\u003cbr\u003e\n• Ductal carcinoma in situ (DCIS)\u003cbr\u003e\n• Triple-negative breast cancer\u003cbr\u003e\n• Inflammatory breast cancer\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Test Type\u003cbr\u003e\n• Clinical Breast Exam\u003cbr\u003e\n• Imaging Tests\u003cbr\u003e\nMammogram\u003cbr\u003e\n MRI\u003cbr\u003e\n Ultrasound\u003cbr\u003e\n PET\u003cbr\u003e\n Others\u003cbr\u003e\n• Blood Tests\u003cbr\u003e\n• Biopsies\u003cbr\u003e\nExcisional biopsy\u003cbr\u003e\n Incisional biopsy\u003cbr\u003e\n Core biopsy\u003cbr\u003e\n Fine-needle aspiration (FNA) biopsy\u003cbr\u003e\n Others\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Spread\u003cbr\u003e\n• Local\u003cbr\u003e\n• Regional\u003cbr\u003e\n• Distant\u003c\/p\u003e\n\n\u003cp\u003eBy Stage\u003cbr\u003e\n• I\u003cbr\u003e\n• II\u003cbr\u003e\n• III\u003cbr\u003e\n• IV\u003c\/p\u003e\n\n\u003cp\u003eBy End User\u003cbr\u003e\n• Hospitals and Clinics\u003cbr\u003e\n• Cancer Diagnostic Centers\u003cbr\u003e\n• Cancer Research Institutes\u003cbr\u003e\n• Medical Research Centers and Institutes\u003cbr\u003e\n• Ambulatory Surgical Centers\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Region\u003cbr\u003e\n• North America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\n• Europe\u003cbr\u003e\nGermany\u003cbr\u003e\nU.K.\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nRest of Europe\u003cbr\u003e\n• South America\u003cbr\u003e\nBrazil\u003cbr\u003e\nArgentina\u003cbr\u003e\nRest of South America\u003cbr\u003e\n• Asia-Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nRest of Asia-Pacific\u003cbr\u003e\n• Middle East and Africa\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eThe major global players in the breast cancer diagnostics market include Siemens Healthineers AG, Kheiron Medical Technologies, Bio-Rad Laboratories, Hologic, Inc., Quest Diagnostics Incorporated, FUJIFILM Holdings Corporation, GE Healthcare, Illumina, Inc., Metaltronica SpA, and Carestream Health among others.\u003c\/p\u003e\n\n\u003cp\u003eKey Developments\u003cbr\u003e\n• In May 2022, the U.S. Department of Health and Human Services (HHS), declared the availability of US$ 5 million for community health centers, funded by HHS’s Health Resources and Services Administration, to increase equitable access to life-saving breast cancer screenings.\u003cbr\u003e\n• In March 2022, Niramai received US FDA clearance for their first medical device, SMILE-100 System (breast thermography).\u003c\/p\u003e\n\n\u003cp\u003eWhy Purchase the Report?\u003cbr\u003e\n• To visualize the global breast cancer diagnostics segmentation based on cancer type, test type, spread, stage, end user, and region, as well as understand key commercial assets and players.\u003cbr\u003e\n• Identify commercial opportunities by analyzing trends and co-development.\u003cbr\u003e\n • Excel data sheet with numerous data points of breast cancer diagnostics market-level with all segments.\u003cbr\u003e\n• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.\u003cbr\u003e\n• Product mapping available as Excel consisting of key products of all the major players.\u003c\/p\u003e\n\n\u003cp\u003eThe global breast cancer diagnostics market report would provide approximately 53 tables, 54 figures, and 195 Pages.\u003c\/p\u003e\n\n\u003cp\u003eTarget Audience 2023\u003cbr\u003e\n• Manufacturers\/ Buyers\u003cbr\u003e\n• Industry Investors\/Investment Bankers\u003cbr\u003e\n• Research Professionals\u003cbr\u003e\n• Emerging Companies\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 195 Pages \/ MCW16248281","offer_id":47648671990066,"sku":null,"price":5220.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-cervical-cancer-diagnostics-market-2023-2030","title":"Global Cervical Cancer Diagnostics Market - 2023-2030","description":"\u003cp\u003eGlobal Cervical Cancer Diagnostics Market - 2023-2030\u003cbr\u003e\nGlobal Cervical Cancer Diagnostics Market reached US$ XX Million in 2022 and is expected to reach US$ XX  Million by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eCervical cancers are caused by the virus HPV, a sexually transmitted infection. HPV spreads through sexual contact (anal, oral, or vaginal) and can lead to cancer. Cervical cancer can be detected through various screening tests. The most common screening test for cervical cancer or precancerous cells (dysplasia) is the Pap test.\u003c\/p\u003e\n\n \u003cp\u003eAbout 80% to 90% of cervical cancers are squamous cell carcinomas, while 10% to 20% are adenocarcinomas. About 14,000 people in the United States are diagnosed with cervical cancer yearly. People between the ages of 35 and 44 are most frequently diagnosed with cervical cancer. The average age at diagnosis is 50. Around 4,000 people die of cervical cancer per year. This rate is on the decline due to screenings and the HPV vaccine.\u003c\/p\u003e\n\n\u003cp\u003eMarket Dynamics\u003c\/p\u003e\n\n\u003cp\u003eIncreasing product approvals\u003c\/p\u003e\n\n\u003cp\u003eEarly cervical cancer diagnosis decreases the burden of disease treatment as the cancer undergoes staging, which makes it harder to diagnose and treat the disease. The leading cause of cervical cancer is the human papillomavirus. Hence, an HPV test is done to diagnose cervical cancer. The development of new HPV tests can increase the chance of accuracy compared to obsolete tests like pap smears. Increasing approvals makes it easier for the availability of the test kit in the market.\u003c\/p\u003e\n\n \u003cp\u003eFor instance, in June 2022, Karkinos Healthcare, an oncology-concentrated health-tech platform, introduced CerviRaksha. This foremost clinically validated HPV test is prequalified by the WHO and authorized by the FDA in collaboration with the Karkinos network clinic physicians and nursemaids.\u003c\/p\u003e\n\n\u003cp\u003eIn February 2023, Becton, Dickinson, and Company received approval from the U.S. Food and Drug Administration (FDA) for its BD Onclarity HPV Assay. The BD Onclarity HPV Assay detects human papillomavirus (HPV).\u003c\/p\u003e\n\n\u003cp\u003eThe increasing adoption of Artificial Intelligence and deep learning in cancer screening modalities, technological advancements in diagnostic procedures, and rising awareness about cervical cancer are a few factors that drive the market in the forthcoming period.\u003c\/p\u003e\n\n\u003cp\u003eFalse positive test results\u003c\/p\u003e\n\n\u003cp\u003eFalse-positive tests are defined as positive screening tests that are not eventually confirmed with high-grade cervical intraepithelial neoplasia (CIN). The growing false positive results are hampering the global cervical cancer diagnostics market growth in the forecast period. For instance, in a study for annual, 3-year, and 5-year triage testing (either LBC with HPV reflex or vice versa), the lifetime chance of a false positive is 35.1%, 13.4%, and 8.3% respectively.\u003c\/p\u003e\n\n\u003cp\u003eSegment Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe global cervical cancer diagnostics is segmented based on test type, cancer type, age group,  stage, end user, and region.\u003c\/p\u003e\n\n\u003cp\u003eThe HPV tests segment accounted for approximately xx% of the market share\u003c\/p\u003e\n\n \u003cp\u003eAn increase in the advancements in screening procedures made testing easy for diagnosing cervical cancer. Several Key companies such as F. Hoffmann-La Roche AG, SANSURE BIOTECH INC., and LifeCell International are developing HPV kits, making it easy for in-home screening of HPV among individuals.\u003c\/p\u003e\n\n \u003cp\u003eIn January 2022, SANSURE BIOTECH INC., an in-vitro diagnostic developments supplier, declared that its ‘HPV DNA Diagnostic Kit (HPV 13+2)’ was authorized by the China National Medical Products Administration (NMPA).\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, in June 2023, LifeCell International launched a self-sampling test kit to help detect cervical cancer-causing viruses. Hence, the product launch increase will drive the market in the forthcoming period.\u003c\/p\u003e\n\n\u003cp\u003eGeographical Analysis\u003c\/p\u003e\n\n\u003cp\u003eNorth America accounted for approximately XX% of the market share in 2022\u003c\/p\u003e\n\n\u003cp\u003eNorth America is estimated to dominate the global cervical cancer diagnostics market. For instance, January has been established as \"\"Cervical Health Awareness Month\"\" by the United States Congress.\u003c\/p\u003e\n\n \u003cp\u003eThe National Cervical Cancer Coalition (NCCC) and its multiple local chapters all over the nation increase awareness regarding cervical cancer, HPV disease, and the significance of earlier diagnosis during January. It is performed to increase community awareness regarding cervical cancer diagnosis and its complications after staging.\u003c\/p\u003e\n\n \u003cp\u003eIn May 2022, the U.S. Department of Health and Human Services (HHS), declared the availability of US$ 5 million for community health centers, funded by HHS’s Health Resources and Services Administration, to increase equitable access to life-saving cervical cancer screenings which makes the screening procedures cost-effective that leads to early detection of cervical cancer in US patients. Hence, the above factors are expected to hold the largest market share in the North American region.\u003c\/p\u003e\n\n\u003cp\u003eCOVID-19 Impact Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe market saw a rise in molecular diagnostic methods, such as HPV DNA testing, and a shift towards personalized medicine. HPV vaccination programs also played a role in preventing cervical cancer, but regular screening was still crucial for early detection and treatment. Increased demand for diagnosing and therapeutic devices has risen dramatically in hospitals. For instance, the need for ventilators, respirators, and in vitro diagnostic (IVD) tests has drastically increased in hospitals across the countries in the region.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation\u003c\/p\u003e\n\n\u003cp\u003eBy Test Type\u003cbr\u003e\n• Pap Smear test\u003cbr\u003e\n• Colposcopy test\u003cbr\u003e\n• HPV test\u003cbr\u003e\n• Imaging Tests\u003cbr\u003e\nPET\u003cbr\u003e\nMRI\u003cbr\u003e\nCT\u003cbr\u003e\nX-Ray\u003cbr\u003e\nOthers\u003cbr\u003e\n• Cervical Biopsies\u003cbr\u003e\nEndocervical curettage test\u003cbr\u003e\nLoop electrosurgical excision procedure (LEEP)\u003cbr\u003e\nConization (a cone biopsy)\u003cbr\u003e\nCystoscopy\u003cbr\u003e\nSigmoidoscopy\u003cbr\u003e\n• Biomarker testing\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Cancer Type\u003cbr\u003e\n• Squamous cell carcinoma\u003cbr\u003e\n• Adenocarcinoma\u003cbr\u003e\n• Small Cell Neuroendocrine Carcinoma\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Age Group\u003cbr\u003e\n• 20-30 years\u003cbr\u003e\n• Above 30 years\u003c\/p\u003e\n\n\u003cp\u003eBy Stage\u003cbr\u003e\n• Stage I\u003cbr\u003e\n• Stage II\u003cbr\u003e\n• Stage III\u003cbr\u003e\n• Stage IV\u003c\/p\u003e\n\n\u003cp\u003eBy End User\u003cbr\u003e\n• Hospitals and Clinics\u003cbr\u003e\n• Cancer Diagnostic Centers\u003cbr\u003e\n• Cancer Research Institutes\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Region\u003cbr\u003e\n• North America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\n• Europe\u003cbr\u003e\nGermany\u003cbr\u003e\nU.K.\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nRest of Europe\u003cbr\u003e\n• South America\u003cbr\u003e\nBrazil\u003cbr\u003e\nArgentina\u003cbr\u003e\nRest of South America\u003cbr\u003e\n• Asia-Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nRest of Asia-Pacific\u003cbr\u003e\n• Middle East and Africa\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eThe major global players in the cervical cancer diagnostics market include F. Hoffmann-La Roche AG, QIAGEN, DaAnGene, Molbio Diagnostics, Cepheid, Norgen Biotek Corp., Atila Diagnostics, Abbott Laboratories, Life Cell International, and Sansure Biotech among others.\u003c\/p\u003e\n\n\u003cp\u003eKey Developments\u003cbr\u003e\n• In June 2023 by LabMedica, low-cost DNA tests for HPV infections could improve access to cervical cancer screening. Rice University bioengineers have developed a low-cost, point-of-care DNA test for HPV infections.\u003cbr\u003e\n• In March 2023, Roche Products (India) Pvt. Ltd., signed a Memorandum of Understanding (MoU) with the Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organization dedicated to promoting cancer awareness, prevention, and early detection of cervical, ovarian cancer and other types of cancers.\u003c\/p\u003e\n\n \u003cp\u003eWhy Purchase the Report?\u003cbr\u003e\n• To visualize the global cervical cancer diagnostics segmentation based on test type, cancer type, age group, stage, end user, and region, as well as understand key commercial assets and players.\u003cbr\u003e\n• Identify commercial opportunities by analyzing trends and co-development.\u003cbr\u003e\n • Excel data sheet with numerous data points of cervical cancer diagnostics market-level with all segments.\u003cbr\u003e\n• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.\u003cbr\u003e\n• Product mapping available as Excel consisting of key products of all the major players.\u003c\/p\u003e\n\n\u003cp\u003eThe global cervical cancer diagnostics market report would provide approximately 77 tables, 82 figures, and 186 Pages.\u003c\/p\u003e\n\n\u003cp\u003eTarget Audience 2023\u003cbr\u003e\n• Manufacturers\/ Buyers\u003cbr\u003e\n• Industry Investors\/Investment Bankers\u003cbr\u003e\n• Research Professionals\u003cbr\u003e\n• Emerging Companies\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 186 Pages \/ MCW16248282","offer_id":47648672088370,"sku":null,"price":5220.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-rubella-diagnostic-testing-market-2023-2030","title":"Global Rubella Diagnostic Testing Market - 2023-2030","description":"\u003cp\u003eGlobal Rubella Diagnostic Testing Market - 2023-2030\u003cbr\u003e\nGlobal Rubella Diagnostic Testing Market reached US$ XX billion in 2022 and is expected to reach US$ XX  billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eMeasles is highly contagious. Around 9 out of 10 people who are not protected will become infected following exposure to the measles virus. A pregnant woman infected with rubella in early pregnancy has up to a 90% chance of giving birth to a baby with congenital rubella syndrome (CRS). One person with measles can infect 12-18 people, making it the most infectious yet vaccine-preventable disease.\u003c\/p\u003e\n\n\u003cp\u003eAround 9 out of 10 susceptible people (unvaccinated\/have never had measles) who are exposed to measles will get sick. 33% of infants with congenital rubella syndrome die before one year. Rubella IgG serology testing should be used for assessing rubella immunity, including before, during, and after pregnancy suspecting congenital rubella syndrome. Rubella infection during pregnancy can lead to miscarriage (loss of the fetus within 20 weeks of conception) and stillbirth (death after 20 weeks).\u003c\/p\u003e\n\n\u003cp\u003eMarket Dynamics\u003c\/p\u003e\n\n\u003cp\u003eIncreasing measles outbreaks in certain parts of the world\u003c\/p\u003e\n\n\u003cp\u003eThe Reoccurrence of measles outbreaks in some parts of the world increases diagnostic testing. According to the Centers for Disease Control and Prevention, although measles was declared eliminated in the United States in 2000, almost 1,300 cases of measles were reported in 31 states in the U.S. in 2019, the most significant number since 1992. According to data, the World Health Organization said in early August 2023, India had the highest number of measles cases compared to the rest of the world, with 57,550 cases as of 2023. Yemen with 24,596 and Pakistan with 10,549 patients.\u003c\/p\u003e\n\n\u003cp\u003eMeasles vaccines saved more than 56 million lives worldwide between 2000-2021. However, the numbers are declining due to its reoccurrence. Diagnostic testing comes into play to treat the disease in individuals living in specific regions where measles outbreaks are observed. According to the United Nations International Children's Emergency Fund (UNICEF), global vaccination coverage has recovered in 2022. However, there are still 20.5 million children missing out on lifesaving vaccines globally, 2.1 million more than in 2019.\u003c\/p\u003e\n\n \u003cp\u003eIn 2022, India accounted for 1.6 million unvaccinated and under-vaccinated children despite achieving 93 percent coverage. These reducing numbers make the reoccurrence of the disease in a few regions and immediately spread to other regions as well because the disease is highly contagious.  The outbreaks happen in those areas where the vaccination is at its lowest. Hence, the above factor is expected to drive the market in the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eSome of the other factors that drive the market are advancements in testing procedures, reoccurrence of rubella outbreaks, and decreased number of vaccinations are a few factors that are expected to drive the market in the forthcoming period.\u003c\/p\u003e\n\n\u003cp\u003eFalse positive test results in pregnant women\u003c\/p\u003e\n\n\u003cp\u003eRubella IgM testing should be limited to suspected rubella cases. It is not recommended for screening asymptomatic people. The presence of rheumatoid factor can also result in a false positive IgM. Due to the possibility of false positive results, IgM should not be included in routine testing to determine evidence of prior rubella immunity. Rubella IgM testing in asymptomatic, unexposed pregnant people is inappropriate because false positive results can occur, which can be misleading.\u003c\/p\u003e\n\n \u003cp\u003eSegment Analysis\u003c\/p\u003e\n\n\u003cp\u003eThe global rubella diagnostic testing is segmented based on diagnostic test, age group, end user, and region.\u003c\/p\u003e\n\n\u003cp\u003eThe  Segment Accounted for Approximately XX% of the Market Share\u003c\/p\u003e\n\n \u003cp\u003eThe enzyme immunoassay (EIA) is expected to hold the largest market share during the forecast period, owing to the rising incidences of rubella and the advantages of the enzyme immunoassay (EIA) method. For instance, the enzyme immunoassay is the most used as it is relatively inexpensive, technically easy to perform, rapid, and susceptible.\u003c\/p\u003e\n\n \u003cp\u003eEIA is used to detect rubella-specific immunoglobulin G (IgG) antibodies. IgM testing is the most commonly performed technique using commercial enzyme immunoassay (EIA) kits. The blood test detects antibodies the immune system makes to kill the rubella virus, which remains in the bloodstream for years. The EIA is also suitable for diagnosing acute infections, as a significant increase in antibody levels was detected in all paired specimens tested from patients with acute rubella infection.\u003c\/p\u003e\n\n\u003cp\u003eIn July 2021, it reported that measles and rubella are two of the most globally critical vaccine-preventable diseases (VPD), and measuring antibodies to measles and rubella viruses in samples collected from serosurveys can play an important role in estimating population immunity and guiding immunization activities and enzyme immunoassay is the most convenient method and accessible approach for detecting the rubella virus. Hence, the efficacy is elevated if ELISA kits are used. This factor is expected to drive the market in the forecast period.\u003c\/p\u003e\n\n\u003cp\u003eGeographical Analysis\u003c\/p\u003e\n\n\u003cp\u003eAsia-Pacific accounted for Approximately XX% of the Market Share in 2022\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific is expected to hold the largest segment in the market. According to information from the Centers for Disease Control and Prevention, India has the highest number of cases between April and September 2022. Pakistan stayed in 7th position with 3635 cases, while the US had 33 cases by the end of 2022.\u003c\/p\u003e\n\n \u003cp\u003eDue to the increased number of cases in 2022, the Indian government has launched a scheme to improve the diagnostic services related to measles disease. For instance, in July 2022, the Pradhan Mantri Surakshit Matritva Abhiyan by the Ministry of Health \u0026amp; Family Welfare (MoHFW), Government of India, to improve the quality and coverage of antenatal care (ANC), including diagnostics and counseling services, as part of the Reproductive Maternal Neonatal Child and Adolescent Health (RMNCH+A) strategy.\u003c\/p\u003e\n\n\u003cp\u003eCOVID-19 Impact Analysis on Rubella Diagnostic Testing Market\u003c\/p\u003e\n\n \u003cp\u003eCOVID-19 negatively impacted the global market during the outburst because to prevent further COVID-19 infection, restrictions and regulations were imposed, making it difficult for people to perform rubella diagnoses affecting the sales of the rubella diagnostic kits. Furthermore, during the pandemic, regular vaccination programs were on hold, which according to NIH estimation, put 80 million infants at risk of infection by measles, polio, and diphtheria, negatively impacting the global market.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation\u003c\/p\u003e\n\n\u003cp\u003eBy Diagnostic Technique\u003cbr\u003e\n• Latex Agglutination\u003cbr\u003e\n• Liver Function Tests\u003cbr\u003e\n• Enzyme Immunoassay (EIA)\u003cbr\u003e\n• Radioimmunoassay (RIA)\u003cbr\u003e\n• Fluorescent Immunoassay (FIA)\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Age Group\u003cbr\u003e\n• Neonates\u003cbr\u003e\n• Teenagers\u003cbr\u003e\n• Adults\u003c\/p\u003e\n\n\u003cp\u003eBy End User\u003cbr\u003e\n• Hospitals and Clinics\u003cbr\u003e\n• Cancer Diagnostic Centers\u003cbr\u003e\n• Ambulatory Surgical Centers\u003cbr\u003e\n• Others\u003c\/p\u003e\n\n\u003cp\u003eBy Region\u003cbr\u003e\n• North America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\n• Europe\u003cbr\u003e\nGermany\u003cbr\u003e\nU.K.\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nRest of Europe\u003cbr\u003e\n• South America\u003cbr\u003e\nBrazil\u003cbr\u003e\nArgentina\u003cbr\u003e\nRest of South America\u003cbr\u003e\n• Asia-Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nRest of Asia-Pacific\u003cbr\u003e\n• Middle East and Africa\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eThe major global players in the rubella diagnostic testing market include Siemens Healthineers AG, Bio Rad Laboratories Inc., Abbott Laboratories, BioMerieux SA, Thermo Fisher Scientific Inc., ZEUS, Scientific Inc., F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, InDevR, Inc., and Beckman Coulter Inc. among others.\u003c\/p\u003e\n\n\u003cp\u003eKey Developments\u003cbr\u003e\n• In 2023, The Immunization Agenda 2030 Measles \u0026amp; Rubella Partnership (M\u0026amp;RP), a partnership led by the American Red Cross, United Nations Foundation, Centers for Disease Control and Prevention (CDC), Gavi, the Vaccines Alliance, the Bill and Melinda French Gates Foundation, UNICEF and WHO, to achieve the IA2030 measles and rubella specific targets.\u003cbr\u003e\n• In August 2022, Roche reported that the United States Food and Drug Administration (USFDA) has approved a label expansion for its Ventana MMR RxDx Panel that provides clinicians with access to a fully automated panel of mismatch repair (MMR) biomarkers tested by immunohistochemistry (IHC).\u003cbr\u003e\n• In 2021, The United Kingdom Health Security Agency's Immunization and Vaccine-Preventable Diseases Division launched a new rash-fever surveillance scheme. The aim is to increase the number of samples tested for measles and rubella diagnostic testing. The program was initiated by the United Kingdom government, which distributed rubella diagnostic kits for rapid rubella testing.\u003c\/p\u003e\n\n\u003cp\u003eWhy Purchase the Report?\u003cbr\u003e\n• To visualize the global rubella diagnostic testing segmentation based on diagnostic test, age group, end user, and region, as well as understand key commercial assets and players.\u003cbr\u003e\n• Identify commercial opportunities by analyzing trends and co-development.\u003cbr\u003e\n • Excel data sheet with numerous data points of rubella diagnostic testing market-level with all segments.\u003cbr\u003e\n• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.\u003cbr\u003e\n• Product mapping available as Excel consisting of key products of all the major players.\u003c\/p\u003e\n\n\u003cp\u003eThe global rubella diagnostic testing market report would provide approximately 61 tables, 61 figures, and 185 Pages.\u003c\/p\u003e\n\n\u003cp\u003eTarget Audience 2023\u003cbr\u003e\n• Manufacturers\/ Buyers\u003cbr\u003e\n• Industry Investors\/Investment Bankers\u003cbr\u003e\n• Research Professionals\u003cbr\u003e\n• Emerging Companies\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 185 Pages \/ MCW16248283","offer_id":47648672153906,"sku":null,"price":5220.0,"currency_code":"USD","in_stock":true}]},{"product_id":"animal-health-market-in-north-america-2023-2027","title":"Animal Health Market in North America 2023-2027","description":"\u003cp\u003eAnimal Health Market In North America 2023-2027\u003cbr\u003e\nThe animal health market in North America is forecasted to grow by USD 4,861.96 mn during 2022-2027, accelerating at a CAGR of 5.32% during the forecast period. The report on the animal health market in North America provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\u003c\/p\u003e\n\n\u003cp\u003eThe report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increase in animals, especially pet ownership, the rising prevalence of diseases in animals, and a rise in the incidence of zoonotic diseases.\u003c\/p\u003e\n\n\u003cp\u003eTechnavio's animal health market in North America is segmented as below:\u003c\/p\u003e\n\n\u003cp\u003eBy Animal TypeLivestockCompanion animalsBy ProductPharmaceuticalFeed additiveBiologicalsThis study identifies the rising awareness regarding animals intestinal health as one of the prime reasons driving the animal health market in North America growth during the next few years. Also, growing focus on innovation in animal health and rising expenditure on animal health will lead to sizable demand in the market.\u003c\/p\u003e\n\n\u003cp\u003eThe report on the animal health market in North America covers the following areas:Animal health market in North America sizingAnimal health market in North America forecastAnimal health market in North America industry analysisThe robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading animal health market in North America vendors that include American Animal Health Inc., Alltech Inc., Bimeda Holdings Ltd., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Eco Animal Health Group Plc, Elanco Animal Health Inc., Huvepharma EOOD, Mars Inc., Merck and Co. Inc., Patterson Companies Inc., Phibro Animal Health Corp., Thermo Fisher Scientific Inc., Vetio, Virbac SA, and Zoetis Inc.. Also, the animal health market in North America analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.\u003c\/p\u003e\n\n\u003cp\u003eThe study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.\u003c\/p\u003e \n\n\u003cp\u003eThe publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 139 Pages \/ MCW16248285","offer_id":47648672350514,"sku":null,"price":3000.0,"currency_code":"USD","in_stock":true}]},{"product_id":"pharmaceutical-contract-management-consulting-in-the-us-industry-market-research-report","title":"Pharmaceutical Contract Management Consulting in the US - Industry Market Research Report","description":"\u003cp\u003ePharmaceutical Contract Management Consulting in the US - Industry Market Research Report\u003cbr\u003e\nPharmaceutical Contract Management Consulting in the US\u003c\/p\u003e\n\n\u003cp\u003eOver the past five years, the patent cliff, an ongoing series of expiration dates for the patents on blockbuster drugs, has stimulated the volume of research and development (R\u0026amp;D) work outsourced by generic pharmaceutical and biotechnology companies, promoting growth for consultants. The outbreak of COVID-19 led to growth for consultants as pharmaceutical manufacturers ramped up R\u0026amp;D expenditures to develop new drugs and looked to consultants to sure up their operations. Industry-wide revenue has been climbing at a CAGR of 1.0% over the past five years and is expected to total $37.6 billion in 2023, when revenue will jump by an estimated 4.1%.\u003c\/p\u003e\n\n\u003cp\u003eThis industry provides consulting to pharmaceutical companies, which includes the assessment of cost structures and client contracting processes. Firms ensure compliance and track performance. This can include the development and implementation of software for these purposes.\u003c\/p\u003e\n\n\u003cp\u003eThis report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 39 Pages \/ MCW16248286","offer_id":47648672645426,"sku":null,"price":1314.0,"currency_code":"USD","in_stock":true}]},{"product_id":"image-guided-radiation-therapy-market-by-product-4d-rt-linac-mri-guided-radiotherapy-portal-ct-imaging-procedure-imrt-stereotactic-particle-application-neck-prostate-breast-cancer-enduser-hospital-acc-region-global-forecasts-to-2028","title":"Image-Guided Radiation Therapy Market by Product (4D RT, LINAC, MRI-guided radiotherapy, Portal CT Imaging), Procedure (IMRT, Stereotactic, Particle), Application (Neck, Prostate, Breast cancer), Enduser (Hospital, ACC) \u0026 Region - Global Forecasts to 2028","description":"\u003cp\u003eImage-Guided Radiation Therapy Market by Product (4D RT, LINAC, MRI-guided radiotherapy, Portal CT Imaging), Procedure (IMRT, Stereotactic, Particle), Application (Neck, Prostate, Breast cancer), Enduser (Hospital, ACC) \u0026amp; Region - Global Forecasts to 2028\u003c\/p\u003e\n\n\u003cp\u003eThe global image-guided radiation therapy market is projected to reach USD 2.4 billion by 2028 from USD 1.9 billion in 2023, growing at a CAGR of 5.2% during the forecast period. The projected surge in market growth for image-guided radiation therapy (IGRT) is underpinned by a confluence of compelling advantages. Notably, IGRT's capacity to achieve exceptional precision in tumor targeting, coupled with its ability to mitigate collateral damage to healthy tissues, stands as a pivotal driver. Furthermore, the escalating global incidence of cancer amplifies the demand for advanced treatment modalities, with IGRT positioned as a forefront solution. This convergence of factors is poised to usher in a phase of robust expansion within the market, consequently shaping the landscape of IGRT adoption in the forthcoming forecasting years.\u003c\/p\u003e\n\n\u003cp\u003e“LINAC (linear accelerator) segment to register largest market share in 2022-2028.”\u003c\/p\u003e\n\n\u003cp\u003eBased on the product, the image-guided radiation therapy market is segmented into 4D gating\/ 4D RT, LINAC (linear accelerator), PET\/ MRI-guided radiation therapy, CT scanning and portal imaging. LINAC (linear accelerator) segment to register the largest market share over the forecast period of 2022-2028. The realm of LINAC technology is marked by continuous evolution, characterized by progressive innovations encompassing imaging modalities, dose delivery methodologies, and treatment validation approaches. This evolutionary trajectory significantly contributes to the perpetual advancement of image-guided radiation therapy (IGRT), thereby playing a pivotal role in amplifying its market presence and prominence.\u003c\/p\u003e\n\n\u003cp\u003e“The Prostate cancer application segment to register highest CAGR over the forecast period of 2023-2028.”\u003c\/p\u003e\n\n\u003cp\u003eBased on the application, the image-guided radiation therapy market is segmented into prostate cancer, lung cancer, head \u0026amp; neck cancer, breast cancer, gastrointestinal cancer, gynecological cancer, and other applications. The rising worldwide prevalence of prostate cancer has catalyzed a discernible surge in the need for advanced and effective treatment methodologies. Within this framework, image-guided radiation therapy (IGRT) assumes a pivotal stance, proffering meticulous tumor targeting founded on precision and augmenting therapeutic outcomes. This escalating requirement for elevated treatment sophistication seamlessly converges with the inherent attributes of IGRT, thereby substantiating its central position in propelling market expansion within the sphere of prostate cancer radiation therapy.\u003c\/p\u003e\n\n\u003cp\u003e“The Stereotactic therapy procedure segment accounted for the highest CAGR of the image-guided radiation therapy market over the forecasting period.”\u003c\/p\u003e\n\n\u003cp\u003eBased on the procedure, the image-guided radiation therapy market is segmented into 3D conformal therapy, IMRT, stereotactic therapy, particle therapy and proton beam therapy. The stereotactic therapy procedure segment exhibited the most substantial Compound Annual Growth Rate (CAGR) within the image-guided radiation therapy market over the projected forecasting period.\u003c\/p\u003e \n\n\u003cp\u003eStereotactic therapy possesses distinct qualities, notably its abbreviated treatment duration and elevated precision, which notably elevate the comfort levels of patients undergoing radiation therapy. This enhancement in the holistic treatment experience aligns seamlessly with the patient-centric philosophy that underscores image-guided radiation therapy (IGRT). The convergence of these attributes not only cultivates positive patient outcomes but also amplifies IGRT's appeal within the market landscape, consequently fostering heightened adoption rates and a more pronounced market presence.\u003c\/p\u003e\n\n\u003cp\u003e“Hospitals’ segment to register for the largest market share of the image-guided radiation therapy market in 2022-2028.”\u003c\/p\u003e\n\n\u003cp\u003eThe major end users in the image-guided radiation therapy market are hospitals. The hospital end-user segment is estimated to hold a significant market share of the image-guided radiation therapy market during the forecast period. Hospitals, characterized by their capacity to provide a comprehensive array of medical services within a singular facility, confer a distinctive convenience to patients undergoing image-guided radiation therapy (IGRT). This convenience stems from the consolidation of diverse medical needs under one roof, thereby mitigating the necessity for patients to seek multiple appointments at disparate venues. This strategic amalgamation of services not only streamlines patient care but also augments the attractiveness of IGRT as a preferred treatment option. As a result, this seamless alignment of convenience and comprehensive care significantly contributes to the advancement and prominence of the image-guided radiation therapy market within hospital settings.\u003c\/p\u003e\n\n\u003cp\u003eTechnological Advances: Hospitals frequently maintain cutting-edge infrastructure and technological capabilities essential for the successful integration of image-guided radiation therapy (IGRT), thus assuring the ready availability of requisite resources. This pivotal attribute distinctly contributes to the advancement and fortification of the image-guided radiation therapy market.\u003c\/p\u003e\n\n\u003cp\u003e“Asia Pacific to register significant growth rate in the market during the forecast period.”\u003c\/p\u003e\n\n\u003cp\u003eFor the forecasting period 2023-2028, the APAC region is expected to register a significant growth rate in the market during the forecast period. Asia Pacific comprises India, China, Japan, Australia, South Korea, and RoAPAC. The Asia-Pacific (APAC) region has witnessed a significant increase in the market growth rate for image-guided radiation therapy. There are several drivers that contributed to this growth:\u003c\/p\u003e\n\n\u003cp\u003eThe maturing demographic profile observed in APAC countries accentuates the imperative for efficacious cancer treatment modalities characterized by minimized treatment-related adverse effects. This resonance with the precision-driven attributes of image-guided radiation therapy (IGRT) substantiates its pivotal role in enhancing the market landscape.\u003c\/p\u003e\n\n\u003cp\u003eThe incorporation of multilingual patient care offerings within APAC hospitals, combined with the accessibility to advanced treatments like image-guided radiation therapy (IGRT), confers a unique allure to the region, particularly among a diverse patient spectrum. This fusion of linguistic inclusiveness and state-of-the-art medical interventions significantly enhances the region's desirability as a favored healthcare destination, thereby fortifying its competitive position within the healthcare market landscape and concomitantly propelling the prominence of IGRT.\u003c\/p\u003e\n\n\u003cp\u003eA breakdown of the primary participants referred to for this report is provided below:\u003c\/p\u003e\n\n\u003cp\u003eBy Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%\u003c\/p\u003e\n\n\u003cp\u003eBy Designation: C-level–27%, Director-level–18%, and Others–55%\u003c\/p\u003e\n\n\u003cp\u003eBy Region: North America–50%, Europe–20%, Asia Pacific–15%, Latin America–10%, and the Middle East \u0026amp; Africa–5%\u003c\/p\u003e\n\n\u003cp\u003eProminent players in this market are Siemens Healthineers AG (Germany), Elekta (Sweden), Accuray Incorporated (US), GE Healthcare Company (US), and Hitachi (Japan), among others.\u003c\/p\u003e\n\n\u003cp\u003eResearch Coverage\u003c\/p\u003e\n\n\u003cp\u003eThe report studies the image-guided radiation therapy market based on products, procedures, applications, end users, and regions.\u003c\/p\u003e\n\n\u003cp\u003eThe report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.\u003c\/p\u003e \n\n\u003cp\u003eThe report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.\u003c\/p\u003e\n\n\u003cp\u003eThe report studies micro markets with respect to their growth trends, prospects, and contributions to the global image-guided radiation therapy market.\u003c\/p\u003e \n\n\u003cp\u003eThe report forecasts the revenue of market segments with respect to five major regions.\u003c\/p\u003e\n\n\u003cp\u003eKey Benefits of Buying the Report:\u003c\/p\u003e\n\n\u003cp\u003eThe report will help the market leaders\/new entrants\/smaller firms in this market with investment evaluation viability within the image-guided radiation therapy market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, growth catalysts, challenges, and prospects, thereby empowering strategic decision-making with astute discernment.\u003c\/p\u003e \n\n\u003cp\u003eThe report provides insights on the following pointers:\u003c\/p\u003e \n\n\u003cp\u003eAnalysis of key drivers (increasing prevalence of cancer patient population, Increasing  government initiatives for cancer management, advancements in non-invasive treatments through radiation therapy), restraints (Dearth of skilled radiologist\/oncologist, high cost of image-guided radiation therapy treatment, Complexity of imaging technology for treatments), opportunities (Expansion of key players in emerging countries, Rising healthcare expenditure across developing countries), and challenges (Availability of alternative technology) influencing the growth of the image-guided radiation therapy market\u003c\/p\u003e \n\n\u003cp\u003eProduct Development\/Innovation: Detailed insights on upcoming technologies, research \u0026amp; development activities, and new product \u0026amp; service launches in the image-guided radiation therapy market.\u003c\/p\u003e\n\n\u003cp\u003eMarket Development: Comprehensive information about lucrative markets – the report analyses the image-guided radiation therapy market across varied regions.\u003c\/p\u003e\n\n\u003cp\u003eMarket Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the image-guided radiation therapy market\u003c\/p\u003e \n\n\u003cp\u003eCompetitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Siemens Healthineers AG (Germany), Elekta (Sweden), and Accuray Incorporated (US), among others.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 198 Pages \/ MCW16248288","offer_id":47648672842034,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}]},{"product_id":"sleep-disorder-clinics-in-the-us-industry-market-research-report","title":"Sleep Disorder Clinics in the US - Industry Market Research Report","description":"\u003cp\u003eSleep Disorder Clinics in the US - Industry Market Research Report\u003cbr\u003e\nSleep Disorder Clinics in the US\u003c\/p\u003e\n\n\u003cp\u003eAccording to the American Sleep Association, between 50.0 million and 70.0 million Americans have ongoing sleep disorders. Increasing awareness of the importance of sleep health and environmental and lifestyle changes that challenge healthy sleep habits in the population have spurred demand and growth in number of sleep disorder clinics. While less-severe sleep disorder cases do not require treatment in a clinic, relying on a specialty doctor to diagnose, follow up and prescribe at-home treatment, some conditions require clinic services. Health insurance policies, private and government-funded, are increasingly covering all or at least part of the costs of tests, diagnoses and remedies provided by sleep disorder clinics. As a result, more patients can access specialized sleep clinics, driving revenue growth for the industry.\u003c\/p\u003e\n\n\u003cp\u003eEstablishments in this industry are devoted to the diagnosis and care of outpatients with disorders that affect, disrupt or more generally involve sleep. Common sleep disorders include insomnia, sleep apnea, restless leg syndrome and sleepwalking. Industry clinics are often associated with hospitals or medical schools.\u003c\/p\u003e\n\n\u003cp\u003eThis report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 36 Pages \/ MCW16248289","offer_id":47648673038642,"sku":null,"price":1314.0,"currency_code":"USD","in_stock":true}]},{"product_id":"childrens-specialty-hospitals-in-the-us-industry-market-research-report","title":"Children's Specialty Hospitals in the US - Industry Market Research Report","description":"\u003cp\u003eChildren's Specialty Hospitals in the US - Industry Market Research Report\u003cbr\u003e\nChildren's Specialty Hospitals in the US\u003c\/p\u003e\n\n\u003cp\u003eThough they represent less than 5% of all US hospitals, children's specialty hospitals are critical to pediatric healthcare. And despite COVID-19 disruptions, the industry experienced growth due to the inelastic demand for children's health services. While the pandemic raised operating costs, telemedicine and government support helped offset significant declines in demand and revenue. The volatility in revenue and expenses caused by the COVID-19 pandemic did not affect industry-wide revenue, which has been declining at a CAGR of only 0.9% over the past five years, and is expected to total $41.2 billion in 2023. In the same year, revenue will jump an estimated 1.2% alone.\u003c\/p\u003e\n\n\u003cp\u003eThis industry includes hospitals that provide diagnostic and medical treatment (surgical and nonsurgical) to inpatients who are typically aged 21 and younger. These hospitals treat a specific type of disease or medical condition (except psychiatric conditions or substance abuse), maintain inpatient beds and provide patients with food services and other services (e.g. outpatient services, X-ray services, laboratory services, operating room services and pharmacy services).\u003c\/p\u003e\n\n\u003cp\u003eThis report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 41 Pages \/ MCW16248290","offer_id":47648673136946,"sku":null,"price":1314.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-gastrointestinal-diseases-therapeutics-market-2023-2027","title":"Global Gastrointestinal Diseases Therapeutics Market 2023-2027","description":"\u003cp\u003eGlobal Gastrointestinal Diseases Therapeutics Market 2023-2027\u003cbr\u003e\nThe gastrointestinal diseases therapeutics market is forecasted to grow by USD 17074.34 mn during 2022-2027, accelerating at a CAGR of 6.67% during the forecast period. The report on the gastrointestinal diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\u003c\/p\u003e\n\n\u003cp\u003eThe report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of gastrointestinal diseases, new gastrointestinal therapeutics product launches, and increasing demand for biologics and targeted therapies.\u003c\/p\u003e\n\n\u003cp\u003eTechnavio's gastrointestinal diseases therapeutics market is segmented as below:\u003c\/p\u003e\n\n\u003cp\u003eBy Drug ClassAnti-inflammatory and immunosuppressorsAcid neutralizersOthersBy TypeBrandedGenericsBy Geographical LandscapeNorth AmericaAsiaEuropeRest of World (ROW)This study identifies the availability of nutritional therapies as one of the prime reasons driving the gastrointestinal diseases therapeutics market growth during the next few years. Also, the emergence of microbiome-based therapies and an increase in self-medication coupled with home-based therapies will lead to sizable demand in the market.\u003c\/p\u003e\n\n\u003cp\u003eThe report on the gastrointestinal diseases therapeutics market covers the following areas:Gastrointestinal diseases therapeutics market sizingGastrointestinal diseases therapeutics market forecastGastrointestinal diseases therapeutics market industry analysisThe robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastrointestinal diseases therapeutics market vendors that include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corp., Eisai Co. Ltd., Eli Lilly and Co., Evoke Pharma Inc., GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Olympus Corp., Ovesco Endoscopy AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA. Also, the gastrointestinal diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.\u003c\/p\u003e\n\n\u003cp\u003eThe study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.\u003c\/p\u003e \n\n\u003cp\u003eThe publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 168 Pages \/ MCW16248293","offer_id":47648673202482,"sku":null,"price":3000.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-liquid-dosage-excipients-growth-opportunities","title":"Global Liquid Dosage Excipients Growth Opportunities","description":"\u003cp\u003eGlobal Liquid Dosage Excipients Growth Opportunities\u003c\/p\u003e \n\n\u003cp\u003eDemand for Patient-centric Parenteral Formulation Accelerates Growth Potential\u003c\/p\u003e\n\n\n\n\u003cp\u003eThe global study on the liquid dosage excipients assesses growth opportunities in the oral liquid and parenteral excipients market from 2022 to 2030 across major regional markets, including North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The oral liquid excipients market provides qualitative and quantitative analyses of different segments such as sweetening agents, pH modifiers and buffering agents, wetting\/solubilizing agents, and others (e.g., chelating agents, preservatives, and flavors). The increase in new drug approvals in the oral liquid formulation space to treat various diseases in children and older adults will drive demand over the forecast period. The segments examined under the global parenteral excipients market include solubilizing agents, buffering agents, preservatives, and others (e.g., tonicity adjusters, chelating agents, antioxidants, and bulking agents). Demand for biologics drugs to treat diseases such as cancer, orphan diseases, and cardiovascular diseases will be the primary growth contributor in the parenteral excipients market during the forecast period.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ - \/ MCW16248294","offer_id":47648673300786,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}]},{"product_id":"syros-pharmaceuticals-syrs-nas-analytics-extensive-financial-metrics-and-benchmarks-against-averages-and-top-companies-within-its-industry","title":"Syros Pharmaceuticals (SYRS:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry","description":"\u003cp\u003eSyros Pharmaceuticals (SYRS:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry\u003cbr\u003e\nSyros Pharmaceuticals (SYRS:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry.\u003c\/p\u003e\n\n\u003cp\u003eKey Findings:This unique new report provides deep financial benchmarks for Syros Pharmaceuticals (SYRS:NAS) compared to its top competitors and compared to the average for all companies within its primary industry.This benchmarking study for Syros Pharmaceuticals (SYRS:NAS) includes growth forecast for its primary industry for the current year and the next 7 years. The purpose of this report is to provide vital corporate-specific benchmarks, comparing the Subject Company to its top competitors (on a company-by-company basis) and to the averages within its primary industry for all key metrics. This is a unique report containing high-value data. The report begins with a superb overview of the primary industry of the Subject Company, including historical industry revenues, revenue forecasts and CAGR. Then the report moves into industry averages and metrics, then into data specific to the Subject Company, with comparative data for the Subject Company's top competitors.\u003c\/p\u003e\n\n\u003cp\u003eThis report will save countless hours of research and analytical work for the end user.\u003c\/p\u003e\n\n\u003cp\u003eCore Benefits:\u003c\/p\u003e\n\n\u003cp\u003e1) Comprehensive benchmarks for the Subject Company:\u003c\/p\u003e\n\n\u003cp\u003ea. Benchmarked against the leading firms in its primary industry\u003cbr\u003e\nb. Benchmarked against the average for publicly-held companies (U.S.) in its industry.\u003cbr\u003e\nc. This includes financial results, ratios, operating\/financial statements and metrics in one package, including both the latest year and 6 most-recent historical years.\u003c\/p\u003e\n\n\u003cp\u003e2) A snapshot overview of the company's primary industry, including current and historic revenues and employment, along with a long term forecast for industry growth, with CAGR (compound annual growth rate), employee population and much more.\u003c\/p\u003e\n\n\u003cp\u003e3) Detailed rankings of the Subject Company against top companies within the industry (U.S.-based firms) for key items including:\u003c\/p\u003e\n\n\u003cp\u003ea. Approximate market capitalization\u003cbr\u003e\nb. Employees\u003cbr\u003e\nc. Revenues\u003cbr\u003e\nd. Net income\u003cbr\u003e\ne. 3-Year revenue growth (%)\u003cbr\u003e\nf. 3-Year income growth (%)\u003cbr\u003e\ng. Return on assets (%)\u003cbr\u003e\nh. Return on equity (%)\u003cbr\u003e\ni. Return on invested capital (%)\u003c\/p\u003e\n\n\u003cp\u003e4) Leading competitors’ profiles.\u003c\/p\u003e \n\n\u003cp\u003eApproximately 70 pages in length. \u003cbr\u003e\nApproximately 28 Charts.\u003c\/p\u003e \n\n\u003cp\u003eThe region is the USA. This report is part of the Plunkett's Corporate Benchmarks series, published by Plunkett Research, Ltd. Plunkett has unique capabilities for creating corporate and industry information, due to research that we have been conducting for more than 20 years. Our access to hundreds of industry tables from our own databases, along with our databases of public and private company information, industry trends analysis and other resources, have been utilized in preparing this report.\u003c\/p\u003e \n\n\u003cp\u003eSimilar reports are available for all significant, U.S. publicly-held firms.\u003c\/p\u003e \n\n\u003cp\u003eDesigned to benefit:\u003c\/p\u003e\n\n\u003cp\u003eInvestment Firms, Private Equity, Hedge Funds, Lenders, Appraisers and Consultants.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 86 Pages \/ MCW16248296","offer_id":47648673366322,"sku":null,"price":2994.0,"currency_code":"USD","in_stock":true}]},{"product_id":"soligenix-inc-sngx-nas-analytics-extensive-financial-metrics-and-benchmarks-against-averages-and-top-companies-within-its-industry","title":"Soligenix Inc (SNGX:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry","description":"\u003cp\u003eSoligenix Inc (SNGX:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry\u003cbr\u003e\nSoligenix Inc (SNGX:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry.\u003c\/p\u003e\n\n\u003cp\u003eKey Findings:This unique new report provides deep financial benchmarks for Soligenix Inc (SNGX:NAS) compared to its top competitors and compared to the average for all companies within its primary industry.This benchmarking study for Soligenix Inc (SNGX:NAS) includes growth forecast for its primary industry for the current year and the next 7 years. The purpose of this report is to provide vital corporate-specific benchmarks, comparing the Subject Company to its top competitors (on a company-by-company basis) and to the averages within its primary industry for all key metrics. This is a unique report containing high-value data. The report begins with a superb overview of the primary industry of the Subject Company, including historical industry revenues, revenue forecasts and CAGR. Then the report moves into industry averages and metrics, then into data specific to the Subject Company, with comparative data for the Subject Company's top competitors.\u003c\/p\u003e\n\n\u003cp\u003eThis report will save countless hours of research and analytical work for the end user.\u003c\/p\u003e\n\n\u003cp\u003eCore Benefits:\u003c\/p\u003e\n\n\u003cp\u003e1) Comprehensive benchmarks for the Subject Company:\u003c\/p\u003e\n\n\u003cp\u003ea. Benchmarked against the leading firms in its primary industry\u003cbr\u003e\nb. Benchmarked against the average for publicly-held companies (U.S.) in its industry.\u003cbr\u003e\nc. This includes financial results, ratios, operating\/financial statements and metrics in one package, including both the latest year and 6 most-recent historical years.\u003c\/p\u003e\n\n\u003cp\u003e2) A snapshot overview of the company's primary industry, including current and historic revenues and employment, along with a long term forecast for industry growth, with CAGR (compound annual growth rate), employee population and much more.\u003c\/p\u003e\n\n\u003cp\u003e3) Detailed rankings of the Subject Company against top companies within the industry (U.S.-based firms) for key items including:\u003c\/p\u003e\n\n\u003cp\u003ea. Approximate market capitalization\u003cbr\u003e\nb. Employees\u003cbr\u003e\nc. Revenues\u003cbr\u003e\nd. Net income\u003cbr\u003e\ne. 3-Year revenue growth (%)\u003cbr\u003e\nf. 3-Year income growth (%)\u003cbr\u003e\ng. Return on assets (%)\u003cbr\u003e\nh. Return on equity (%)\u003cbr\u003e\ni. Return on invested capital (%)\u003c\/p\u003e\n\n\u003cp\u003e4) Leading competitors’ profiles.\u003c\/p\u003e \n\n\u003cp\u003eApproximately 70 pages in length. \u003cbr\u003e\nApproximately 28 Charts.\u003c\/p\u003e \n\n\u003cp\u003eThe region is the USA. This report is part of the Plunkett's Corporate Benchmarks series, published by Plunkett Research, Ltd. Plunkett has unique capabilities for creating corporate and industry information, due to research that we have been conducting for more than 20 years. Our access to hundreds of industry tables from our own databases, along with our databases of public and private company information, industry trends analysis and other resources, have been utilized in preparing this report.\u003c\/p\u003e \n\n\u003cp\u003eSimilar reports are available for all significant, U.S. publicly-held firms.\u003c\/p\u003e \n\n\u003cp\u003eDesigned to benefit:\u003c\/p\u003e\n\n\u003cp\u003eInvestment Firms, Private Equity, Hedge Funds, Lenders, Appraisers and Consultants.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 84 Pages \/ MCW16248297","offer_id":47648673464626,"sku":null,"price":2994.0,"currency_code":"USD","in_stock":true}]},{"product_id":"europe-durable-medical-equipment-market-by-product-type-personal-mobility-devices-medical-furniture-bathroom-safety-devices-monitoring-therapeutic-devices-by-end-user-hospitals-ascs-home-care-settings-by-application-orthopedics-cardiovasc","title":"Europe Durable Medical Equipment Market, By Product Type (Personal Mobility Devices, Medical Furniture \u0026 Bathroom Safety Devices, Monitoring \u0026 Therapeutic Devices); By End User (Hospitals, ASCs, Home Care Settings); By Application (Orthopedics. Cardiovasc","description":"\u003cp\u003eEurope Durable Medical Equipment Market, By Product Type (Personal Mobility Devices, Medical Furniture \u0026amp; Bathroom Safety Devices, Monitoring \u0026amp; Therapeutic Devices); By End User (Hospitals, ASCs, Home Care Settings); By Application (Orthopedics. Cardiovascular, Respiratory, Diabetes Care, Neurology); By Country (Germany, United Kingdom, Italy, France, Spain, Belgium, Russia, The Netherlands, Rest of Europe), Trend Analysis, Competitive Landscape \u0026amp; Forecast, 2019–2029\u003cbr\u003e\nEurope Durable Medical Equipment Market Size Expanding to Cross USD 78 Billion by 2029\u003c\/p\u003e\n\n\u003cp\u003eEurope durable medical equipment market is flourishing because of the growing focus on the prevention and management of increasing prevalence of chronic diseases majorly driven by rapidly aging population in the region.\u003c\/p\u003e \n\n\u003cp\u003eBlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Europe durable medical equipment market size at USD 51.14 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects Europe durable medical equipment market size to grow at a significant CAGR of 6.25% reaching a value of USD 78.17 billion by 2029. Major growth drivers for the Europe durable medical equipment market include rapidly aging European population, escalating chronic maladies, and rapid medical technology advancements. Nations boasting well-established healthcare systems and greater healthcare spending typically exhibit larger DME sectors. Escalating chronic conditions such as diabetes, cardiovascular ailments, and respiratory disorders continue to surge across Europe. Durable medical equipment assumes a pivotal role in managing these conditions and ameliorating patient life quality. The pivot towards home-based care, propelled by patient preferences and cost containment, empowers patients with remote medical care options and curtails hospitalization rates. The uptake of telehealth and remote monitoring technologies, particularly accelerated by the COVID-19 pandemic, establishes links between durable medical equipment and remote patient monitoring, enhancing healthcare decisions. The mounting awareness among patients and healthcare providers about the benefits of durable medical equipment in health condition management has significantly contributed to the market's growth trajectory. Healthcare professionals are increasingly acknowledging the pivotal role of durable medical equipment in enhancing patient outcomes. However, the factors such as stringent regulations and limited reimbursement are anticipated to restrain the overall market growth during the period in analysis.\u003c\/p\u003e\n\n\u003cp\u003eEurope Durable Medical Equipment Market – Overview\u003c\/p\u003e\n\n\u003cp\u003eEurope durable medical equipment (DME) market refers to the sector within the European healthcare industry that involves the production, distribution, and utilization of various medical devices and equipment designed for extended and repeated use by patients for medical purposes. These devices are prescribed by healthcare professionals to assist in the treatment, management, and improvement of various health conditions and disabilities. DME includes a wide range of products, such as mobility aids, orthopedic devices, respiratory equipment, patient monitoring devices, and other durable medical devices, that contribute to enhancing the quality of life, facilitating medical care, and promoting independence for individuals with health-related needs.\u003c\/p\u003e\n\n\u003cp\u003eImpact of COVID-19 on Europe Durable Medical Equipment Market\u003c\/p\u003e \n\n\u003cp\u003eCOVID-19 pandemic had a mixed impact on the Europe durable medical equipment market. Initially, disrupted supply chains and manufacturing processes slowed operations. However, the crisis highlighted DME's significance in home healthcare and remote monitoring. Demand surged for disposable DME due to infection prevention needs. Telemedicine adoption soared, boosting sales of remote patient monitoring devices. Governments allocated resources to medical equipment, and regulatory flexibility expedited approvals. Economic uncertainties hindered purchasing power, leading to delayed non-essential acquisitions. Ultimately, the pandemic reshaped DME priorities, emphasizing patient safety, remote care capabilities, and readiness for future health crises.\u003c\/p\u003e\n\n\u003cp\u003eEurope Durable Medical Equipment Market – By Product Type\u003c\/p\u003e\n\n\u003cp\u003eBased on product type, the Europe durable medical equipment market is divided into Personal Mobility Devices, Medical Furniture \u0026amp; Bathroom Safety Devices, and Monitoring \u0026amp; Therapeutic Devices segments. The medical furniture \u0026amp; bathroom safety devices segment is expected to hold the highest share in the Europe durable medical equipment market by product type during the forecast period. It can be attributed to the aging population's needs, fall prevention concerns, the trend toward home care, regulatory standards, medical rehabilitation requirements, growing awareness, technological advancements, and government support for accessible living solutions. These factors collectively underscore the significance of medical furniture and bathroom safety devices for both seniors and individuals with disabilities. Also, the medical furniture \u0026amp; bathroom safety devices include medical bed \u0026amp; mattress and commode \u0026amp; toilet. Meanwhile, the monitoring and therapeutic devices segment is expected to witness the fastest growth rate during the forecast period due to escalating demand for advanced medical technologies.\u003c\/p\u003e \n\n\u003cp\u003eIncreasing prevalence of chronic diseases necessitates continuous patient monitoring and personalized treatment approaches. Technological innovations like wearable health trackers, remote patient monitoring systems, and smart therapeutic devices cater to these needs. Moreover, the pandemic accelerated telemedicine adoption, boosting the requirement for remote monitoring tools. Also, the monitoring and therapeutic devices segment include blood glucose monitor, oxygen equipment, vital sign monitor, and infusion pump. Amongst them, the vital sign monitor sub-segment is expected to dominate the market during the forecast period. It can be attributed to the rising diabetic patient population in the area. According to World Health Organization (WHO) estimations, diabetes-related fatalities are projected to double from 2005 to 2030 in this region.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eMajor players operating in the Europe durable medical equipment market include Invacare Corporation, Hill-Rom Holdings Inc., Stryker Corporation, Medtronic plc, Becton, Dickinson and Company, Medline Industries Inc., Johnson \u0026amp; Johnson, Abbott Laboratories, Koninklijke Philips N.V., Siemens AG, General Electric Company, Arjo AB, DeVilbiss Healthcare LLC, Handicare Group AB, and Sunrise Medical. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.\u003c\/p\u003e\n\n\u003cp\u003eThe in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Europe Durable Medical Equipment Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Europe Durable Medical Equipment Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 200 Pages \/ MCW16248298","offer_id":47648673530162,"sku":null,"price":4319.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-open-angle-glaucoma-therapeutics-market-2023-2027","title":"Global Open-Angle Glaucoma Therapeutics Market 2023-2027","description":"\u003cp\u003eGlobal Open-Angle Glaucoma Therapeutics Market 2023-2027\u003cbr\u003e\nThe open-angle glaucoma therapeutics market is forecasted to grow by USD 2363.93 mn during 2022-2027, accelerating at a CAGR of 6.4% during the forecast period. The report on the open-angle glaucoma therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\u003c\/p\u003e\n\n\u003cp\u003eThe report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by promising pipeline and recent approvals, increasing demand for combination drugs, and rising geriatric population.\u003c\/p\u003e\n\n\u003cp\u003eTechnavio's open-angle glaucoma therapeutics market is segmented as below:\u003c\/p\u003e\n\n\u003cp\u003eBy ChannelHospital pharmacyRetail pharmacyOnline pharmacyBy ProductPGAsNon-PGAsBy Geographical LandscapeNorth AmericaEuropeAsiaRest of World (ROW)This study identifies the development of biologics as one of the prime reasons driving the open-angle glaucoma therapeutics market growth during the next few years. Also, strategic alliances in global open-angle glaucoma therapeutics market and growing awareness about glaucoma will lead to sizable demand in the market.\u003c\/p\u003e\n\n\u003cp\u003eThe report on the open-angle glaucoma therapeutics market covers the following areas:Open-angle glaucoma therapeutics market sizingOpen-angle glaucoma therapeutics market forecastOpen-angle glaucoma therapeutics market industry analysisThe robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading open-angle glaucoma therapeutics market vendors that include AbbVie Inc., Alcon Inc., Bausch Health Companies Inc., D.Western Therapeutics Institute Inc, Hikma Pharmaceuticals Plc, Inotek Pharmaceuticals, Merck and Co. Inc., Nicox S.A., Novartis AG, Ocuphire Pharma Inc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the open-angle glaucoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.\u003c\/p\u003e\n\n\u003cp\u003eThe study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.\u003c\/p\u003e \n\n\u003cp\u003eThe publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 161 Pages \/ MCW16248299","offer_id":47648682803506,"sku":null,"price":3000.0,"currency_code":"USD","in_stock":true}]},{"product_id":"bric-icp-procedures-count-and-forecast-to-2030","title":"BRIC ICP Procedures Count and Forecast to 2030","description":"\u003cp\u003eBRIC ICP Procedures Count and Forecast to 2030\u003cbr\u003e\nSummary\u003c\/p\u003e\n\n\u003cp\u003eGlobalData’s “BRIC ICP Procedures Outlook to 2030” is a comprehensive databook report, covering key procedures data on the BRIC ICP Procedures.\u003c\/p\u003e\n\n\u003cp\u003eThe BRIC ICP Procedures report provides key information and data on -Procedure volume data for ICP Procedures related to the country. Data is provided from 2015 to 2030.Scope\u003c\/p\u003e\n\n\u003cp\u003eBRIC ICP Procedures is segmented as follows -ICP ProceduresReasons to Buy\u003c\/p\u003e\n\n\u003cp\u003eBRIC ICP Procedures report helps you to develop -Business strategies by identifying the key segments poised for strong growth in the future.Market-entry and market expansion strategies.Develop investment strategies by identifying the key segments expected to register strong growth in the near future.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 34 Pages \/ MCW16248300","offer_id":47648682869042,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}]},{"product_id":"neuroprosthetics-technologies-and-global-markets","title":"Neuroprosthetics: Technologies and Global Markets","description":"\u003cp\u003eNeuroprosthetics: Technologies and Global Markets\u003c\/p\u003e\n\n\u003cp\u003eReport Scope:\u003c\/p\u003e\n\n\u003cp\u003eThis research study aims to thoroughly assess and analyze the neuroprosthetics market, revenue forecasts and future trends, globally, and to provide strategic recommendations for the success of market participants. The scope of the study is global. Current and projected market forecasts during the forecast period (2023 to 2028) are discussed. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type, application and region from 2023 through 2028.\u003c\/p\u003e\n\n\u003cp\u003eThis report also includes an analysis of leading and emerging competitors in the worldwide neuroprosthetics market. Profiles of leading product manufacturers and emerging players with novel products in development are also analyzed. This report assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment.\u003c\/p\u003e\n\n\u003cp\u003eReport Includes:\u003c\/p\u003e\n\n\u003cp\u003e32 data tables and 49 additional tables\u003c\/p\u003e\n\n\u003cp\u003eA comprehensive overview and an up-to-date analysis of the global market for Neuroprosthetics\u003c\/p\u003e\n\n\u003cp\u003eAnalyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024 and 2026, and projections of compound annual growth rates (CAGRs) through 2028\u003c\/p\u003e\n\n\u003cp\u003eEstimation of the actual market size and revenue forecast for global neuroprosthetics market in USD million values, and corresponding market share analysis based on product, type of stimulation technology, application, and region\u003c\/p\u003e\n\n\u003cp\u003eIn-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall market\u003c\/p\u003e\n\n\u003cp\u003eDiscussion of ESG developments in Neuroprosthetics market, and an understanding of the importance of ESG, consumer attitudes towards sustainability, risks and opportunity assessment, and ESG followed practices by product manufacturers and industry participants\u003c\/p\u003e\n\n\u003cp\u003eA relevant patent analysis with significant allotments of key patent grants on Neuroprosthetics\u003c\/p\u003e\n\n\u003cp\u003eReview of the recent merger and acquisition (M\u0026amp;A) activities, venture fundings, and other impactful strategies contributing to the growth of this market\u003c\/p\u003e\n\n\u003cp\u003eIdentification of leading and emerging competitors in the worldwide neuroprosthetics market, and analysis of competitive landscape based on recent developments, segmental revenues, and operational integration\u003c\/p\u003e\n\n\u003cp\u003eCompany profiles of major players within the industry, including Abbott Laboratories, Boston Scientific Corp., Cochlear Ltd., Medtronic, and Sonova\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 168 Pages \/ MCW16248303","offer_id":47648683295026,"sku":null,"price":6600.0,"currency_code":"USD","in_stock":true}]},{"product_id":"vbi-vaccines-inc-vbiv-nas-analytics-extensive-financial-metrics-and-benchmarks-against-averages-and-top-companies-within-its-industry","title":"VBI Vaccines Inc (VBIV:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry","description":"\u003cp\u003eVBI Vaccines Inc (VBIV:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry\u003cbr\u003e\nVBI Vaccines Inc (VBIV:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry.\u003c\/p\u003e\n\n\u003cp\u003eKey Findings:This unique new report provides deep financial benchmarks for VBI Vaccines Inc (VBIV:NAS) compared to its top competitors and compared to the average for all companies within its primary industry.This benchmarking study for VBI Vaccines Inc (VBIV:NAS) includes growth forecast for its primary industry for the current year and the next 7 years. The purpose of this report is to provide vital corporate-specific benchmarks, comparing the Subject Company to its top competitors (on a company-by-company basis) and to the averages within its primary industry for all key metrics. This is a unique report containing high-value data. The report begins with a superb overview of the primary industry of the Subject Company, including historical industry revenues, revenue forecasts and CAGR. Then the report moves into industry averages and metrics, then into data specific to the Subject Company, with comparative data for the Subject Company's top competitors.\u003c\/p\u003e\n\n\u003cp\u003eThis report will save countless hours of research and analytical work for the end user.\u003c\/p\u003e\n\n\u003cp\u003eCore Benefits:\u003c\/p\u003e\n\n\u003cp\u003e1) Comprehensive benchmarks for the Subject Company:\u003c\/p\u003e\n\n\u003cp\u003ea. Benchmarked against the leading firms in its primary industry\u003cbr\u003e\nb. Benchmarked against the average for publicly-held companies (U.S.) in its industry.\u003cbr\u003e\nc. This includes financial results, ratios, operating\/financial statements and metrics in one package, including both the latest year and 6 most-recent historical years.\u003c\/p\u003e\n\n\u003cp\u003e2) A snapshot overview of the company's primary industry, including current and historic revenues and employment, along with a long term forecast for industry growth, with CAGR (compound annual growth rate), employee population and much more.\u003c\/p\u003e\n\n\u003cp\u003e3) Detailed rankings of the Subject Company against top companies within the industry (U.S.-based firms) for key items including:\u003c\/p\u003e\n\n\u003cp\u003ea. Approximate market capitalization\u003cbr\u003e\nb. Employees\u003cbr\u003e\nc. Revenues\u003cbr\u003e\nd. Net income\u003cbr\u003e\ne. 3-Year revenue growth (%)\u003cbr\u003e\nf. 3-Year income growth (%)\u003cbr\u003e\ng. Return on assets (%)\u003cbr\u003e\nh. Return on equity (%)\u003cbr\u003e\ni. Return on invested capital (%)\u003c\/p\u003e\n\n\u003cp\u003e4) Leading competitors’ profiles.\u003c\/p\u003e \n\n\u003cp\u003eApproximately 70 pages in length. \u003cbr\u003e\nApproximately 28 Charts.\u003c\/p\u003e \n\n\u003cp\u003eThe region is the USA. This report is part of the Plunkett's Corporate Benchmarks series, published by Plunkett Research, Ltd. Plunkett has unique capabilities for creating corporate and industry information, due to research that we have been conducting for more than 20 years. Our access to hundreds of industry tables from our own databases, along with our databases of public and private company information, industry trends analysis and other resources, have been utilized in preparing this report.\u003c\/p\u003e \n\n\u003cp\u003eSimilar reports are available for all significant, U.S. publicly-held firms.\u003c\/p\u003e \n\n\u003cp\u003eDesigned to benefit:\u003c\/p\u003e\n\n\u003cp\u003eInvestment Firms, Private Equity, Hedge Funds, Lenders, Appraisers and Consultants.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 86 Pages \/ MCW16248304","offer_id":47648683360562,"sku":null,"price":2994.0,"currency_code":"USD","in_stock":true}]},{"product_id":"ultragenyx-pharmaceutical-inc-rare-nas-analytics-extensive-financial-metrics-and-benchmarks-against-averages-and-top-companies-within-its-industry","title":"Ultragenyx Pharmaceutical Inc (RARE:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry","description":"\u003cp\u003eUltragenyx Pharmaceutical Inc (RARE:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry\u003cbr\u003e\nUltragenyx Pharmaceutical Inc (RARE:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry.\u003c\/p\u003e\n\n\u003cp\u003eKey Findings:This unique new report provides deep financial benchmarks for Ultragenyx Pharmaceutical Inc (RARE:NAS) compared to its top competitors and compared to the average for all companies within its primary industry.This benchmarking study for Ultragenyx Pharmaceutical Inc (RARE:NAS) includes growth forecast for its primary industry for the current year and the next 7 years. The purpose of this report is to provide vital corporate-specific benchmarks, comparing the Subject Company to its top competitors (on a company-by-company basis) and to the averages within its primary industry for all key metrics. This is a unique report containing high-value data. The report begins with a superb overview of the primary industry of the Subject Company, including historical industry revenues, revenue forecasts and CAGR. Then the report moves into industry averages and metrics, then into data specific to the Subject Company, with comparative data for the Subject Company's top competitors.\u003c\/p\u003e\n\n\u003cp\u003eThis report will save countless hours of research and analytical work for the end user.\u003c\/p\u003e\n\n\u003cp\u003eCore Benefits:\u003c\/p\u003e\n\n\u003cp\u003e1) Comprehensive benchmarks for the Subject Company:\u003c\/p\u003e\n\n\u003cp\u003ea. Benchmarked against the leading firms in its primary industry\u003cbr\u003e\nb. Benchmarked against the average for publicly-held companies (U.S.) in its industry.\u003cbr\u003e\nc. This includes financial results, ratios, operating\/financial statements and metrics in one package, including both the latest year and 6 most-recent historical years.\u003c\/p\u003e\n\n\u003cp\u003e2) A snapshot overview of the company's primary industry, including current and historic revenues and employment, along with a long term forecast for industry growth, with CAGR (compound annual growth rate), employee population and much more.\u003c\/p\u003e\n\n\u003cp\u003e3) Detailed rankings of the Subject Company against top companies within the industry (U.S.-based firms) for key items including:\u003c\/p\u003e\n\n\u003cp\u003ea. Approximate market capitalization\u003cbr\u003e\nb. Employees\u003cbr\u003e\nc. Revenues\u003cbr\u003e\nd. Net income\u003cbr\u003e\ne. 3-Year revenue growth (%)\u003cbr\u003e\nf. 3-Year income growth (%)\u003cbr\u003e\ng. Return on assets (%)\u003cbr\u003e\nh. Return on equity (%)\u003cbr\u003e\ni. Return on invested capital (%)\u003c\/p\u003e\n\n\u003cp\u003e4) Leading competitors’ profiles.\u003c\/p\u003e \n\n\u003cp\u003eApproximately 70 pages in length. \u003cbr\u003e\nApproximately 28 Charts.\u003c\/p\u003e \n\n\u003cp\u003eThe region is the USA. This report is part of the Plunkett's Corporate Benchmarks series, published by Plunkett Research, Ltd. Plunkett has unique capabilities for creating corporate and industry information, due to research that we have been conducting for more than 20 years. Our access to hundreds of industry tables from our own databases, along with our databases of public and private company information, industry trends analysis and other resources, have been utilized in preparing this report.\u003c\/p\u003e \n\n\u003cp\u003eSimilar reports are available for all significant, U.S. publicly-held firms.\u003c\/p\u003e \n\n\u003cp\u003eDesigned to benefit:\u003c\/p\u003e\n\n\u003cp\u003eInvestment Firms, Private Equity, Hedge Funds, Lenders, Appraisers and Consultants.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 86 Pages \/ MCW16248305","offer_id":47648683458866,"sku":null,"price":2994.0,"currency_code":"USD","in_stock":true}]},{"product_id":"opiant-pharmaceuticals-opnt-nas-analytics-extensive-financial-metrics-and-benchmarks-against-averages-and-top-companies-within-its-industry","title":"Opiant Pharmaceuticals (OPNT:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry","description":"\u003cp\u003eOpiant Pharmaceuticals (OPNT:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry\u003cbr\u003e\nOpiant Pharmaceuticals (OPNT:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry.\u003c\/p\u003e\n\n\u003cp\u003eKey Findings:This unique new report provides deep financial benchmarks for Opiant Pharmaceuticals (OPNT:NAS) compared to its top competitors and compared to the average for all companies within its primary industry.This benchmarking study for Opiant Pharmaceuticals (OPNT:NAS) includes growth forecast for its primary industry for the current year and the next 7 years. The purpose of this report is to provide vital corporate-specific benchmarks, comparing the Subject Company to its top competitors (on a company-by-company basis) and to the averages within its primary industry for all key metrics. This is a unique report containing high-value data. The report begins with a superb overview of the primary industry of the Subject Company, including historical industry revenues, revenue forecasts and CAGR. Then the report moves into industry averages and metrics, then into data specific to the Subject Company, with comparative data for the Subject Company's top competitors.\u003c\/p\u003e\n\n\u003cp\u003eThis report will save countless hours of research and analytical work for the end user.\u003c\/p\u003e\n\n\u003cp\u003eCore Benefits:\u003c\/p\u003e\n\n\u003cp\u003e1) Comprehensive benchmarks for the Subject Company:\u003c\/p\u003e\n\n\u003cp\u003ea. Benchmarked against the leading firms in its primary industry\u003cbr\u003e\nb. Benchmarked against the average for publicly-held companies (U.S.) in its industry.\u003cbr\u003e\nc. This includes financial results, ratios, operating\/financial statements and metrics in one package, including both the latest year and 6 most-recent historical years.\u003c\/p\u003e\n\n\u003cp\u003e2) A snapshot overview of the company's primary industry, including current and historic revenues and employment, along with a long term forecast for industry growth, with CAGR (compound annual growth rate), employee population and much more.\u003c\/p\u003e\n\n\u003cp\u003e3) Detailed rankings of the Subject Company against top companies within the industry (U.S.-based firms) for key items including:\u003c\/p\u003e\n\n\u003cp\u003ea. Approximate market capitalization\u003cbr\u003e\nb. Employees\u003cbr\u003e\nc. Revenues\u003cbr\u003e\nd. Net income\u003cbr\u003e\ne. 3-Year revenue growth (%)\u003cbr\u003e\nf. 3-Year income growth (%)\u003cbr\u003e\ng. Return on assets (%)\u003cbr\u003e\nh. Return on equity (%)\u003cbr\u003e\ni. Return on invested capital (%)\u003c\/p\u003e\n\n\u003cp\u003e4) Leading competitors’ profiles.\u003c\/p\u003e \n\n\u003cp\u003eApproximately 70 pages in length. \u003cbr\u003e\nApproximately 28 Charts.\u003c\/p\u003e \n\n\u003cp\u003eThe region is the USA. This report is part of the Plunkett's Corporate Benchmarks series, published by Plunkett Research, Ltd. Plunkett has unique capabilities for creating corporate and industry information, due to research that we have been conducting for more than 20 years. Our access to hundreds of industry tables from our own databases, along with our databases of public and private company information, industry trends analysis and other resources, have been utilized in preparing this report.\u003c\/p\u003e \n\n\u003cp\u003eSimilar reports are available for all significant, U.S. publicly-held firms.\u003c\/p\u003e \n\n\u003cp\u003eDesigned to benefit:\u003c\/p\u003e\n\n\u003cp\u003eInvestment Firms, Private Equity, Hedge Funds, Lenders, Appraisers and Consultants.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 82 Pages \/ MCW16248306","offer_id":47648683589938,"sku":null,"price":2994.0,"currency_code":"USD","in_stock":true}]},{"product_id":"pharmaceutical-quality-management-systems-market-by-solution-type-deviation-capa-audit-risk-compliance-inspection-document-change-training-management-deployment-mode-cloud-on-premise-and-end-user-pharmaceutical-cdmo-cro-global-forecas","title":"Pharmaceutical Quality Management Systems Market by Solution Type (Deviation, CAPA, Audit, Risk \u0026 Compliance, Inspection, Document, Change, Training Management), Deployment Mode (Cloud, On-premise), and End User (Pharmaceutical, CDMO\/CRO) - Global Forecas","description":"\u003cp\u003ePharmaceutical Quality Management Systems Market By Solution Type (Deviation, CAPA, Audit, Risk \u0026amp; Compliance, Inspection, Document, Change, Training Management), Deployment Mode (Cloud, On-premise), and End User (Pharmaceutical, CDMO\/CRO)—Global Forecast to 2030\u003cbr\u003e\nThe pharmaceutical quality management systems market is expected to reach $3.97 billion by 2030, at a CAGR of 15.6% from 2023 to 2030.\u003c\/p\u003e\n\n\u003cp\u003eSucceeding extensive secondary and primary research and in-depth analysis of the market scenario, the report studies the key industry drivers, restraints, challenges, and opportunities. The growth of this market is driven by the increasing costs of drug manufacturing, pharmaceutical companies growing need to comply with regulatory requirements, the rapid growth of the pharmaceutical industry, and the benefits of software-based quality management systems. Additionally, the growing generic drugs \u0026amp; and biopharmaceuticals markets and pharmaceutical companies' increasing preference for platform-as-a-service solutions are expected to generate growth opportunities for the players in this market. However, the high costs of deploying pharmaceutical quality management systems restrain the growth of this market. Security concerns related to on-cloud deployments among pharmaceutical organizations are a major challenge for market growth.\u003c\/p\u003e\n\n\u003cp\u003eBased on solution type, the pharmaceutical quality management systems market is segmented into non-conformance\/deviation management, CAPA management, audit management, risk \u0026amp; compliance management, suppliers \u0026amp; materials management, inspection management, document management, change management, training management, and other solution types. The CAPA management segment is expected to grow at the highest CAGR during the forecast period. The need for Corrective and Preventive Action (CAPA) management in the pharmaceutical industry is driven by several factors that ensure product quality, patient safety, and regulatory compliance. CAPA management is essential for addressing issues and preventing their recurrence, further contributing to the overall integrity of pharmaceutical operations.\u003c\/p\u003e\n\n\u003cp\u003eBased on deployment mode, the global pharmaceutical quality management systems market is segmented into cloud\/web-based and on-premise. In 2023, the cloud\/web-based segment is expected to account for the largest share of the pharmaceutical quality management systems market. The largest share of this segment is attributed to several advantages offered by cloud\/web-based deployments over on-premise deployments, such as cost minimization, easy accessibility, adjustability, and updated cloud systems. Another major advantage of web-based deployments is the lower risk of data loss through better encryption and data backup.\u003c\/p\u003e\n\n\u003cp\u003eBased on end user, the global pharmaceutical quality management systems market is segmented into pharmaceutical and biotechnology companies, contract development and manufacturing organizations\/contract research organizations, and research laboratories. The pharmaceutical and biotechnology companies segment is expected to grow at the highest CAGR during the forecast period. The highest CAGR of the segment is attributed to increasing R\u0026amp;D investments by pharmaceutical \u0026amp; biotechnology companies, widespread utilization of quality management systems to ensure product quality, and a growing emphasis on personalized medicine research.\u003c\/p\u003e\n\n\u003cp\u003eAn in-depth analysis of the geographical scenario of the pharmaceutical quality management systems market provides detailed qualitative and quantitative insights into five major geographies: North America, Europe, Asia-Pacific, Latin America, and the Middle East \u0026amp; Africa, along with the coverage of major countries in each region. Asia-Pacific is slated to register with the highest CAGR during the forecast period. The healthcare needs of people in Asia–Pacific countries are progressively increasing due to the rising burden of chronic diseases. A large population pool and government initiatives to improve healthcare facilities and services in these countries are the key factors supporting the growth of the Asia-Pacific market. These countries have also been identified as low-cost destinations for pharmaceutical manufacturers for a long time, which further supports the growth of this market in Asia-Pacific.\u003c\/p\u003e\n\n\u003cp\u003eSome of the key players operating in the global pharmaceutical quality management systems market are Honeywell International Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ANTARES VISION S.p.A (Italy), Dassault Systèmes SE (France), EtQ Management Consultants, Inc. (U.S.), Ideagen PLC (U.K.), Körber AG (Germany), LogicGate, Inc. (U.S.), ComplianceQuest, Inc (U.S.), AssurX, Inc. (U.S.), and AXSource Consulting, Inc. (U.S.).\u003c\/p\u003e\n\n\u003cp\u003eScope of the Report:\u003c\/p\u003e\n\n\u003cp\u003ePharmaceutical Quality Management Systems Market Assessment by Solution TypeNon-conformance\/Deviation managementDocument ManagementCAPA ManagementRisk \u0026amp; Compliance ManagementInspection ManagementAudit ManagementSuppliers \u0026amp; Materials ManagementTraining ManagementChange ManagementOther Solution Types(Other solution types include complaint management, out-of-specification, release management, incidents \u0026amp; and occurrence management, post-market surveillance, design control, and asset management.)\u003c\/p\u003e\n\n\u003cp\u003ePharmaceutical Quality Management Systems Market Assessment, by Deployment ModeCloud\/Web-basedOn-PremisePharmaceutical Quality Management Systems Market Assessment, by End UserPharmaceutical and Biotechnology CompaniesCDMO\/CROResearch LaboratoriesPharmaceutical Quality Management Systems Market Assessment, by GeographyNorth AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalySpainIrelandBelgiumNetherlandsRest of EuropeAsia-PacificChinaJapanIndiaSingaporeMalaysiaPhilippinesVietnamRest of Asia-PacificLatin AmericaBrazilMexicoRest of Latin AmericaMiddle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003ePharmaceutical Quality Management Systems Market - Global Opportunity Analysis and Industry Forecast (2023–2030) - Report SummaryReport MetricsDetailsYears Considered2021 - 2030Base Year2022Forecast Period2023-2030Page Count215Units ReferencedValue (USD Million)Segments\/Key TopicsMarket by Solution Type, Deployment Mode, End UserRegions CoveredNorth America, Europe, Asia-Pacific, Latin America, Middle East \u0026amp; AfricaKey Companies MentionedHoneywell International Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ANTARES VISION S.p.A (Italy), Dassault Systèmes SE (France), EtQ Management Consultants, Inc. (U.S.), Ideagen PLC (U.K.), Körber AG (Germany), LogicGate, Inc. (U.S.), ComplianceQuest, Inc (U.S.), AssurX, Inc. (U.S.), and AXSource Consulting, Inc. (U.S.).\u003c\/p\u003e\n\n\u003cp\u003eFAQs About the Report\u003c\/p\u003e\n\n\u003cp\u003eWhat is the focus of the Pharmaceutical Quality Management Systems Market study?\u003c\/p\u003e\n\n\u003cp\u003eThe pharmaceutical quality management systems market report covers market sizes \u0026amp; forecasts for solution types. The pharmaceutical quality management systems market study includes the value analysis of various segments and subsegments of the Pharmaceutical Quality Management Systems Market at the country \u0026amp; regional level.\u003c\/p\u003e\n\n\u003cp\u003eWhat is the revenue generated from the sales of pharmaceutical quality management systems across the globe? At what rate is the demand expected to grow for the next 5–7 years?\u003c\/p\u003e\n\n\u003cp\u003eThe pharmaceutical quality management systems market is projected to reach $3.97 billion by 2030, at a CAGR of 15.6% from 2023 to 2030.\u003c\/p\u003e\n\n\u003cp\u003eWhich type of solution segment is estimated to hold the major share of the market in 2023?\u003c\/p\u003e\n\n\u003cp\u003eThe non-conformance\/deviation management segment is estimated to account for the largest share of the pharmaceutical quality management systems market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eWhich deployment mode segment is projected to gain more traction in the Pharmaceutical Quality Management Systems Market?\u003c\/p\u003e\n\n\u003cp\u003eThe cloud\/web-based segment is projected to gain more traction in the pharmaceutical quality management systems market.\u003c\/p\u003e\n\n\u003cp\u003eWhat are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the Pharmaceutical Quality Management Systems Market?\u003c\/p\u003e\n\n\u003cp\u003eThe growth of the pharmaceutical quality management systems market is mainly attributed to the growth of this market is driven by the increasing costs of drug manufacturing, pharmaceutical companies’ growing need to comply with regulatory requirements, the rapid growth of the pharmaceutical industry, and the benefits of software-based quality management systems. Moreover, the growing generic drugs \u0026amp; biopharmaceuticals markets and pharmaceutical companies' increasing preference for platform-as-a-service solutions are expected to generate growth opportunities for the players in this market.\u003c\/p\u003e\n\n\u003cp\u003eWho are the major players operating in the Pharmaceutical Quality Management Systems Market?\u003c\/p\u003e\n\n\u003cp\u003eThe key players operating in the pharmaceutical quality management systems market are Honeywell International Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ANTARES VISION S.p.A (Italy), Dassault Systèmes SE (France), EtQ Management Consultants, Inc. (U.S.), Ideagen PLC (U.K.), Körber AG (Germany), LogicGate, Inc. (U.S.), ComplianceQuest, Inc (U.S.), AssurX, Inc. (U.S.), and AXSource Consulting, Inc. (U.S.).\u003c\/p\u003e\n\n\u003cp\u003eWhich countries will likely offer significant growth opportunities for the vendors in this market during the analysis period?\u003c\/p\u003e\n\n\u003cp\u003eEmerging economies in Asia-Pacific, including China and India, are expected to offer growth opportunities for the players in this market. Government initiatives for improving domestic manufacturing, an established pharmaceutical market, increasing R\u0026amp;D expenditures by pharmaceutical and biopharmaceutical companies, favorable regulatory policies, and the surge in the aging population are the key factors driving the market's growth.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 215 Pages \/ MCW16248308","offer_id":47648683721010,"sku":null,"price":5010.0,"currency_code":"USD","in_stock":true}]},{"product_id":"pharmaceutical-grade-lithium-carbonate-market-by-application-extended-release-immediate-release-purity-99-above-99-and-region-asia-pacific-europe-north-america-middle-east-africa-and-south-america-global-forecast-to-2028","title":"Pharmaceutical Grade Lithium Carbonate Market by Application (Extended Release, Immediate Release), Purity (99%, Above 99%), and Region (Asia Pacific, Europe, North America, Middle East \u0026 Africa, and South America) - Global Forecast to 2028","description":"\u003cp\u003ePharmaceutical Grade Lithium Carbonate Market by Application (Extended Release, Immediate Release), Purity (99%, Above 99%), and Region (Asia Pacific, Europe, North America, Middle East \u0026amp; Africa, and South America) - Global Forecast to 2028\u003c\/p\u003e\n\n\u003cp\u003eThe pharmaceutical grade lithium carbonate market is projected to grow from USD 141 million in 2023 to USD 166 million by 2028, at a CAGR of 3.3% from 2023 to 2028. Lithium carbonate is commonly used as a mood stabilizer in the treatment of mental conditions such as bipolar disorder. As mental health awareness increases and more people seek treatment, the demand for pharmaceutical grade lithium carbonate is expected to increase.\u003c\/p\u003e \n\n \u003cp\u003e“By application, extended release segment is expected to be the larger segment during 2023 to 2028.”\u003c\/p\u003e \n\n\u003cp\u003eThe pharmaceutical grade lithium carbonate extended release medications release the drug gradually over an extended period of time. This leads to more consistent drug levels in the bloodstream, reducing the fluctuations that can occur with immediate release medications. This steadier concentration of medicine in the body can lead to better therapeutic outcomes and reduced side effects. Also, many patients suffering from anxiety and other mental illness requires long-term treatment. Extended release formulations are particularly beneficial for these conditions because they provide a sustained effect over time, reducing the need for frequent dosing and improving the patient’s quality of life.\u003c\/p\u003e\n\n\u003cp\u003e“By region, North America is expected to be the largest market in 2023, by value.”\u003c\/p\u003e\n\n\u003cp\u003eMental health awareness has been on the rise in North America, leading to greater recognition and diagnosis of conditions like bipolar disorder. Lithium carbonate is a common treatment for bipolar disorder, and as more individuals seek treatment, the demand for pharmaceutical grade lithium carbonate is expected to increase. North America has a well-developed healthcare infrastructure, which allows for the effective distribution and access to pharmaceuticals. The availability of healthcare services and medications, including pharmaceutical grade lithium carbonate, contributes to market growth.\u003c\/p\u003e\n\n\u003cp\u003eProfile break-up of primary participants for the report:\u003c\/p\u003e\n\n\u003cp\u003eBy Company Type: Tier 1 - 65%, Tier 2 - 20%, and Tier 3 - 15%\u003c\/p\u003e \n\n\u003cp\u003eBy Designation: C-level Executives - 25%, Directors - 30%, and Others - 45%\u003c\/p\u003e\n\n\u003cp\u003eBy Region: North America - 20%, Europe - 15%, Asia Pacific - 55%, Middle East \u0026amp; Africa - 3%, South America - 7%\u003c\/p\u003e\n\n\u003cp\u003eThe pharmaceutical grade lithium carbonate contactor report is dominated by players, such as Livent Corporation (US), Albemarle Corporation (US), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (China), American Elements (US), Globe Química (US), Jiangsu Nhwa Pharmaceutical Co., Ltd. (China), Panchsheel Organics Ltd (POLTD) (India), Blanver (Brazil), and others.\u003c\/p\u003e\n\n\u003cp\u003eResearch Coverage:\u003c\/p\u003e\n\n\u003cp\u003eThe report defines, segments, and projects the size of the pharmaceutical grade lithium carbonate contactor market based on application, purity, and region. It strategically profiles the key players and comprehensively analyzes their market share and core competencies. It also tracks and analyzes competitive developments, such as product launch, agreement, acquisition, and investments undertaken by them in the market.\u003c\/p\u003e \n\n\u003cp\u003eReasons to Buy the Report:\u003c\/p\u003e\n\n\u003cp\u003eThe report is expected to help the market leaders\/new entrants in the market by providing them with the closest approximations of revenue numbers of the pharmaceutical grade lithium carbonate contactor market and its segments. This report is also expected to help stakeholders obtain an improved understanding of the competitive landscape of the market, gain insights to improve the position of their businesses and make suitable go-to-market strategies. It also enables stakeholders to understand the pulse of the market and provide them information on key market drivers, restraints, challenges, and opportunities.\u003c\/p\u003e \n\n\u003cp\u003eThe report provides insights on the following pointers:\u003c\/p\u003e\n\n\u003cp\u003eAnalysis of key drivers (rising cases of mental illness), restraints (side effects and safety concerns), opportunities (potential for new applications owing to clinical research and innovation), and challenges (stigma and perception of mental health disorder) influencing the growth of the pharmaceutical grade lithium carbonate contactor market.\u003c\/p\u003e  \n\n\u003cp\u003eProduct Development\/Innovation: Detailed insights on upcoming technologies, research \u0026amp; development activities in the pharmaceutical grade lithium carbonate contactor market.\u003c\/p\u003e\n\n\u003cp\u003eMarket Development: Comprehensive information about lucrative markets – the report analyses the pharmaceutical grade lithium carbonate contactor market across varied regions.\u003c\/p\u003e \n\n\u003cp\u003eMarket Diversification: Exhaustive information about new products, various production technologies, untapped geographies, recent developments, and investments in the pharmaceutical grade lithium carbonate contactor market.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players such as Livent Corporation (US), Albemarle Corporation (US), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (China), American Elements (US), Globe Química (US), Jiangsu Nhwa Pharmaceutical Co., Ltd. (China), Panchsheel Organics Ltd (POLTD) (India), Blanver (Brazil), among others in the pharmaceutical grade lithium carbonate contactor market.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 144 Pages \/ MCW16248310","offer_id":47648683819314,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}]},{"product_id":"eu5-icp-procedures-count-and-forecast-to-2030","title":"EU5 ICP Procedures Count and Forecast to 2030","description":"\u003cp\u003eEU5 ICP Procedures Count and Forecast to 2030\u003cbr\u003e\nSummary\u003c\/p\u003e\n\n\u003cp\u003eGlobalData’s “EU5 ICP Procedures Outlook to 2030” is a comprehensive databook report, covering key procedures data on the EU5 ICP Procedures.\u003c\/p\u003e\n\n\u003cp\u003eThe EU5 ICP Procedures report provides key information and data on -Procedure volume data for ICP Procedures related to the country. Data is provided from 2015 to 2030.Scope\u003c\/p\u003e\n\n\u003cp\u003eEU5 ICP Procedures is segmented as follows -ICP ProceduresReasons to Buy\u003c\/p\u003e\n\n\u003cp\u003eEU5 ICP Procedures report helps you to develop -Business strategies by identifying the key segments poised for strong growth in the future.Market-entry and market expansion strategies.Develop investment strategies by identifying the key segments expected to register strong growth in the near future.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 38 Pages \/ MCW16248312","offer_id":47648683950386,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}]},{"product_id":"north-america-icp-procedures-count-and-forecast-to-2030","title":"North America ICP Procedures Count and Forecast to 2030","description":"\u003cp\u003eNorth America ICP Procedures Count and Forecast to 2030\u003cbr\u003e\nSummary\u003c\/p\u003e\n\n\u003cp\u003eGlobalData’s “North America ICP Procedures Outlook to 2030” is a comprehensive databook report, covering key procedures data on the North America ICP Procedures.\u003c\/p\u003e\n\n\u003cp\u003eThe North America ICP Procedures report provides key information and data on -Procedure volume data for ICP Procedures related to the country. Data is provided from 2015 to 2030.Scope\u003c\/p\u003e\n\n\u003cp\u003eNorth America ICP Procedures is segmented as follows -ICP ProceduresReasons to Buy\u003c\/p\u003e\n\n\u003cp\u003eNorth America ICP Procedures report helps you to develop -Business strategies by identifying the key segments poised for strong growth in the future.Market-entry and market expansion strategies.Develop investment strategies by identifying the key segments expected to register strong growth in the near future.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 30 Pages \/ MCW16248314","offer_id":47648684146994,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}]},{"product_id":"asia-pacific-apac-icp-procedures-count-and-forecast-to-2030","title":"Asia-Pacific (APAC) ICP Procedures Count and Forecast to 2030","description":"\u003cp\u003eAsia-Pacific (APAC) ICP Procedures Count and Forecast to 2030\u003cbr\u003e\nSummary\u003c\/p\u003e\n\n\u003cp\u003eGlobalData’s “Asia-Pacific ICP Procedures Outlook to 2030” is a comprehensive databook report, covering key procedures data on the Asia-Pacific ICP Procedures.\u003c\/p\u003e\n\n\u003cp\u003eThe Asia-Pacific ICP Procedures report provides key information and data on -Procedure volume data for ICP Procedures related to the country. Data is provided from 2015 to 2030.Scope\u003c\/p\u003e\n\n\u003cp\u003eAsia-Pacific ICP Procedures is segmented as follows -ICP ProceduresReasons to Buy\u003c\/p\u003e\n\n\u003cp\u003eAsia-Pacific ICP Procedures report helps you to develop -Business strategies by identifying the key segments poised for strong growth in the future.Market-entry and market expansion strategies.Develop investment strategies by identifying the key segments expected to register strong growth in the near future.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 38 Pages \/ MCW16248316","offer_id":47648684245298,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}]},{"product_id":"asia-pacific-enteral-and-parenteral-medical-nutrition-market-forecast-to-2028-regional-analysis-by-indication-elderly-gastrointestinal-disorders-ibd-ibs-and-others-diabetes-cancer-respiratory-disorders-alzheimer-s-disease-dementia-renal-dise","title":"Asia Pacific Enteral and Parenteral Medical Nutrition Market Forecast to 2028 - Regional Analysis By Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer’s Disease, Dementia, Renal Dise","description":"\u003cp\u003eAsia Pacific Enteral and Parenteral Medical Nutrition Market Forecast to 2028 - Regional Analysis By Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer’s Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole Source), Form (Liquid, Powder, and Semi Solid), Product Type (General and Disease Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18-60 Years, 3-18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)\u003cbr\u003e\nThe Asia Pacific enteral and parenteral medical nutrition market is expected to grow from US$ 2,339.32 million in 2023 to US$ 3,352.69 million by 2028. It is estimated to grow at a CAGR of 7.5% from 2023 to 2028.\u003c\/p\u003e\n\n\u003cp\u003eGrowing Strategic Initiatives by Companies Fuels Asia Pacific Enteral and Parenteral Medical Nutrition Market\u003c\/p\u003e\n\n\u003cp\u003eCompanies operating in the enteral and parenteral medical nutrition market constantly focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a greater than existing customer base. A few of the noteworthy developments in the enteral and parenteral medical nutrition market are mentioned such as- In June 2022, Nestle Health Science acquired The Better Health Company (TBHC) from CDH Investments and TBHC founding shareholders. The acquisition includes the GO Healthy brand, along with its vitamin and supplement lineups; the Manuka honey brand Egmont; and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins, minerals, and supplements. The acquisition helped Nestle Health Science strengthen and expand its presence in New Zealand, Australia, and other Asia Pacific countries. In September 2021, Abbott introduced plant-based protein and organic food ingredients—PediaSure Harvest and Ensure Harvest—for people relying on feeding tubes. Harvest products can be used as sole-source nutrition or a supplement to satisfy daily nutrition requirements. In December 2020, Abbott launched the Pedialyte Hydration Solution, a new formulation designed with key nutrients to support immune health. Pedialyte with immune support includes prebiotics, vitamin B12, vitamin C, vitamin E, and zinc, specifically chosen for their importance in the development and improvement of the immune system. In October 2020, Nutricia (part of Danone) acquired Real Food Blends. The company helps contribute to the real food blends mission and portfolio by bringing more unique and nutritious choices to children and adults dependent on feeding tubes. Therefore, introducing products such as ready-to-drink and ready-to-use nutritional supplements; the development of innovative products targeting various health issues; and strategic moves such as expansions and acquisitions allow companies in the enteral and parenteral medical nutrition market to create new or improved products and new business to remain competitive in the market. Thus, such strategic growth initiatives create significant growth opportunities in the market.\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific Enteral and Parenteral Medical Nutrition Market Overview\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific (APAC) is the fastest-growing regional market for enteral and parenteral medical nutrition and is segmented into China, Japan, India, South Korea, Australia, Indonesia, Thailand, Vietnam, and the Rest of Asia Pacific. Factors contributing to the growth of the market in the region are the rising prevalence of chronic diseases and the growing presence of market players across the region, conferring the highest manufacturing of enteral \u0026amp; parenteral nutrition products. Furthermore, supportive government initiatives and research in the field of nutrition boost market growth.\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific Enteral and Parenteral Medical Nutrition Market Revenue and Forecast to 2028 (US$ Million)\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific Enteral and Parenteral Medical Nutrition Market Segmentation\u003c\/p\u003e\n\n\u003cp\u003eThe Asia Pacific enteral and parenteral medical nutrition market is segmented into indication, nutrition type, form, product type, route of administration, age group, and distribution channel, and country.\u003c\/p\u003e\n\n\u003cp\u003eBased on indication, the Asia Pacific enteral and parenteral medical nutrition market is segmented into elderly, gastrointestinal disorders, diabetes, cancer, respiratory disorders, alzheimer’s disease, dementia, renal disease, liver failure, post covid-19, and other indications. The elderly segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023. Gastrointestinal disorders are segmented into IBD, IBS, and others.\u003c\/p\u003e\n\n\u003cp\u003eBased on nutrition type, the Asia Pacific enteral and parenteral medical nutrition market is segmented into supplemental and sole source. The supplemental segment held a larger share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on form, the Asia Pacific enteral and parenteral medical nutrition market is segmented into liquid, powder, and semi solid. The liquid segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on product type, the Asia Pacific enteral and parenteral medical nutrition market is segmented into general and disease specific. The general segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on route of administration, the Asia Pacific enteral and parenteral medical nutrition market is segmented into oral, tube feed, and parenteral. The parenteral segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on age group, the Asia Pacific enteral and parenteral medical nutrition market is segmented into above 60 years, 18-60 years, 3-18 years, and below 3 years. The above 60 years segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on distribution channel, the Asia Pacific enteral and parenteral medical nutrition market is segmented into a hospital pharmacies, retail stores, e-commerce, and others. The hospital pharmacies segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023\u003c\/p\u003e\n\n\u003cp\u003eBased on country, the Asia Pacific enteral and parenteral medical nutrition market is segmented into China, Japan, India, Australia, South Korea, Indonesia, Thailand, Vietnam, and the Rest of Asia Pacific. China dominated the share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eAbbott Laboratories; B. Braun SE; Baxter International Inc; Fresenius Kabi AG; Nestle SA; and Nutricia International BV are some of the leading companies operating in the Asia Pacific enteral and parenteral medical nutrition market.\u003c\/p\u003e \n\n\u003cp\u003eReasons to Buy\u003c\/p\u003e\n\n\u003cp\u003eSave and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific enteral and parenteral medical nutrition market.\u003cbr\u003e\nHighlights key business priorities in order to assist companies to realign their business strategies.\u003cbr\u003e\nThe key findings and recommendations highlight crucial progressive industry trends in Asia Pacific enteral and parenteral medical nutrition market, thereby allowing players across the value chain to develop effective long-term strategies.\u003cbr\u003e\nDevelop\/modify business expansion plans by using substantial growth offering developed and emerging markets.\u003cbr\u003e\nScrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.\u003cbr\u003e\nEnhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 348 Pages \/ MCW16248319","offer_id":47648684343602,"sku":null,"price":3600.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-pneumococcal-vaccine-market-2023-2027","title":"Global Pneumococcal Vaccine Market 2023-2027","description":"\u003cp\u003eGlobal Pneumococcal Vaccine Market 2023-2027\u003cbr\u003e\nThe pneumococcal vaccine market is forecasted to grow by USD 2,820.53 mn during 2022-2027, accelerating at a CAGR of 5.81% during the forecast period. The report on the pneumococcal vaccine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\u003c\/p\u003e\n\n\u003cp\u003eThe report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expanding immunization programs by government in developing countries, increasing awareness regarding vaccination, and growing incidences of pneumococcal diseases.\u003c\/p\u003e\n\n\u003cp\u003eTechnavio's pneumococcal vaccine market is segmented as below:\u003c\/p\u003e\n\n\u003cp\u003eBy TypePneumococcal conjugate vaccinePneumococcal polysaccharide vaccineBy Distribution ChannelNon-governmental organizationsGovernment authoritiesDistribution partner companiesBy Geographical LandscapeNorth AmericaEuropeAsiaRest of World (ROW)This study identifies the advancements in vaccine technologies as one of the prime reasons driving the pneumococcal vaccine market growth during the next few years. Also, emergence of novel pneumococcal vaccines and emergence of combination vaccines will lead to sizable demand in the market.\u003c\/p\u003e\n\n\u003cp\u003eThe report on the pneumococcal vaccine market covers the following areas:Pneumococcal vaccine market sizingPneumococcal vaccine market forecastPneumococcal vaccine market industry analysisThe robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pneumococcal vaccine market vendors that include Astellas Pharma Inc., CSL Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Sinovac Biotech Ltd., SK Inc., Biological E. Ltd., Inventprise Inc., Petrovax, Vaxcyte Inc., and Walvax Biotechnology Co. Ltd.. Also, the pneumococcal vaccine market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.\u003c\/p\u003e\n\n\u003cp\u003eThe study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.\u003c\/p\u003e \n\n\u003cp\u003eThe publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 155 Pages \/ MCW16248322","offer_id":47648684474674,"sku":null,"price":3000.0,"currency_code":"USD","in_stock":true}]},{"product_id":"europe-enteral-and-parenteral-medical-nutrition-market-forecast-to-2028-regional-analysis-by-indication-elderly-gastrointestinal-disorders-ibd-ibs-and-others-diabetes-cancer-respiratory-disorders-alzheimer-s-disease-dementia-renal-disease-l","title":"Europe Enteral and Parenteral Medical Nutrition Market Forecast to 2028 - Regional Analysis By Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer’s Disease, Dementia, Renal Disease, L","description":"\u003cp\u003eEurope Enteral and Parenteral Medical Nutrition Market Forecast to 2028 - Regional Analysis By Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer’s Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole Source), Form (Liquid, Powder, and Semi Solid), Product Type (General and Disease Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18-60 Years, 3-18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)\u003cbr\u003e\nThe Europe enteral and parenteral medical nutrition market is expected to grow from US$ 6,472.35 million in 2023 to US$ 9,054.89 million by 2028. It is estimated to grow at a CAGR of 6.9% from 2023 to 2028.\u003c\/p\u003e\n\n\u003cp\u003eIncreasing Cases of Malnutrition and Premature Births Fuels Europe Enteral and Parenteral Medical Nutrition Market\u003c\/p\u003e\n\n\u003cp\u003eMalnutrition includes being undernourished, overweight or obese, having inadequate vitamins or minerals, and having a non-communicable disease due to a bad diet. According to a Specialized Nutrition Europe study, nearly 40% of hospitalized adult patients were malnourished in Europe in 2019. Nutritional support delivered through enteral \u0026amp; parenteral means, depending on the need, is an important and appropriate way of treating most malnutrition cases. Thus, the huge burden of malnutrition in children and adults drives the demand for enteral and parenteral nutrition formulae and products. Preterm birth refers to a baby being born too early, i.e., before the completion of 37 weeks of pregnancy. As per the WHO data published in 2023, ~13.4 million preterm birth (more than 1 in 10 births) were reported worldwide in 2020. Most medical guidelines advise enteral nutrition for supporting the optimal growth of preterm infants if they are unable to drink, suck, swallow, and breathe, also parenteral nutrition is preferred in such babies due to sucking or swallowing difficulties as a complication of an immature birth or due to neuromuscular, heart, or other disorders. Hence, with the high number of preterm births, the demand for enteral and parenteral medical nutrition is on the rise in the region.\u003c\/p\u003e\n\n\u003cp\u003eEurope Enteral and Parenteral Medical Nutrition Market Overview\u003c\/p\u003e\n\n\u003cp\u003eThe Europe enteral and parenteral medical nutrition market is segmented into Germany, the UK, France, Italy, Spain, Poland, Switzerland, Sweden, Belgium, the Netherlands, and the Rest of Europe. Europe occupies a significant position in the Europe enteral and parenteral medical nutrition market and is estimated to register a robust growth rate over the forecast period. The market growth can be attributed to increasing geriatric population, rising incidence of chronic diseases and neurological disorders such as stroke and cerebral aneurysms, and product innovations by the players operating in the region.\u003c\/p\u003e\n\n\u003cp\u003eEurope Enteral and Parenteral Medical Nutrition Market Revenue and Forecast to 2028 (US$ Million)\u003c\/p\u003e\n\n\u003cp\u003eEurope Enteral and Parenteral Medical Nutrition Market Segmentation\u003c\/p\u003e\n\n\u003cp\u003eThe Europe enteral and parenteral medical nutrition market is segmented into indication, nutrition type, form, product type, route of administration, age group, and distribution channel, and country.\u003c\/p\u003e\n\n\u003cp\u003eBased on indication, the Europe enteral and parenteral medical nutrition market is segmented into elderly, gastrointestinal disorders, diabetes, cancer, respiratory disorders, alzheimer’s disease, dementia, renal disease, liver failure, post covid-19, and other indications. The elderly segment held the largest share of the Europe enteral and parenteral medical nutrition market in 2023. Gastrointestinal disorders are segmented into IBD, IBS, and others.\u003c\/p\u003e\n\n\u003cp\u003eBased on nutrition type, the Europe enteral and parenteral medical nutrition market is segmented into supplemental and sole source. The supplemental segment held a larger share of the Europe enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on form, the Europe enteral and parenteral medical nutrition market is segmented into liquid, powder, and semi solid. The liquid segment held the largest share of the Europe enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on product type, the Europe enteral and parenteral medical nutrition market is segmented into general and disease specific. The general segment held the largest share of the Europe enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on route of administration, the Europe enteral and parenteral medical nutrition market is segmented into oral, tube feed, and parenteral. The parenteral segment held the largest share of the Europe enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on age group, the Europe enteral and parenteral medical nutrition market is segmented into above 60 years, 18-60 years, 3-18 years, and below 3 years. The above 60 years segment held the largest share of the Europe enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on distribution channel, the Europe enteral and parenteral medical nutrition market is segmented into a hospital pharmacies, retail stores, e-commerce, and others. The hospital pharmacies segment held the largest share of the Europe enteral and parenteral medical nutrition market in 2023\u003c\/p\u003e\n\n\u003cp\u003eBased on country, the Europe enteral and parenteral medical nutrition market is segmented into Germany, the UK, France, Italy, Spain, Poland, Switzerland, Sweden, Belgium, the Netherlands, and the Rest of Europe. Germany dominated the share of the Europe enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eAbbott Laboratories; AYMES International Ltd; B. Braun SE; Baxter International Inc; Charing Cross Scientific AS; Fresenius Kabi AG; Medifood International SA; Nestle SA; Nutricia International BV; and Smartfish AS are some of the leading companies operating in the Europe enteral and parenteral medical nutrition market.\u003c\/p\u003e \n\n\u003cp\u003eReasons to Buy\u003c\/p\u003e\n\n\u003cp\u003eSave and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe enteral and parenteral medical nutrition market.\u003cbr\u003e\nHighlights key business priorities in order to assist companies to realign their business strategies.\u003cbr\u003e\nThe key findings and recommendations highlight crucial progressive industry trends in Europe enteral and parenteral medical nutrition market, thereby allowing players across the value chain to develop effective long-term strategies.\u003cbr\u003e\nDevelop\/modify business expansion plans by using substantial growth offering developed and emerging markets.\u003cbr\u003e\nScrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.\u003cbr\u003e\nEnhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 417 Pages \/ MCW16248332","offer_id":47648684736818,"sku":null,"price":3600.0,"currency_code":"USD","in_stock":true}]},{"product_id":"north-america-enteral-and-parenteral-medical-nutrition-market-forecast-to-2028-regional-analysis-by-indication-elderly-gastrointestinal-disorders-ibd-ibs-and-others-diabetes-cancer-respiratory-disorders-alzheimer-s-disease-dementia-renal-dis","title":"North America Enteral and Parenteral Medical Nutrition Market Forecast to 2028 - Regional Analysis By Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer’s Disease, Dementia, Renal Dis","description":"\u003cp\u003eNorth America Enteral and Parenteral Medical Nutrition Market Forecast to 2028 - Regional Analysis By Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer’s Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole Source), Form (Liquid, Powder, and Semi Solid), Product Type (General and Disease Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18-60 Years, 3-18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)\u003cbr\u003e\nThe North America enteral and parenteral medical nutrition market is expected to grow from US$ 8,049.98 million in 2023 to US$ 11,030.78 million by 2028. It is estimated to grow at a CAGR of 6.5% from 2023 to 2028.\u003c\/p\u003e\n\n\u003cp\u003eRise in Prevalence of Gastrointestinal Diseases Fuels North America Enteral and Parenteral Medical Nutrition Market\u003c\/p\u003e\n\n\u003cp\u003eCrohn’s disease, bowel obstruction, ulcerative colitis, short bowel syndrome, microscopic colitis, and certain cancers are a few examples of gastrointestinal diseases.\u003c\/p\u003e\n\n\u003cp\u003eBased on the Global Burden of Disease Study 2019, ~4.9 million cases of inflammatory bowel disease (IBD) were recorded worldwide in 2019; China (911,405) and the US (762,890) had the highest number of cases, with prevalence of 66.9 and 245.3 cases per 100,000 people, respectively. Crohn’s disease and ulcerative colitis are two of the commonly diagnosed IBDs. Crohn’s disease is a complex, chronic disorder primarily affecting the digestive system. It is the most common disease in North America. Moreover, short bowel syndrome (SBS) occurs in ~3 per 1 million people yearly. As per the article titled “Understanding Short Bowel Syndrome: Current Status and Future Perspectives, published in 2020, the prevalence of SBS has increased by more than twofold in the last 40 years. The prevalence was ~30 cases per million in the US.\u003c\/p\u003e\n\n\u003cp\u003ePatients with gastrointestinal diseases are at an elevated risk of nutritional deterioration as they are asked to fast before undergoing diagnostic tests. They may also face nutritional deterioration due to therapeutic dietary restriction and loss of appetite caused by anorexia or altered nutritional requirement, which can be a result of the disease itself. Thus, medical nutrition is recommended for gastrointestinal disease patients as these patients cannot ingest food. Thus, the enteral and parenteral routes are preferred to provide them with essential nutrients. Enteral feeding refers to food nutrition intake directly through the mouth or through a tube that passes the digestive tract (mouth to stomach\/small intestine and then anus). This type of nutrition is preferred to provide treatment support for patients suffering from chronic ailments, such as neurological disorders, gastrointestinal diseases, and inherited metabolic diseases. Some people may not show compatibility toward tube insertion, which makes meeting their calorie and nutrient needs difficult. In such cases, parenteral nutrition is preferred to ensure their bodies remain hydrated and meet the calorie and other nutrient intake required to maintain physical well-being and function. Parenteral nutrition is indicated when patients cannot meet their nutritional needs due to diseases, such as cancer and chronic diseases affecting the gastrointestinal tract. This type of nutrition is the cornerstone of therapy for most patients with severe SBS. Therefore, the elevating prevalence of gastrointestinal diseases drives the growth of the North America enteral and parenteral medical nutrition market.\u003c\/p\u003e\n\n\u003cp\u003eNorth America Enteral and Parenteral Medical Nutrition Market Overview\u003c\/p\u003e\n\n\u003cp\u003eThe enteral and parenteral medical nutrition market in North America has been segmented into the US and Canada. The US held a larger share of the market in 2022. The rising prevalence of chronic diseases, growing strategic developments by market players, and increasing preference for enteral and parenteral nutrition contribute to the market progress in this region. Moreover, an upsurge in knowledge among individuals about the benefits of medical nutrition, such as tube feeding, in the treatment of chronic health conditions further contributes to the market growth.\u003c\/p\u003e\n\n\u003cp\u003eNorth America Enteral and Parenteral Medical Nutrition Market Revenue and Forecast to 2028 (US$ Million)\u003c\/p\u003e\n\n\u003cp\u003eNorth America Enteral and Parenteral Medical Nutrition Market Segmentation\u003c\/p\u003e\n\n\u003cp\u003eThe North America enteral and parenteral medical nutrition market is segmented into indication, nutrition type, form, product type, route of administration, age group, and distribution channel, and country.\u003c\/p\u003e\n\n\u003cp\u003eBased on indication, the North America enteral and parenteral medical nutrition market is segmented into elderly, gastrointestinal disorders, diabetes, cancer, respiratory disorders, alzheimer’s disease, dementia, renal disease, liver failure, post covid-19, and other indications. The elderly segment held the largest share of the North America enteral and parenteral medical nutrition market in 2023. Gastrointestinal disorders are segmented into IBD, IBS, and others.\u003c\/p\u003e\n\n\u003cp\u003eBased on nutrition type, the North America enteral and parenteral medical nutrition market is segmented into supplemental and sole source. The supplemental segment held a larger share of the North America enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on form, the North America enteral and parenteral medical nutrition market is segmented into liquid, powder, and semi solid. The liquid segment held the largest share of the North America enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on product type, the North America enteral and parenteral medical nutrition market is segmented into general and disease specific. The general segment held the largest share of the North America enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on route of administration, the North America enteral and parenteral medical nutrition market is segmented into oral, tube feed, and parenteral. The parenteral segment held the largest share of the North America enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on age group, the North America enteral and parenteral medical nutrition market is segmented into above 60 years, 18-60 years, 3-18 years, and below 3 years. The above 60 years segment held the largest share of the North America enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on distribution channel, the North America enteral and parenteral medical nutrition market is segmented into a hospital pharmacies, retail stores, e-commerce, and others. The hospital pharmacies segment held the largest share of the North America enteral and parenteral medical nutrition market in 2023\u003c\/p\u003e\n\n\u003cp\u003eBased on country, the North America enteral and parenteral medical nutrition market is segmented into the US and Canada. The US dominated the share of the North America enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eAbbott Laboratories; B. Braun SE; Baxter International Inc; Fresenius Kabi AG; Medica Nutrition Inc; Medtrition Inc; Nestle SA; Nutricia International BV; and Nutrisens SAS are some of the leading companies operating in the North America enteral and parenteral medical nutrition market.\u003c\/p\u003e \n\n\u003cp\u003eReasons to Buy\u003c\/p\u003e\n\n\u003cp\u003eSave and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America enteral and parenteral medical nutrition market.\u003cbr\u003e\nHighlights key business priorities in order to assist companies to realign their business strategies.\u003cbr\u003e\nThe key findings and recommendations highlight crucial progressive industry trends in North America enteral and parenteral medical nutrition market, thereby allowing players across the value chain to develop effective long-term strategies.\u003cbr\u003e\nDevelop\/modify business expansion plans by using substantial growth offering developed and emerging markets.\u003cbr\u003e\nScrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.\u003cbr\u003e\nEnhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 217 Pages \/ MCW16248336","offer_id":47648684966194,"sku":null,"price":3600.0,"currency_code":"USD","in_stock":true}]},{"product_id":"contract-research-organisations-cros-market-report-2023-2033","title":"Contract Research Organisations (CROs) Market Report 2023-2033","description":"\u003cp\u003eContract Research Organisations (CROs) Market Report 2023-2033\u003c\/p\u003e\n\n\u003cp\u003eThe Contract Research Organisations (CROs) Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.\u003c\/p\u003e\n\n\u003cp\u003eThe market for biopharmaceuticals is rising, there is an increase in the need for healthcare due to an ageing population, and the biotech, pharmaceutical, and medical device industries are expanding to fulfil this demand. As a result, the demand for effective clinical studies has increased in order to ensure the efficacy and safety of products. Worldwide, there are around 266 thousand open clinical trials ongoing. More than 105,000 open clinical investigations are now being conducted just in the United States.\u003c\/p\u003e\n\n\u003cp\u003eThe burden of uncommon diseases is increasing internationally, which has led to an increase and innovation in the creation of medicines. While it is still true that only a small portion of terminal rare diseases receive their initial treatment each year and that over 90% of these diseases await therapy approval. In 2021, the CDC reported that 475 million individuals, or nearly 10% of the world's population, were thought to be living with a rare disease. 15.2 million Individuals are predicted to receive clinical genetic testing for a rare disease during the course of the next five years. A rising number of nations are putting in place government programs to assist people with rare illnesses.\u003c\/p\u003e\n\n\u003cp\u003eIntellectual Property Issues Likely to Challenge Industry Growth\u003c\/p\u003e\n\n\u003cp\u003eIntellectual property is one of the key barriers to outsourcing clinical trials, which might restrict the expansion of contract research organisations' markets. Because copyrighted products make up the majority of therapeutic candidates, a contract research organisation may increase the danger of data leaks.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, pharmaceutical companies that develop novel medicines are expected to provide clinical data about safety and efficacy to the relevant governmental and regulatory bodies in order for their treatments to be approved. As a result, the guidelines for pre- and post-grant disagreement as well as issues pertaining to the patent are quite strict. However, it improves the efficiency of inspection and has assisted in the cancellation of patents. It is crucial to focus more emphasis on clinical trial agreements since the government thoroughly evaluates clinical trial-related issues as well. However, these issues harm the CRO's reputation and may stop the sector for contract research organisations from expanding.\u003c\/p\u003e\n\n\u003cp\u003eWhat Questions Should You Ask Before Buying a Market Research Report?How is the contract research organisations (CROs) market evolving?What is driving and restraining the contract research organisations (CROs) market?How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?How will the market shares for each contract research organisations (CROs) submarket develop from 2022 to 2033?What will be the main driver for the overall market from 2023 to 2033?Will leading contract research organisations (CROs) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?Who are the leading players and what are their prospects over the forecast period?What are the contract research organisations (CROs) projects for these leading companies?How will the industry evolve during the period between 2023 and 2033? What are the implications of contract research organisations (CROs) projects taking place now and over the next 10 years?Is there a greater need for product commercialisation to further scale the contract research organisations (CROs) market?Where is the contract research organisations (CROs) market heading and how can you ensure you are at the forefront of the market?What are the best investment options for new product and service lines?What are the key prospects for moving companies into a new growth path and C-suite?You need to discover how this will impact the Contract Research Organisations (CROs) market today, and over the next 10 years:Our 353-page report provides 141 tables, 201 charts, and graphs exclusively to you.The report highlights key lucrative areas in the industry so you can target them – NOW.It contains in-depth analysis of global, regional and national sales and growth.It highlights for you the key successful trends, changes and revenue projections made by your competitors.This report tells you TODAY how the Contract Research Organisations (CROs) market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.\u003c\/p\u003e\n\n\u003cp\u003eForecasts to 2033 and other analyses reveal commercial prospectsIn addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.You will find original analyses, with business outlooks and developments.Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Contract Research Organisations (CROs) prices and recent developments.This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.\u003c\/p\u003e\n\n\u003cp\u003eSegments Covered in the Report\u003c\/p\u003e\n\n\u003cp\u003eServicePreclinicalClinicalPhase IPhase IIPhase IIIPhase IVLaboratory ServicesConsulting ServicesData Management ServicesCompany SizeLarge Pharma \u0026amp; Biotech CompaniesMid-sized Pharma \u0026amp; Biotech CompaniesSmall Pharma \u0026amp; Biotech CompaniesDrug TypeSmall MoleculesLarge MoleculesTherapeutic AreaOncologyCNSCardiologyInfectiousMetabolicOther Therapeutic AreaIn addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:\u003c\/p\u003e\n\n\u003cp\u003eNorth AmericaU.S.CanadaEuropeGermanyUKFranceItalySpainSwitzerlandNetherlandsRest of EuropeAsia PacificChinaJapanIndiaAustraliaSouth KoreaSingaporeRest of Asia PacificLatin AmericaBrazilMexicoArgentinaRest of Latin AmericaMEAGCCSouth AfricaEgyptRest of MEAThe report also includes profiles and for some of the leading companies in the Contract Research Organisations (CROs) Market, 2023 to 2033, with a focus on this segment of these companies’ operations.\u003c\/p\u003e\n\n\u003cp\u003eLeading companies and the potential for market growthAllucentAnthem Biosciences Private LimitedBio-TechneCharles River LaboratoriesCaidyaCMIC HOLDINGS Co., Ltd.Eurofins ScientificEvotec SEFrontage LabsICON plcInotivIQVIA Inc.Labcorp Drug DevelopmentMedpaceParexel International (MA) CorporationPPD (Thermo Fisher Scientific Inc.)Syneos HealthSyngene International LimitedThe Emmes Company, LLCWorldwide Clinical TrialsWuxi AppTecOverall world revenue for Contract Research Organisations (CROs) Market, 2023 to 2033 in terms of value the market will surpass US$68 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.\u003c\/p\u003e\n\n\u003cp\u003eHow will the Contract Research Organisations (CROs) Market, 2023 to 2033 report help you?\u003c\/p\u003e\n\n\u003cp\u003eIn summary, our 350+ page report provides you with the following knowledge:Revenue forecasts to 2033 for Contract Research Organisations (CROs) Market, 2023 to 2033, with forecasts for services, company size, drug type, and therapeutic area, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.Revenue forecasts to 2033 for five regional and 25 key national markets See forecasts for the Contract Research Organisations (CROs) Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, Singapore, Argentina, GCC, South Africa, and Egypt among other prominent economies.Prospects for established firms and those seeking to enter the market – including company profiles for 21 of the major companies involved in the Contract Research Organisations (CROs) Market, 2023 to 2033.Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.\u003c\/p\u003e\n\n\u003cp\u003eInformation found nowhere else\u003c\/p\u003e\n\n\u003cp\u003eWith our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Contract Research Organisations (CROs) Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.\u003c\/p\u003e\n\n\u003cp\u003ePlease Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..\u003c\/p\u003e\n\n\u003cp\u003eThe publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 353 Pages \/ MCW16248338","offer_id":47648685195570,"sku":null,"price":5926.0,"currency_code":"USD","in_stock":true}]},{"product_id":"benign-prostatic-hyperplasia-treatment-devices-market-size-share-trends-analysis-report-by-treatment-by-procedure-by-product-resectoscopes-urology-laser-by-end-use-by-region-and-segment-forecasts-2023-2030","title":"Benign Prostatic Hyperplasia Treatment Devices Market Size, Share \u0026 Trends Analysis Report By Treatment, By Procedure, By Product (Resectoscopes, Urology Laser), By End-use, By Region, And Segment Forecasts, 2023 - 2030","description":"\u003cp\u003eBenign Prostatic Hyperplasia Treatment Devices Market Size, Share \u0026amp; Trends Analysis Report By Treatment, By Procedure, By Product (Resectoscopes, Urology Laser), By End-use, By Region, And Segment Forecasts, 2023 - 2030\u003cbr\u003e\nBenign Prostatic Hyperplasia Treatment Devices Market Growth \u0026amp; Trends\u003cbr\u003e\nThe global benign prostatic hyperplasia treatment devices market size is anticipated to reach USD 2.79 billion by 2030, registering at a CAGR of 8.90% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increasing application of the robotic system used for the benign prostatic hyperplasia (BPH) treatments, enhancements in the aquablation therapy, early disease diagnosis and increasing health awareness among people drive the market growth. Due to the rising prevalence of BPH and the ongoing development of novel therapy alternatives, the BPH treatment device market is anticipated to expand globally.\u003c\/p\u003e\n\n\u003cp\u003eAquablation therapy involves the use of a system that combines water and radiofrequency energy. Normally, either local or general anesthesia is used during the surgery. When compared to the open surgical treatments for BPH, aquablation therapy has a number of advantages, including less bleeding and a shorter catheterization period. For instance, in April 2023, according to PROCEPT BioRobotics Corporation, 5-year results from the WATER II Study showed that Aquablation therapy, a minimally invasive robotic surgical procedure for benign prostatic hyperplasia, safely and effectively relieved persistent symptoms in men with large prostates (80 to 150 mL) and maintains sexual function for up to five years. The study, which was released in the Journal of Urology, showed that patients' symptoms and quality of life kept improving significantly over time.\u003c\/p\u003e\n\n\u003cp\u003eThe key players are also involved in developing implants for the treatment of benign prostatic hyperplasia. The positive outcomes from the clinical studies have a positive impact on the market growth. For instance, as per the article published in Urology Times, the company ProVerum Limited invented the nitinol expander device for people with BPH in June 2022. The first treatment using the revolutionary ProVee System was successfully conducted in the key ProVIDE trial at Avant Concierge Urology. A self-expanding implant called ProVee gently reshapes and widens a restricted urethra to increase urine flow shortly after it is in place and also improves the quality of life in the patients. Thus, due to such advancements, the demand for Benign Prostatic Hyperplasia (BPH) treatment devices will increase in the near future.\u003cbr\u003e\nBenign Prostatic Hyperplasia Treatment Devices Market Report Highlights Based on treatment, minimal invasive surgery dominated the BPH treatment devices market with a revenue share of 72.16 % in 2022, owing to the less postpartum pain and discomfort that may result from smaller incisions and less tissue manipulation Based on procedure, Transurethral Resection of the Prostate (TURP) segment dominated the market in 2022 with a revenue share of 25.32%. The TURP procedure is considered a golden standard and the most effective BPH treatment Based on end-use, hospitals held a majority share of the market with 64.77% in 2022. The increasing number of patients being admitted to hospitals due to surgeries, therapies, and treatments is expected to increase the demand for neurovascular catheters in the near future North America led the market with the maximum revenue share of 34.95% in 2022. Rising demand for minimally invasive surgeries and rising government initiatives for improving healthcare infrastructures are among the key factors driving the market growth. In addition, technological advancement and innovation of new noninvasive techniques will create lucrative opportunities for the segmentPlease note The report will be delivered in 2-3 business days upon order notification.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 120 Pages \/ MCW16248342","offer_id":47648685326642,"sku":null,"price":7140.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-cannabis-packaging-market-2023-2027","title":"Global Cannabis Packaging Market 2023-2027","description":"\u003cp\u003eGlobal Cannabis Packaging Market 2023-2027\u003cbr\u003e\nThe cannabis packaging market is forecasted to grow by USD 5,818 million during 2022-2027, accelerating at a CAGR of 25.26% during the forecast period. The report on the cannabis packaging market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\u003c\/p\u003e\n\n\u003cp\u003eThe report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing millennial purchasing power in key cannabis industry, rising number of countries decriminalizing and legalizing cannabis, and increasing medicinal application of cannabis.\u003c\/p\u003e\n\n\u003cp\u003eTechnavio's cannabis packaging market is segmented as below:\u003c\/p\u003e\n\n\u003cp\u003eBy MaterialGlassMetalPlasticsCardboard containersBy TypeRigid packagingFlexible packagingBy Geographical LandscapeNorth AmericaAPACEuropeSouth AmericaMiddle East and AfricaThis study identifies the emergence of smart packaging of cannabis as one of the prime reasons driving the cannabis packaging market growth during the next few years. Also, increasing focus on sustainable packaging and increasing innovations in cannabis packaging will lead to sizable demand in the market.\u003c\/p\u003e\n\n\u003cp\u003eThe report on the cannabis packaging market covers the following areas:Cannabis packaging market sizingCannabis packaging market forecastCannabis packaging market industry analysisThe robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cannabis packaging market vendors that include Berry Global Inc., Cannabis Promotions, Cannaline, Diamond Packaging, Drug Plastics Group, Dymapak Quark Distribution Inc., Elevate Packaging Inc., Green Rush Packaging, Greenlane Holdings Inc., Kaya Packaging, Kynd Packaging LLC, Max Bright Packaging Ltd., MMC Depot, N2 Packaging Systems LLC, Norkol Inc., Packaging Bee, RXD Co., Sana Packaging, StoreSac, and The Boxmaker Inc.. Also, the cannabis packaging market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.\u003c\/p\u003e\n\n\u003cp\u003eThe study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.\u003c\/p\u003e \n\n\u003cp\u003eThe publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 149 Pages \/ MCW16248346","offer_id":47648685457714,"sku":null,"price":3000.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-enteral-syringe-market-2023-2027","title":"Global Enteral Syringe Market 2023-2027","description":"\u003cp\u003eGlobal Enteral Syringe Market 2023-2027\u003cbr\u003e\nThe enteral syringe market is forecasted to grow by USD 411.85 mn during 2022-2027, accelerating at a CAGR of 5.7% during the forecast period. The report on the enteral syringe market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\u003c\/p\u003e\n\n\u003cp\u003eThe report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of chronic conditions, growing demand for home enteral nutrition, and growing preference for minimally invasive procedures.\u003c\/p\u003e\n\n\u003cp\u003eTechnavio's enteral syringe market is segmented as below:\u003c\/p\u003e\n\n\u003cp\u003eBy ProductDisposable syringesReusable syringesBy ApplicationAdultsNeonates and pediatricsBy Geographical LandscapeNorth AmericaEuropeAsiaRest of World (ROW)This study identifies the growing number of target population as one of the prime reasons driving the enteral syringe market growth during the next few years. Also, updated regulatory guidelines for designing and manufacturing enteral syringes and increasing awareness about enteral feeding in critical care conditions will lead to sizable demand in the market.\u003c\/p\u003e\n\n\u003cp\u003eThe report on the enteral syringe market covers the following areas:Enteral syringe market sizingEnteral syringe market forecastEnteral syringe market industry analysisThe robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading enteral syringe market vendors that include Amsino International Inc., Andway Healthcare Ltd., Avanos Medical Inc, B.Braun SE, Baxter International Inc., Becton Dickinson and Co., Cardinal Health Inc., Danone SA, DMC Medical Ltd., GBUK Group Ltd, Jiangsu Caina Medical Co. Ltd., Micsafe Medical Group, Kentec Medical Inc., Medela AG, Medicina Ltd., Medline Industries LP, Miktell Ltd., Terumo Corp., Thermo Fisher Scientific Inc., and Vygon SAS. Also, the enteral syringe market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.\u003c\/p\u003e\n\n\u003cp\u003eThe study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.\u003c\/p\u003e \n\n\u003cp\u003eThe publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 161 Pages \/ MCW16248348","offer_id":47648685523250,"sku":null,"price":3000.0,"currency_code":"USD","in_stock":true}]},{"product_id":"middle-east-africa-enteral-and-parenteral-medical-nutrition-market-forecast-to-2028-regional-analysis-by-indication-elderly-gastrointestinal-disorders-ibd-ibs-and-others-diabetes-cancer-respiratory-disorders-alzheimer-s-disease-dementia-re","title":"Middle East \u0026 Africa Enteral and Parenteral Medical Nutrition Market Forecast to 2028 - Regional Analysis By Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer’s Disease, Dementia, Re","description":"\u003cp\u003eMiddle East \u0026amp; Africa Enteral and Parenteral Medical Nutrition Market Forecast to 2028 - Regional Analysis By Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer’s Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole Source), Form (Liquid, Powder, and Semi Solid), Product Type (General and Disease Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18-60 Years, 3-18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)\u003cbr\u003e\nThe Middle East \u0026amp; Africa enteral and parenteral medical nutrition market is expected to grow from US$ 539.80 million in 2023 to US$ 661.18 million by 2028. It is estimated to grow at a CAGR of 4.1% from 2023 to 2028.\u003c\/p\u003e\n\n\u003cp\u003eSpecific Formulations and Plant-Based Nutrition Products Fuels Middle East \u0026amp; Africa Enteral and Parenteral Medical Nutrition Market\u003c\/p\u003e\n\n\u003cp\u003eThere is a surge in the demand for products that help consumers proactively manage their health, especially those focused on specific needs in terms of energy levels, immunity, and disease treatment. Nutritional requirements differ based on the type of illness. Functionality and specific formulations of the enteral and parenteral products do not interfere with the existing treatment provided to patients and help deliver a more precise and enhanced treatment as per the requirement. The macro and micronutrient formulations of enteral and parenteral nutrition and its applications vary based on various diseases, such as cancer and gastrointestinal diseases. Isocaloric enteral nutrition formulation (1 kcal\/ml) is generally prescribed to achieve estimated or measured caloric goals, while energy-dense formulae (\u0026gt;1 kcal\/ml) are prescribed to increase calorie delivery in patients with gastrointestinal dysfunction.\u003c\/p\u003e\n\n\u003cp\u003eMoreover, pharmaceutical companies provide enteral and parenteral nutrition with individualized (patient-specific) constituents. Standardized parenteral nutrition products contain fixed constituents and are designed to meet the average patient’s nutritional requirements considering different requirements in different age groups. These nutrition products can be sourced as institution-specific standardized formulations or patient-specific formulations. For example, Impact (offered by Nestle) is a clinically proven nutritional solution for managing patients undergoing major elective surgeries to reduce postoperative complications and hospital stay duration and improve clinical outcomes. Peptamen Formula (Nestle) is the only peptide-based formula with enzymatically hydrolyzed 100% whey protein that helps overcome tube-feeding intolerance. Such tube-feeding formulas are specialized enteral nutrition products designed to support absorption and overcome tolerance mechanisms in individuals with gastrointestinal disorders.\u003c\/p\u003e\n\n\u003cp\u003eFurther, a surge in the number of people turning to plant-based food triggers the demand for plant-based nutrition products worldwide. People are more likely to show intolerance to artificial\/synthetically sourced ingredients used in higher numbers, which may lead to adverse reactions. Thus, the fewer ingredients, the better the final product. The Innova Consumer Survey 2020 showed that health, diet variety, sustainability, and taste are among the top reasons why people consider plant-based alternatives. According to Abbott, consumers and patients relying on tube feeding are no exception to this trend. Companies in the enteral and parenteral medical nutrition market anticipate that a growing focus on healthy foods would translate into a preference for healthier nutrition products. In September 2021, Abbott introduced a portfolio of plant-based proteins and organic food ingredients for children and adults. Similarly, olive oil-based parenteral nutrition products are also gaining popularity.\u003c\/p\u003e\n\n\u003cp\u003eTherefore, functional, and patient-centric formulations and plant-based nutrition products are the prime emerging trends in the enteral and parenteral medical nutrition market.\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa Enteral and Parenteral Medical Nutrition Market Overview\u003c\/p\u003e\n\n\u003cp\u003eThe Middle East \u0026amp; Africa enteral and parenteral medical nutrition market is categorized into the UAE, Saudi Arabia, South Africa, Iran, Israel, Egypt, and the Rest of Middle East \u0026amp; Africa. In 2021, Saudi Arabia held a significant share of the enteral and parenteral medical nutrition market in the region. The enteral and parenteral medical nutrition market is expected to grow due to the increasing cases of cancer and stroke, as well as growing malnutrition among adults and premature babies across the region. Moreover, the growing government initiatives in the region propels the market growth.\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa Enteral and Parenteral Medical Nutrition Market Revenue and Forecast to 2028 (US$ Million)\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa Enteral and Parenteral Medical Nutrition Market Segmentation\u003c\/p\u003e\n\n\u003cp\u003eThe Middle East \u0026amp; Africa enteral and parenteral medical nutrition market is segmented into indication, nutrition type, form, product type, route of administration, age group, and distribution channel, and country.\u003c\/p\u003e\n\n\u003cp\u003eBased on indication, the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market is segmented into elderly, gastrointestinal disorders, diabetes, cancer, respiratory disorders, alzheimer’s disease, dementia, renal disease, liver failure, post Covid-19, and other indications. The elderly segment held the largest share of the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market in 2023. Gastrointestinal disorders are segmented into IBD, IBS, and others.\u003c\/p\u003e\n\n\u003cp\u003eBased on nutrition type, the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market is segmented into supplemental and sole source. The supplemental segment held a larger share of the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on form, the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market is segmented into liquid, powder, and semi solid. The liquid segment held the largest share of the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on product type, the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market is segmented into general and disease specific. The general segment held the largest share of the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on route of administration, the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market is segmented into oral, tube feed, and parenteral. The parenteral segment held the largest share of the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on age group, the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market is segmented into above 60 years, 18-60 years, 3-18 years, and below 3 years. The above 60 years segment held the largest share of the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eBased on distribution channel, the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market is segmented into a hospital pharmacies, retail stores, e-commerce, and others. The hospital pharmacies segment held the largest share of the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market in 2023\u003c\/p\u003e\n\n\u003cp\u003eBased on country, the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market is segmented into Saudi Arabia, South Africa, the UAE, Iran, Israel, Egypt, and the Rest of Middle East \u0026amp; Africa. Saudi Arabia dominated the share of the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market in 2023.\u003c\/p\u003e\n\n\u003cp\u003eAbbott Laboratories; B. Braun SE; Baxter International Inc; Easy Line Ltd; Fresenius Kabi AG; Nestle SA; and Nutricia International BV are some of the leading companies operating in the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market.\u003c\/p\u003e \n\n\u003cp\u003eReasons to Buy\u003c\/p\u003e\n\n\u003cp\u003eSave and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East \u0026amp; Africa enteral and parenteral medical nutrition market.\u003cbr\u003e\nHighlights key business priorities in order to assist companies to realign their business strategies.\u003cbr\u003e\nThe key findings and recommendations highlight crucial progressive industry trends in Middle East \u0026amp; Africa enteral and parenteral medical nutrition market, thereby allowing players across the value chain to develop effective long-term strategies.\u003cbr\u003e\nDevelop\/modify business expansion plans by using substantial growth offering developed and emerging markets.\u003cbr\u003e\nScrutinize in-depth Middle East \u0026amp; Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.\u003cbr\u003e\nEnhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 335 Pages \/ MCW16248350","offer_id":47648685752626,"sku":null,"price":3600.0,"currency_code":"USD","in_stock":true}]},{"product_id":"global-gonorrhea-therapeutics-market-2023-2027","title":"Global Gonorrhea Therapeutics Market 2023-2027","description":"\u003cp\u003eGlobal Gonorrhea Therapeutics Market 2023-2027\u003cbr\u003e\nThe gonorrhea therapeutics market is forecasted to grow by USD 506.68 mn during 2022-2027, accelerating at a CAGR of 5.47% during the forecast period. The report on the gonorrhea therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\u003c\/p\u003e\n\n\u003cp\u003eThe report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of gonorrhea, high-risk complications associated with gonorrhea, and growing use of new diagnostic tests.\u003c\/p\u003e\n\n\u003cp\u003eTechnavio's gonorrhea therapeutics market is segmented as below:\u003c\/p\u003e\n\n\u003cp\u003eBy Distribution ChannelHospital pharmaciesRetail pharmaciesOnline pharmaciesBy TherapyMonotherapyCombination therapyBy Geographical LandscapeNorth AmericaEuropeAsiaRest of World (ROW)This study identifies the rising government initiatives to combat antibiotic resistance as one of the prime reasons driving the gonorrhea therapeutics market growth during the next few years. Also, advent of vaccines for prevention of gonorrhea and increased adoption of expedited partner therapy will lead to sizable demand in the market.\u003c\/p\u003e\n\n\u003cp\u003eThe report on the gonorrhea therapeutics market covers the following areas:Gonorrhea therapeutics market sizingGonorrhea therapeutics market forecastGonorrhea therapeutics market industry analysisThe robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gonorrhea therapeutics market vendors that include Apotex Inc., Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cipla Ltd., Debiopharm International SA, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd., Mayne Pharma Group Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Therapyx Inc., and Entasis Therapeutics. Also, the gonorrhea therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.\u003c\/p\u003e\n\n\u003cp\u003eThe study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.\u003c\/p\u003e \n\n\u003cp\u003eThe publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 162 Pages \/ MCW16248352","offer_id":47648686309682,"sku":null,"price":3000.0,"currency_code":"USD","in_stock":true}]},{"product_id":"mental-health-substance-abuse-clinics-in-canada-industry-market-research-report","title":"Mental Health \u0026 Substance Abuse Clinics in Canada - Industry Market Research Report","description":"\u003cp\u003eMental Health \u0026amp; Substance Abuse Clinics in Canada - Industry Market Research Report\u003cbr\u003e\nMental Health \u0026amp; Substance Abuse Clinics in Canada\u003c\/p\u003e\n\n\u003cp\u003eThe industry in Canada provides a variety of outpatient care services for patients struggling with depression, schizophrenia, bipolar disorder, alcoholism and other drug-related issues. In addition, industry clinics treat a variety of illnesses commonly affecting the elderly, such as dementia and Alzheimer's disease. Improving economic conditions along with greater societal awareness of mental health issues have contributed to industry revenue growth in recent years. The COVID-19 pandemic also to fueled demand for industry services, as the pandemic caused significant mental stress for many Canadians. Accordingly, industry revenue is expected to grow at a CAGR of 4.4% to reach $4.6 billion in 2023, when revenue is set to grow 2.0%. In spite of growing revenue, industry profit is has declined in recent years as wage costs have grown amid a persistent labor shortage.\u003c\/p\u003e\n\n\u003cp\u003eThe Mental Health and Substance Abuse Clinics industry in Canada provides outpatient services related to the diagnosis and treatment of mental health disorders and substance abuse problems. Moreover, these operators may provide counselling and information pertaining to these issues.\u003c\/p\u003e\n\n\u003cp\u003eThis report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"September, 2023 \/ 38 Pages \/ MCW16248354","offer_id":47648686407986,"sku":null,"price":1050.0,"currency_code":"USD","in_stock":true}]}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0792\/8053\/7906\/collections\/McKInsey_well_400_x_400_px_2000_x_2000_px_1000_x_1000_px_400_x_400_px_17.jpg?v=1709719816","url":"https:\/\/www.hardmanwell.com\/collections\/pharmaceuticals.oembed?page=66","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}